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Introduction: Many studies analyse body composition
changes in older adults. However, few studies analyse body
composition in elderly people with functional measures.
Studies using Double X-Ray analysis (DXA) or Bioimpedance
analysis proved to be reliable but expensive or only possible
in a laboratory environment.
The purpose of our study was to analyse changes in body
composition over three years using anthropometric measures
in a sample of elderly people in order to perceive functional
changes.
Methods: Forty-three participants (12 men; 31 women) aged
60 years and over and independent in activities of daily life
were assessed using anthropometric measures in a ﬁrst mo-
ment and past three years. Weight, height, waist and hip cir-
cumference were measured, and body mass index (BMI) and
waist-to-hip ratio (WHR) were also calculated. Skeletal mus-
cle mass (SMM) was also calculated using Al-Gindan et al.
(2014) equations and normalized for height to found skeletal
muscle index (SMI) in order to analyze cut-off points associ-
ated with physical disability according to Janssen et al (2004).
Results: A signiﬁcant difference was found over three years in
SMM (p = 0.007), SMI (p = 0.027), BMI (p = 0.041) and WHR
(p = 0.003). The majority of the participants has decreased
SMM, SMI and BMI and increased WHR, which favors a worst
prognostic for comorbidities associated with these variables,
and a tendency for sarcopenic obesity seems to be present al-
though more studies are needed. Also, we found that using
cut-off points for disability risk 83.3% of the men and 38.7%
of the women of our sample were at moderate or high risk
of disability. Three years later this percentage has increased
but only for women to 54.8%.
Conclusions: Although men are at risk of disability, women
quickly lose their functional capacity, making necessary a




Prevalence of cachexia in dogs with congestive
heart failure
Pamela L. Bay, Lisa M. Freeman & John E. Rush
Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA
Background and Aims: Congestive heart failure (CHF) is a
common, naturally occurring disease in pet dogs that is of-
ten associated with cardiac cachexia, as deﬁned by a loss of
muscle. One study of dogs with dilated cardiomyopathy
(DCM) and CHF showed that 54% of dogs were affected
by cachexia. No studies have been conducted to conﬁrm
these ﬁndings in dogs with DCM or to assess prevalence
in CHF from other forms of heart disease causing CHF.
Therefore, the aim of this study was to determine preva-
lence of cardiac cachexia in dogs with CHF due to acquired
heart disease.
Methods: Dogs with CHF evaluated by the Cardiology Service
at the Cummings School of Veterinary Medicine between
June 2015 and June 2017 were eligible. Dogs with DCM and
myxomatous mitral valve disease (MMVD) were enrolled.
Data from the medical records were retrospectively
reviewed, including body weight, body condition score
(BCS), and muscle condition score (MCS). Body condition
score, which assesses fat stores, was measured on a 1–9
scale, with 1 = emaciated, 9 = obese, and 4–5 considered
ideal. Muscle condition was categorized using the World
Small Animal Veterinary Association scoring system as normal
muscle, mild muscle loss, moderate muscle loss, or severe
muscle loss.
Results: Median age of the dogs (n = 196) was 10.7 years
(range, 1.7–18.0 years). Underlying diseases included MMVD
(n = 168) and DCM (n = 28). Mean body weight was 7.6 kg
(range, 2.4–75.8 kg). Only 6.1% of dogs were underweight
(BCS < 4/9), and 41.8% of dogs were overweight or obese
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(BCS > 5/9). However, muscle loss was identiﬁed in 48.0% of
dogs: Mild muscle loss: 73/196 (37.3%), moderate muscle
loss: 14/196 (7.1%), and severe muscle loss: 7/196 (3.6%).
52.0% of dogs were assessed to have normal muscle. Muscle
condition score and BCS were not signiﬁcantly different be-
tween dogs with MMVD or DCM.
Conclusions: Although many dogs were overweight or obese,
cachexia was present in 48% of dogs with CHF.
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Introduction: Cachexia is common in several chronic diseases
and signiﬁcantly increases morbidity and mortality. There is a
lack of data regarding cachexia hospitalization burden and
mortality after cachexia hospitalization. Thus, we aimed to
identify all patients that were hospitalized due to cachexia
and determine their mortality and prognostic implications
of different comorbidities.
Methods: The Slovenian National Hospitalization Database
has been searched for all individuals with main Cachexia
hospitalization (ICD-10 codes: C80, R64 and B22.2) between
2004 and 2015, and sex, age, length of stay and comor-
bidities were recorded. For all patients with cachexia
hospitalization, date of death was recorded from Slovenian
Death Registry. Prevalence of comorbidities during cachexia
hospitalization were calculated and hazard ratios (HR) for
mortality for sex, age and patients’ comorbidities were
calculated using multiple Cox proportional hazards model.
Results: Overall, we identiﬁed 1774 main cachexia hospitali-
zations in 1406 patients. Main cachexia hospitalizations
contributed to 17.7% of all the hospitalizations of an individ-
ual during the study period. Cancer, cardiovascular and
pulmonary diseases were the most prevalent in cachexia
patients (62%, 27% and 10%, respectively). In-hospital
mortality was 29%. Median survival for discharged patients
were 103 days (95% conﬁdence intervals, 90–123 days).
Older patients, those with cancer and pulmonary disease,
had signiﬁcantly higher HR for mortality (1.16 for 10 year
increase, 1.79 and 1.34, respectively).
Conclusions: Patients hospitalized due to cachexia have
extremely poor prognosis. Cancer, which is the most preva-
lent comorbidity in patients hospitalized due to cachexia, is
associated with the worst prognosis.
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Background: By population prevalence, there are more
chronic obstructive pulmonary disease (COPD) cases than
cancer cases with cachexia. The consensus deﬁnition of
cachexia incorporates weight loss (WL) >5% in 12 months
in addition to 3 out of 5 of decreased muscle strength,
fatigue, anorexia, low fat-free mass index (FFMI) and abnor-
mal biochemistry (anemia, CRP, IL6, albumin). More recently,
cancer cachexia has been classiﬁed using WL >5% or, in the
presence of low BMI or FFMI, WL >2%. Further, the impor-
tance of pre-cachexia (WL ≤5%, anorexia and inﬂammation)
has been highlighted as more advanced cachexia may
indicate a refractory state. Thus, we aimed to examine the
prevalence of cachexia using these deﬁnitions in a cohort of
COPD cases from the ECLIPSE Study.
Methods: A total of 1901 COPD cases were assessed for
cachexia. Annual weight, muscle strength, FFMI and anemia
data were analyzed. Fatigue and anorexia data were available
at baseline and end of study. CRP levels were measured at
baseline and over the ﬁrst year. The consensus deﬁnition
was coded at each annual visit an individual participated in
the study. Where data were not available for the speciﬁc visit,
an aggregate was created (e.g., ever had fatigue). Participants
who exhibited WL at an early visit with evidence it was
regained were coded as non-cachectic.
Results: The prevalence of cachexia based on the consensus
deﬁnition ranged from 4.0% (Year 1) to 6.6% (Year 3). Over
3 years of the study, 11% of COPD cases were classiﬁed as
cachectic at some time point. The prevalence of cachexia
using the cancer cachexia deﬁnition ranged from 9.7% (Year
1) to 17.7% (Year 3). The prevalence of pre-cachexia ranged
from 2.0% (Year 2) to 3.1% (Year 1).
Summary: Based on deﬁnition of cachexia and visit used, the
prevalence in a large cohort of COPD cases ranged from 4.0%
to 17.7%.
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SARA-data: Integrated, real-time ICT Platform for
the SARA interventional Clinical Trial in Age-related
SARcopenia
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Gianluca Zia1
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Introduction: SARA-Int(erventional), a randomized, double-
blind clinical trial, will evaluate the safety and efﬁcacy of
two oral doses of SARconeos (BIO101) versus placebo over
6 months in 333 sarcopenic or obese sarcopenic patients
Aged ≥65 years complaining of loss of strength and muscular
function.
Methods: We deployed an integrated Information&Commu-
nication Technology (ICT) platform, SARA-data, to monitor
on quasi real-time different source data (clinical, imaging
(DEXA), laboratory and physical activity). Data can be gener-
ated at investigation sites, by the centralised lab and by the
patients themselves via wearable devices and auto-
evaluation questionnaires.
Bluecompanion implemented for Biophytis SARA Data, which
allows to collect and integrate on one single web-based por-
tal: an electronic Case Report Form (Clean WEB by Telemed-
icine), participants row data from DEXA scans, and
biochemistry-haematology results from a centralised labora-
tory, including sarcopenia-related biomarkers. Of note, con-
tinuous physical activity recording is enabled during the
whole clinical trial duration by providing each older partici-
pant with a wrist-worn accelerometer. The device transmits
anonymised activity data to SARA platform via a non-
intrusive, unattended, home-centred machine-to-machine
technology.
This kind of high volume data, directly generated by the
patient during several months, fulﬁls the deﬁnition “Big data
in health”, encompassing “high volume, high diversity
biological, clinical, environmental, and lifestyle information
collected from single individuals to large cohorts, in relation
to their health and wellness status, at one or several time
points” (Auffray C. et al., 2016), and will constitute an
important resource for additional, supportive analyses
complementing standardised muscular function assessments.
These data are generated in a real-life context and could
provide answers to speciﬁc questions by regulators and
payers.
Conclusions: SARA-data are a single real-time ICT platform
enabling data capture, storage, analysis and retrieval of
long-term clinical data generated during SARA-Int, a random-
ized CT evaluating Sarconeos (Bio101) in Age-related
Sarcopenia, including Sarcopenic Obesity.
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Background and Purpose: Body weight loss after stroke has
been shown in several clinical trials. Cachexia after stroke
has not been studied systematically yet. The purpose of this
prospective study was to investigate dynamical changes of
body composition and body weight one year after ischemic
stroke, and its association with functional outcome.
Methods: 67 consecutive patients with acute ischemic stroke
(age 69 ± 11 years, BMI 27 ± 4 kg/m2) with mild to moderate
neurological deﬁcit (mean NIHSS 4.3, range 0–12) were
analyzed. Body composition was examined by dual energy
X-ray absorptiometry (DEXA) in acute phase (4 ± 2 days)
and at 1-year follow-up (389 ± 26 days). Cachexia was deﬁned
according to consensus deﬁnition by body weight loss ≥5%
within one year and clinical symptoms. Functional assess-
ments included Barthel Index (BI), modiﬁed Rankin scale
(mRS), and muscle strength tests.
Results: Cachexia was diagnosed in 21% of the patients at 1-
year follow-up. Most changes of body composition concerned
the fat tissue with the highest fat mass decline of 12.5% in
cachectic patients, followed by 5% loss in non-cachectic
patients with weight loss, and fat mass increase by 8% in
patients with weight gain. In addition, cachectic patients lost
3% of the lean mass (P < 0.05).
At baseline patients who developed cachexia during follow
up were older (75 ± 9 years), had moderate neurologic deﬁcit
(mean NIHSS 5.8), and the lowest physical and functional
capacity. They remained with the worse functional impair-
ment (mRS 2.1 ± 1.6, P < 0.05, Barthel Index 74 ± 36,
P = 0.002) and handgrip strength (22.4 ± 14.9 kg, P < 0.05)
compared to other patients at 1-year FU. After adjustment
for multiple confounders, patients with higher functional
impairment (OR 1.87, 95% CI 1.09–3.20) and neurologic
deﬁcit (OR 3.63, 95% CI 0.97–13.6) were at risk for cachexia.
Conclusions: The most changes of body composition after
stroke with mild-to-moderate neurologic deﬁcit concerned
the fat tissue. Attention should be focused on identiﬁcation
and targeting of cachexia in the early phase following the
stroke.




Ultrasound: a new strategy to evaluate body
composition in crohn’s patients undergoing
hematopoietic stem cell transplantation (HSCT)
Andrea Z. Pereira1, Sandra E.A. Gonçalves1, Bianca L. de Sá2,
Marister Cocco3, Andreza A.F. Ribeiro1 & Nelson Hamerschlak1
1Oncology and Hematology Department, Hospital Israelita Albert Einstein, S. Paolo,
Brazil, 2Nutrition Department, Hospital Israelita Albert Einstein, S.Paulo, Brazil,
3Physiotherapy Department, Hospital Israelita Albert Einstein, S.Paulo, Brazil
Introduction: Crohn disease is a chronic inﬂammatory disor-
der of the gastrointestinal tract with a strong polygenic im-
mune component. In refractory cases, autologous HSCT can
decrease disease activity and mucosal healing and improve
quality of life. Reduced muscular mass and excess visceral
fat in patients undergoing HSCT are associated with higher
mortality, longer hospitalization, longer use of immunosup-
pressive drugs, graft-versus-host disease, shorter disease-free
interval after the HSCT and comorbidities leading to shorter
survival time.
Objectives: To evaluate muscle thickness and visceral fat
by US.
Methods: We evaluated 5 HSCT patients (≥18 years) at Hos-
pital Israelita Albert Einstein, São Paulo, Brazil, on their ﬁrst
day of hospitalization, before HSCT and after the engraft-
ment. The thickness of the right femoral quadriceps muscle
(RFQ), measured at 6 cm from the top edge of the patella
was measured using US in B-mode. The VF was measured in
the abdominal region, by the thickness of the fat layer be-
tween the linea alba and the anterior wall of the aorta.
Results: Most patients were men (75%) with a mean age of
35 years (±14 years). Most patients were undernutrition, with
body mass index (BMI) of 21 kg/m2 (±2.5 kg/m2). The average
time EN was 11 days (±1 day). In the baseline, RFQ was 1.5 cm
(±0.2 cm), and the VF was 4.2 cm (±1.3 cm). After engrafment,
RFQ was 1.3 cm (±0.2 cm), and the VF was 4.2 cm (±1.2 cm).
There wasn’t signiﬁcant difference between baseline and
after engraftment, although RFQ had reduced in all patients.
Conclusions: In this cohort of patients, we found reduced
muscle thickness after engraftment, and VF didn’t have any
alterations. The US was a practical, economical and effective
method to evaluate these patients.
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Elderly patients undergone hematopoietic stem
cell transplantation: body composition and
engraftment
Andrea Z. Pereira1, Ludmila M. Koch1, Polianna M.R. Souza1,
Bianca L. de Sá2, Andreza A.F. Ribeiro1 & Nelson Hamerschlak1
1Oncology and Hematology Department, Hospital Israelita Albert Einstein, S.Paulo,
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Introduction: Hematopoietic Stem Cell Transplantation
(HSCT) in elderly is a brand-new issue. Changes in body
composition after HSCT have been the subject of previous
studies; however, there aren’t many studies in elderly people.
Objectives: To evaluate muscle thickness and visceral fat by
US; % muscle mass, % fat mass and phase angle by BIA. To
correlate body composition with engraftment (EN).
Methods: In this prospective study, we evaluated 16 HSCT pa-
tients (≥60 years) at Hospital Israelita Albert Einstein, São
Paulo, Brazil, on their ﬁrst day of hospitalization, before HSCT
and after the EN. The thickness of the right femoral quadri-
ceps muscle (RFQ), measured at 6 cm from the top edge of
the patella was measured using ultrasound (US) in B-mode,
transversal plane. The visceral fat (VF) was measured in the
abdominal region, by the thickness of the fat layer between
the linea alba and the anterior wall of the aorta. The % mus-
cle mass (MM), % fat mass (FM) and phase angle (PA) were
evaluated by Bioimpedanciometry(BIA).
Results: Most patients were men (75%) with a mean age of
64(±5.0 years). We had 50% of autologous HSCT and 50%
allogenic HSCT. Themean time ENwas 13(±4 days). In the base-
line, weight was 80(±17 kg), RFQ was 1.8(±0.3 cm) and the VF
was 5.5(± 2.0 cm); %MM was 68.5(±11); %FM was 27.5(±7.5);
PA was 5.3((±0.7). After EN, weight was 73(±13 kg). RFQ was
1.5(±0.3 cm) and the VF was 5,0(±2.2 cm); %MM was
55.5(±20.5); %FMwas 25(±7.0); PAwas 7.4(±0.8). Therewasn’t
signiﬁcant difference between baseline and after engraftment,
although all measurements had reduced in all patients,
exception for PA and VF had increased. We found the negative
correlation between engraftment and RFQ(rp:0,6), indepen-
dently of HSCT type by regression. (rp:0,6).
Conclusions: In this cohort of patients, muscle thickness and
mass was reduced, and visceral fat and phase angle was
increased after engraftment. The higher muscle thickness
correlated faster engraftment.
Elderly quilombolas: Prevalence of sarcopenia using
algorithm proposed by the European working group on
sarcopenia in older people.
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Prognostic value of psoas muscle area and density
in patients undergoing cardiovascular surgery
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Japan, 5Department of Cardiovascular Medicine, Kitasato University Graduate
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Introduction: Low skeletal muscle area and density, as deter-
mined by computed tomography (CT), have yet to be examined
and compared in terms of prognostic capability in patients re-
quiring open cardiovascular surgery. This study was performed
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to examine whether psoas muscle area and density are
associated with postoperative mortality and physical
performance in patients undergoing cardiovascular surgery.
Methods: We reviewed the ﬁndings in 773 consecutive
patients undergoing preoperative CT imaging including the
level of the third lumbar vertebra for clinical purposes.
Skeletal muscle area was calculated from psoas muscle
cross-sectional area (CSA) on preoperative CT images at the
level of the third lumbar vertebra divided by the square of
the patient’s height to give the skeletal muscle index (SMI:
cm2/m2). Skeletal muscle density determined by muscle
attenuation (MA) was calculated by measuring the average
Hounsﬁeld units of the psoas muscle CSA. Quadriceps
strength and 6-minute walking distance were examined as
indices of physical performance.
Results: The mean age of the study population was
68.6 ± 14.0 years, and 64.7% of the patients were male. Mul-
tivariate Cox regression analysis showed that low MA (hazard
ratio [HR], 2.18; 95% conﬁdence interval [CI], 1.14–4.16,
P = 0.018), but not low SMI (HR, 1.35; 95% CI, 0.71–2.56,
P = 0.361), was signiﬁcantly associated with all-cause mortal-
ity. Kaplan–Meier analysis showed that low MA, but not low
SMI, predicted poor prognosis (P = 0.014). Correlation analy-
sis indicated that MA was more strongly associated with
quadriceps strength and 6-minute walking distance than SMI.
Conclusions: Low skeletal muscle density, but not skeletal
muscle area, predicted survival in patients undergoing car-
diac surgery.
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Introduction: Body mass index is cited as an index to
recognize signiﬁcant correlation with skeletal muscle mass.
However, body weight changes due to edema are often
observed in chronic heart failure (CHF). We investigated the
usefulness of body weight for evaluating skeletal muscle
mass wasting in congested CHF outpatients.
Methods: Totally 45 CHF outpatients with brain natriuretic
peptide (BNP) ≥200 pg/ml were enrolled. Total skeletal muscle
mass was measured at the level of the third lumbar vertebra
using available preoperative computed tomography images
(Cutoff value: male 36.2cm2/m2, female 29.6cm2/m2).
It was investigated on the relationship between skeletal
muscle mass and each nutritional indicator.
Results: The mean age was 75.6 ± 6.4 years old, body mass
index (BMI) was 22.4 ± 2.9 kg/m2 and left ventricular ejection
fraction was 44.3 ± 18.9%. Median BNP was 417.5 pg/ml (in-
terquartile range, 271.1–590.8). Of the study patients, 53.3%
patients were male, 26.7% patients had ischemic heart fail-
ure, 57.8% patients had New York Heart Association (NYHA)
classiﬁcation ≥2, and 68.9% patients had Mini Nutritional As-
sessment Short Form (MNA-SF) score ≤ 11. Correlation be-
tween skeletal muscle mass and each index was BMI
(r = 0.51, p < 0.01), Geriatric Nutritional Risk Index (GNRI;
r = 0.42, p = 0.04), MNA-SF(r = 0.28, p = 0.15) and serum al-
bumin value (Alb; r = 0.06, p = 0.77). The logistic regression
analysis indicated that the odds ratio, in BMI, was 0.66 (95%
conﬁdence interval; 0.48–0.85, p < 0.01) and area under the
receiver operating characteristic curve (AUC) was 0.76, sug-
gesting that BMI might be independent predictors for muscle
mass wasting.
Conclusions: Though the congested state of CHF outpatients,
it was suggested the usefulness of body weight for predicting
skeletal muscle mass.
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Comparison of height-, weight-, body surface
area-, and body mass index-adjusted muscle mass
indices for prediction of physical performance in
Korean hemodialysis patients
Jun Chul Kim1, Jun Young Do2, Kyu Hyang Cho2 & Seok Hui Kang2
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Introduction: Our study aims to evaluate the association
between height-, weight-, body surface area- (BSA), or body
mass index- (BMI) adjusted muscle mass indices and physical
performance in Korean hemodialysis patients.
Methods: Patients were included if they were on HD for
≥6 months (n = 84). Each patient’s appendicular skeletal mus-
cle mass (ASM, the sum of both upper extremities and lower
extremities) was measured by dual X-ray absorptiometry.
ASM was adjusted to body weight (BW, kg), height2 (Ht2,
m2), BSA (m2), or BMI (kg/m2). Low muscle mass was deﬁned
as muscle mass of 2SD below sex-speciﬁc means of healthy
young adults (20–29 years). Each participant performed a gait
speed test (GS), a hand grip strength (HGS) test, a sit-to-stand
test performed 5 times (5STS), a sit-to-stand for 30 second
test (STS30), a 6-minute walk test (6MWT), a timed up and
go test (TUG), and an average steps count (AS).
Results: In men, Pearson’s correlation coefﬁcients for GS,
5STS, STS30, 6-MWT, TUG, and AS were highest in ASM/Ht2.
Results from partial correlation or linear regression analyses
displayed similar trends to those derived from Pearson’s
correlation analyses. ASM/Ht2 had the greatest negative
predictive value for low GS. Patients with low muscle mass
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had signiﬁcantly lower physical performances (HGS, 5STS,
6MWT, TUG) than those with normal muscle mass by
ASM/Ht2. In women, the association between muscle mass
indices and physical performance was lack.
Conclusions: Height adjusted muscle mass may be the
best for predicting physical performance in men on
hemodialysis.
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Prevalence and progression of limb contractures
amongst long-term care residents: data from a
5-year observational study
Kuen Lam1, Joseph Kwan2, Chi Wai Kwan3 & Iris Chi4
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Background: Limb contractures are associated with poor
outcomes and quality of life in long-term care facility (LTCF)
residents. We aimed to study the prevalence and progression
of limb contractures over a 5-year follow-up period amongst
LTCF residents in Hong Kong.
Methods: From the Hong Kong Longitudinal Study on LTCF
Residents between 2005 and 2015, we analyzed the data
for residents who had assessment from the 1st up to 5th year
since admission. Trained nurses, social workers and therapists
utilized the Minimum Data Set Resident Assessment
Instrument (MDS-RAI 2.0) in 10 residential LTCFs. Limb
contractures were deﬁned as functional limitation in the
range of motion involving the upper or lower limbs. Primary
outcomes were annual prevalence and time trend of limb
contractures over 5 years.
Results: We analyzed the data for 1,736 older residents
(611 men, mean age 83.2 years). During the ﬁrst 5 years
since admission, the annual prevalence of upper limb con-
tractures increased from 30% to 36%, and lower limb con-
tractures increased from 41% to 56%. Time trends were
as follows: the proportion of residents who had no contrac-
tures on admission remained contracture-free after 5 years
was 59.7% for upper limbs and 39.8% for lower limbs,
while the proportion of residents who had developed new
contractures after 5 years was 15.1% for upper limbs and
26.5% for lower limbs. The proportion of residents who
had unilateral contractures on admission which had im-
proved after 5 years was 4.1% for both upper limbs and
lower limbs, and the proportion of residents who had ei-
ther unilateral or bilateral contractures on admission which
did not change after 5 years was 21.2% in upper limbs and
29.6% in lower limbs.
Conclusions: Joint contractures are highly prevalent amongst
residents admitted to the LTCF, and many residents develop
new or worse contractures during the ﬁrst 5 years of their
admission. Further studies are needed to identify the poten-
tial strategies to prevent functional decline in this vulnerable
group.
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Introduction: Frailty is a state of vulnerability to stressors
resulting in higher morbidity, mortality and healthcare
utilization in older adults. Multiple instruments are used to
measure frailty; most are time-consuming. The Care Assess-
ment Need (CAN) score is automatically generated from elec-
tronic health record data using a statistical model; it is
expressed as a percentile, ranging from 0 (lowest risk) to 99
(highest risk). The CAN score is a known predictor of high risk
for hospitalization and mortality at 90 days and one year. The
purpose of the study was to validate the CAN score as a screen-
ing tool for frailty among older adults in clinical practice.
Methods: This cross-sectional study compared the CAN score
with a reference standard. The reference standard, a 40-item
Frailty Index, was generated using retrospective data
collected during a Comprehensive Geriatric Assessment
(CGA) performed by geriatric medicine physicians. To assess
the ability of the CAN score to correctly identify frailty, we
calculated the sensitivity, speciﬁcity, positive predictive value
(PPV), negative predictive value (NPV) and diagnostic
accuracy (assessed by the area under the receiver operating
characteristic (ROC) curve).
Results: 184 patients over age 65 were included in the study:
98% male, 61% White, 80% non-Hispanic. Our CGA-based
Frailty Index deﬁned 13% as robust, 55% as prefrail and
32% as frail. For the frail, statistical analysis demonstrated
that a threshold CAN score of 52.5 provides sensitivity,
speciﬁcity, PPV and NPV of 91%, 40%, 27%, and 95%, respec-
tively. Area under the ROC curve was 0.749 (SD = 0.038,
p = 0.0005, 95% CI = 0.674–0.823).
Conclusions: CAN score is a potential screening tool for frailty
among older adults as it is generated automatically and
provides acceptable diagnostic accuracy. Hence, CAN score
may offer useful information to Primary Care Providers for
early clinical interventions.
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community-dwellers: results from the Milan-EXPO
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Liang-Kung Chen2,3, Li-Ning Peng2,3, Riccardo Calvani1, Anna Picca1,
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Background: Age- and gender-speciﬁc curves of muscle mass
and strength, using data from large samples of community-
dweller people, need to be better established and so are pos-
sible differences among ethnic groups. The aims of the pres-
ent study were to analyze age- and gender-speciﬁc changes in
measures of muscle and strength among community-living
persons and to identify differences between Caucasian and
Asiatic individuals.
Methods: The Italian survey (“Longevity Check-up”), con-
ducted during EXPO 2015 in Milan, consisted of a population
assessment aimed at evaluating the prevalence of speciﬁc
health metrics in persons outside of a conventional research
setting (n = 1924), with a special focus on muscle mass and
strength. The Taiwanese survey used the ﬁrst-wave sampling
from the I-Lan Longitudinal Aging Study (ILAS) collected from
August 2011 to August 2013 (n = 1839). Muscle mass was es-
timated by using calf circumference of the dominant side.
Muscle strength was determined through handgrip strength
testing.
Results: The mean age of the 1924 Italian participants was
62.5±8.3 years, of whom 1031 (53.6%) were women. Simi-
larly, the mean age of the Taiwanese sample was
63.9±9.3 years with 966 (52.5%) women. Overall, cross-
sectional observations suggest that calf circumference de-
cline with age in both genders. The calf circumference was
signiﬁcantly greater among Italian participants compared
with Taiwanese people in all age groups. A similar effect of
age was observed for muscle strength. As for calf circumfer-
ence, muscle strength was signiﬁcantly greater among Italian
persons relative to Taiwanese participants.
Conclusions: Muscle mass and strength curves for Caucasian
and Asiatic people may be used to derive reference values for
subsequent use in research and clinical settings. In particular,
the analyses of trajectories of muscle parameters may help
identify cutoffs for estimating risk of adverse events as well
as the optimal timing for intervening.
2-15
Associations between lean mass, strength and
mortality in the elderly: the EXERNET study
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Introduction: Negative changes in lean mass (LM) and muscle
strength (MS) have been shown to occur across the aging
process1. These changes are linked with morbidity and have
a negative effect on physical ability and independence in
older adults and also increase risk of falls. However, the link
between LM and mortality in the elderly is not clear.
Purpose: The aim of this study was to investigate the rela-
tionship between LM, MS and mortality in the elderly.
Methods: In this prospective longitudinal study a total of 223
seniors (64 men and 159 women) (age 73 ± 5.8 years) were
evaluated in Zaragoza-Aragon (Spain) during 2008, as part
of the elderly EXERNETmulti-centre study2. Whole body mus-
cle mass was measured with dual energy X-ray absorptiome-
try (kg). MS of upper and lower extremities was assessed
using two tests from the “Senior Fitness Test”: “Chair Stand
Test” and “Arm Curl Test”. Access to mortality data was ob-
tained from the Spanish Statistical Ofﬁce (INE) register in
2017. The Mann–Whitney U test was used to compare differ-
ences between groups (deceased vs alive).
Results: There were 19 deaths among the original partici-
pants. The mean total LM was 55.5 kg in men and 39.9 kg
in women. No association was found between LM and mor-
tality. However, MS in lower and upper body were statistically
lower (p < 0.05) in the deceased group (12.7 ± 4.4 and
13.3 ± 4.9, respectively) compared with those still alive
(14.3 ± 3.1 and 16.2 ± 3.8, respectively). These differences
were maintained after adjustment for daily sitting time.
Conclusions: Lean mass is not associated with mortality in el-
derly people. However, there is an inverse association be-
tween muscular strength and mortality suggesting that
functionally rather that the size of the muscle seems related
to mortality.
Acknowledgements: The elderly EXERNET multi-centre study
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Introduction: The sarcopenia is a syndrome characterized by
the progressive and generalized loss of skeletal muscle mass
and strength. The aim of this study was to evaluate the
prevalence of sarcopenia in a convenience sample of elderly
women submitted to bone densitometry and living in the
urban and rural area in the South of Brazil.
Methods: This is a cross-sectional study with elderly (over
60 years old) who performed bone densitometry. Sarcopenia
was deﬁned according to the criteria recommended by the
European Working Group on Sarcopenia in Older People
(EWGSOP): muscle mass was evaluated through the
Dual-energy X-Ray absorptiometry, muscle strength was
measured by using the handgrip strength, and muscular
performance was assessed through the 4 m gait speed test.
Sociodemographic data was evaluated through a speciﬁc
questionnaire.
Results: A total of 205 elderly women with a mean age of
67.3 ± 5.9 years were included in the study, the majority living
in rural areas (65.9%), aged 60–69 years (66.3%), Caucasian
(71.2%), with 4 to 8 years of schooling (47.3%), with partner
(61.5%) and retired (92.2%). The prevalence of sarcopenia
was 2.4% of the total sample (5 subjects), with a signiﬁcant
higher prevalence in the urban area (5.1%) when compared
to the rural area (0.7%), (p = 0.047). There was a signiﬁcant
association with the living area (urban × rural) and schooling
(p < 0.001), occupation (p = 0.010), socioeconomic status
(p = 0.001) and smoking (p = 0.006). The environment in
which the elderly women lived was independently associated
with sarcopenia OR = 9.561 (95%CI: 1.021–89.523)
(p = 0.048). The prevalence of sarcopenia was signiﬁcantly
higher in the urban elderly than in rural women. After
multivariate analysis, the residence was still independently
associated with sarcopenia.
Conclusions: In a sample of elderly women of the south region
of Brazil, 2.4% of the total sample presented sarcopenia.
Residence was independently associated with sarcopenia,
showing a greater chance of sarcopenia in the urban elderly.
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Introduction: Anemia is common in old age, and the preva-
lence increases with aging. It is known that the physical
performance declines with aging, and anemia is associated
with the frailty, but whether gender factor affects functional
decline is still controversial. The aim of this study is to ﬁnd
out the different associations of anemia with muscle strength
and physical performance between old-men and old-women.
Methods: We recruited baseline data from a population-
based cohort study on old-aged Koreans, known as ‘the
Korean Longitudinal Study on Health and Aging’ (KLoSHA). A
total of 542 people aged 65 years and above were included.
Data regarding age, gender, hemoglobin level, body weight,
height, body mass index (BMI), physical activity score, muscle
strength, muscle mass, pain related dysfunction (WOMAC-K),
depressive symptoms (GDS-K), global cognition (MMSE),
comorbid conditions and physical performance measure with
short physical performance battery (SPPB) were included and
analyzed.
Results: Skeletal muscle mass, strength and SPPB were
highly associated with anemia. SPPB of old-women with ane-
mia was lower than those without anemia (7.76 ± 2.47 vs
8.93 ± 2.53), but there’s no deﬁnite difference in strength
whether anemia presents or not (43.1 ± 19.5 Nm vs
48.4 ± 16.9 Nm). In contrast, old men with anemia and with-
out anemia showed similar SPPB (9.44 ± 2.19 vs 9.95 ± 2.26),
but the strength of men with anemia was signiﬁcantly lower
than that without anemia (62.4 ± 22.8 Nm vs
79.8 ± 27.1 Nm). In the multivariate linear regression analysis,
SPPB of both men and women with anemia related with only
WOMAC-K, while one without anemia has multiple related
variables with such as MMSE, Age and physical activity
other than WOMAC-K.
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Conclusions: We found out that anemia associated differ-
ently with muscle strength and physical performance be-
tween old men and old women. Additionally, managing pain
along with treatment of anemia in both old men and women
may be key source in developing model for promoting better
health.
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Introduction: Sarcopenia is a geriatric syndrome that in-
creases the risk of falls and severe fractures, physical depen-
dence and death. The relationship between obesity, muscle
and its function, as well as the effect on its metabolism are
important to understand sarcopenia because the body fat af-
fects the metabolism and muscle. In Mexico over 70% of the
adult population is overweight. The objective of this study is
to evaluate the association between sarcopenia, obesity and
metabolic syndrome.
Methods: Observational, analytical, prospective study of
cases and controls incident in 2016 and 2017. Sampling is
done for convenience in subjects older than 60 years of the
Geriatric Care Clinic (ISEM). Clinical records were reviewed
to obtain biochemical and sociodemographic data; diagnostic
tests for Sarcopenia (percentage of bioelectrical impedance
muscle mass, hand grip and short battery of physical tests,
SPPB) were performed.
Data were analyzed using non-conditional multiple logistic re-
gression models to obtain the odds ratios (OR), (conﬁdence
intervals calculated at 95%).
Results: 97 patients were recruited, of which 62 were cases
and 35 controls. The higher weight was found in controls
(72.9 kg DE +/ 11.4 vs. to 68.8 kg DE +/ 12.2). However,
mean body mass index (BMI) and fat percentage were
higher in cases than in controls. In cases with severe
sarcopenia, it was observed more fat than muscle (mean
of 8.6 kg).
There was a cut of the total patients (35 cases/35 controls)
to obtain preliminary results, founding that for each unit that
increase the fat percentage, the risk to sarcopenia increase
30%. The rest of the 27 controls will be added to the study
in August.
Conclusions: Excess body fat reduces the quality of muscle
function, especially strength, probably by fat inﬁltration in
the muscle. However sarcorpenia in elderly is related with
overweight and desnutrition.
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Introduction: Sarcopenia is considered a geriatric syndrome.
Currently, there is no agreed deﬁnition of sarcopenia, so it
is still a challenge to establish the actual prevalence of
sarcopenia in the elderly in different races/ethnicities, espe-
cially in elderly quilombolas.
Objective: Identify sarcopenia in the elderly living in maroon
settlement using the algorithm proposed by the European
Working Group on Sarcopenia in Older People.
Patients and Methods: This is a cross-sectional study with
70 participants (SD 65.58 ± 6.67 years) men and women
living in the Quilombo communities called Malhadinha
and Córrego Fundo, located in the city of Brejinho
Nazaré-Tocantins-Brazil. For the diagnosis of sarcopenia
we used the recommendations proposed by the European
Working Group on Sarcopenia in Older People. Muscle
mass was analyzed by the Dual-energy X-ray absorptiome-
try and the handgrip strength by hand dynamometer. The
physical performance was analyzed using the walking
speed test. We used the SF-36 questionnaire to analyze
the quality of life.
Results: We identiﬁed a prevalence of sarcopenia of 10% in
the sample. The sarcopenic individuals were classiﬁed as
low handgrip strength. All individuals in the sample had
adequate physical performance.
Conclusions: We conclude that the identiﬁcation of the
prevalence of sarcopenia in the elderly maroons was high.
The algorithm proposed by the European Working Group on
Sarcopenia in Older People had clinical applicability in the
study population.
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Association between sarcopenia and quality of life
in quilombola elderly in Brazil
Luiz Sinésio Silva Neto, Margô Gomes de Oliveira Karnikowski,
Neila Barbosa Osório, Leonardo Costa Pereira,
Liana Barbaresco Gomide & João Paulo Chieregato Matheus
University of Federal Tocantins, Palmas, Brazil
Sarcopenia has a direct and indirect impact on the quality of
life of elderly populations of different races and ethnicities.
No study has yet analyzed these variables in populations of
elderly people of the “quilombola” ethnic group.
Objective: We aimed to verify the association between
sarcopenia and quality of life in quilombola elderly using
the Baumgartner and the EWGSOP criteria.
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Methods: This was a cross-sectional study of 70 male and
female participants. Quality of life was evaluated using the
multidimensional SF-36 of the Medical Outcomes Study.
Sarcopenia was diagnosed according to the Baumgartner
cutoff for appendicular skeletal muscle mass and the criteria
recommended by the EWGSOP. Muscle mass and fat mass
percentages were analyzed by DXA, while handgrip strength
(HGS) was evaluated using a hand-held dynamometer. Physi-
cal performance was assessed through a gait speed test.
Results: The prevalence of sarcopenia was 15% according to
the Baumgartner cutoff and 10% according to EWGSOP
criteria. Quilombola elderly classiﬁed as physically active or
very active were at least six times less likely to develop
sarcopenia than those classiﬁed as irregularly active or seden-
tary. HGS was negatively associated with a diagnosis of
sarcopenia according to both sets of criteria. Subjects with
sarcopenia reported lower scores than those without the
condition on the physical role functioning and bodily pain
domains of the SF-36.
Conclusion: In this sample of quilombola elderly, quality of
life was negatively associated with sarcopenia, regardless of
the classiﬁcation criteria used. Additionally, the results
showed that diagnostic criteria for sarcopenia should include
reductions in lean mass in addition to measures of function-
ing and physical performance because some subjects showed
the former symptom without any alteration of the latter two
variables.
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Background and Aims: Cachexia occurs in cats with naturally
occurring heart failure, kidney disease, cancer, and other
chronic diseases. Muscle loss can be assessed subjectively
using a muscle condition score, but is difﬁcult to quantify in
cats as CT and DEXA require general anesthesia. Therefore,
non-invasive methods for quantifying muscle loss are
needed. We previously quantiﬁed an ultrasound technique
of muscle normalized with vertebral size in dogs. The goal
of this study was to assess this technique in cats.
Methods: Thirty healthy pet cats between 1 and 6 years of
age were enrolled in the study. All cats were neutered and
in ideal body condition. Transverse ultrasound images of
epaxial muscle height (mean, 3 measurements each side)
were obtained at the 13th thoracic vertebra using a
12–5 Mhz linear transducer. Fourth thoracic vertebral (T4)
length was measured from a thoracic radiograph and the
ratio of the epaxial muscle height to T4 length was calculated
and compared to body weight using the Pearson correlation
coefﬁcient.
Results: One cat was identiﬁed to have a cardiac murmur, so
29 cats completed the study. Mean body weight was
5.05 ± 1.40 kg (range, 2.23–8.05 kg). Mean epaxial muscle
height = 1.27 ± 0.13 cm which was signiﬁcantly correlated
with body weight (r = 0.65; P < 0.001). The ratio of epaxial
muscle height to T4 length was not correlated with body
weight (r = 0.18; P = 0.34). The range of values for the ratio
of epaxial muscle height to T4 length in healthy pet cats was
0.93–01.55.
Conclusions: Since the ratio of epaxial muscle height to T4
was independent of body weight, it appears to be a good
way of normalizing muscle size across cats of different body
weights. Studies assessing this method in cats of different
levels of adiposity and in those with cachexia and sarcopenia
are warranted.
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Background and Aims: Sarcopenia has been documented in
aging dogs by CT, DEXA, and ultrasound. In addition to reduc-
tions in muscle mass, qualitative changes in muscle also occur
during aging in humans, but changes in muscle density have
not been documented in dogs. Therefore, the objective of
this study was to measure muscle CT attenuation of healthy
young and old dogs.
Methods: Healthy young (1–5 years old) and old (>8 years
old) pet Labrador Retrievers of optimal body weight were el-
igible for the study. A CT was performed under mild sedation,
and the mean muscle attenuation of the left epaxial
(paravertebral) muscles over the 13th thoracic vertebral body
was measured. To determine the mean values, multiple free-
hand regions of interest were drawn on the axial images and
histogram analysis was performed.
Results: Nine young dogs (5 female, 4 male; mean
age = 2 ± 1 years) and 11 old dogs (9 female, 2 male; mean
age = 9 ± 1 years) were enrolled. Body weight was not differ-
ent between groups [mean weight for all dogs = 30.7 ± 5.1 kg).
Mean CT attenuation of the epaxial muscles was signiﬁcantly
lower in old compared to young dogs (P = 0.005). There was a
signiﬁcant negative correlation between CT attenuation and
age (r = 0.74, P < 0.001).
Conclusions: Qualitative and quantitative muscle changes oc-
cur in aging in both dogs and humans. Additional studies
evaluating functional muscle changes in this canine model
are warranted, as are studies to evaluate potential beneﬁts
of exercise and nutritional modiﬁcations.
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Introduction: Hip fracture and sarcopenia are critical causes
of mortality and loss of function in elderly patients, and com-
prehensive rehabilitation is important for preventing disabil-
ity and maintaining health. This study evaluates the effects
of Fragility Fracture Integrated Rehabilitation Management
(FIRM) on functional outcome in sarcopenic and non-
sarcopenic patients in inpatient care following hip fracture
surgery.
Methods: Patients over 65 years who underwent hip surgery
for fragility hip fracture at two university hospitals in Korea
from July 2016 to May 2017 were entered the prospective
study. After surgery, all patients received FIRM of advanced
physical, occupational therapy and education for 2 weeks.
The patients were divided into two groups according to the
presence of sarcopenia based on Asian Working Group for
Sarcopenia (AWGS) criteria. The demographic and functional
characteristics were analyzed before and after FIRM to evalu-
ate the short-term outcome during inpatient care.
Results: Overall, 56 patients were eligible for the study and
patients satisﬁed the criteria of sarcopenia were 18 (32.1%).
There were no signiﬁcant differences in premorbid ambula-
tory status between the groups. Berg Balance Scale (BBS),
Modiﬁed Rivermead Mobility Index (MRMI) and Korean
Instrumental Activities of Daily Living were signiﬁcantly differ-
ent between the groups at baseline. KOVAL, MRMI, BBS, Mini
Mental State Examination and Modiﬁed Barthel Index were
signiﬁcantly improved, and there were no differences in the
change between in the both groups after FIRM, but func-
tional ambulatory category was signiﬁcantly more improved
in non-sarcopenic group.
Conclusions: The functional level of hip fracture patients with
sarcopenia was lower than that of the patients those without
sarcopenia. FIRM may be effective for short-term functional
recovery in elderly patients who suffered fragility hip fracture
with or without sarcopenia.
2-24
Appendicular skeletal muscle mass index adjusted
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Introduction: Severe burns are inevitably accompanied by a
hypermetabolic and hypercatabolic response. These result
in a loss of skeletal muscle mass, bone mineral mass and
fat mass. Appropriate appendicular skeletal muscle mass indi-
ces (ASMIs) is needed in burn patients for proper nutritional
intervention. This paper aims to compare diverse ASMIs and
to suggest more suitable index for burn survivors.
Methods: We conducted retrospective study with 162 burn
patients. Appendicular skeletal muscle mass (ASM) mea-
sured by dual-energy X-ray absorptiometry was divided by
height squared (kg/m2), weight (Wt)(%) and body mass in-
dex (BMI) to obtain ASMIs. Sarcopenia was deﬁned as
the ASMI of 1 SD below the sex-speciﬁc mean for young
Korean adults.
Results: The mean age of patients was 31.17 ± 5.08 years old.
ASM loss was dependent on the burn percentage of total body
surface (β = 0.23, P = 0.001) with adjusting for age, sex,
height (Ht), weight(Wt) and BMI. ASM/Ht2 in the group of
≥20% burn surface area (BSA) was signiﬁcantly lower than in
<20% BSA group (P = 0.005), while ASM/Wt(%) and
ASM/BMI were not different between two groups (P = 0.14,
P = 0.36). Independent association between BSA and
sarcopenia was showed in multiple logistic regression analysis
after adjustment for sex, age, Ht,Wt and BMI in ≥10% BSA (ad-
justed ORs (AORs) = 1.23 [95% CI 0.42–3.57]), ≥20% BSA
(AORs = 1.41 [0.53–3.76]) and ≥30% BSA group (AORs = 3.47
[1.26–9.06]).
Conclusions: This studydemonstratesASM/Ht2 is relatedmore
closely to burn injury. The burn groups were at higher risk for
sarcopenia depending on the size of BSA, especially ≥30% BSA.
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Handgrip strength and falls among
community-dwelling older adults
Beatriz Fernandes1,3, Alejandro Mercant-Galán2,3 & Teresa Tomás1,3
1Escola Superior de Tecnologia da Saúde de Lisboa – Instituto Politécnico de Lisboa,
Portugal, 2Universidad de Jáen, 32GHRG - Gerontology and Geriatric Health
Research Group
Introduction: Falls prevention in older adults includes early
screening for fall risk; risk factor assessment and specialized
intervention. Several variables such as balance, gait speed
and mobility have been used to assess the risk of falling.
More recently, handgrip strength has also been identiﬁed
for this purpose. The aim of this study was to investigate
the relationship between handgrip strength and balance, gait
speed and mobility in community-dwelling older adults.
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Methods: A sample of 45 community-dwelling older adults
(16 M; 30F), aged 76.9 ± 8.6 was enrolled in the study.
Inclusion criteria were age 65 and over; ability to walk auton-
omously (with or without assistive devices) and to understand
and perform the tests. Participants were excluded if they had
limitations interfering with the performance of tests and med-
ical contraindications for exercise. Balance was assessed with
the Berg Balance Scale (BBS), mobility with the 8-foot-up-and-
go-test, gait speed with the 4 meter walk test and handgrip
strength with the hydraulic dynamometer Jamar®.
A Spearman’s correlation was run to investigate whether
there were associations between variables.
Results: A strong positive correlation was found between
handgrip strength and balance (rs = 0.645, p = 0.000) and
handgrip strength and gait speed (rs = 0.593, p = 0.000).
Results from the 8-foot-up-and-go-test (7.8 ± 3.4 s) did not
revealed increased risk of falling; however, there was a strong
negative correlation between mobility and balance
(rs = 0.758, p = 0.000), gait speed (rs = 0.681, p = 0.000)
and handgrip strength (rs = 0.632, p = 0.000).
Conclusions: For our participants as handgrip strength
increases gait speed and balance also increase. Decreases in
balance, gait speed and handgrip strength are related to
mobility decline which is related to an increased risk of
falling. Our results point-out handgrip strength as a valuable
measure to identify the risk of falling. Further studies with




High risk of fall, fracture and rapid bone
microstructure deterioration in men with poor
physical performance – the prospective STRAMBO
study
Pawel Szulc, Philippe Wagner & Roland Chapurlat
INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France
Introduction: Poor physical leg capacity is associated with
poor bone microarchitecture (Blaizot, Osteopor Int, 2012)
and may increase the risk of fall and fracture. We assessed
the association of physical performance of lower limbs with
subsequent changes in distal tibia bone microarchitecture
and the risk of fall and fracture in older men.
Methods: A cohort of 817 men aged 60–87 was followed up
prospectively for 8 yrs. At baseline, physical performance
was assessed using a score based on the clinical tests (chair
tests, standing with feet in side by side position with eyes
open or closed, 10-step tandem walk forward and back-
ward). The score accounted for the ability and time needed
to perform each test (Szulc, JBMR, 2009). Every year, men
replied to questionnaires covering incident falls and frac-
tures. Distal tibia bone microarchitecture was assessed by
high-resolution pQCT (XtremeCT Scanco) at baseline and af-
ter 4 and 8 yrs. Statistical analyses were adjusted for rele-
vant confounders.
Results: Compared with men having good physical perfor-
mance (best quartile), men with poor performance had
greater decrease in cortical thickness (2.05 ± 0.19 vs.
0.82 ± 0.11%/yr, p < 0.001) and cortical density
(0.79 ± 0.06 vs. –0.42 ± 0.03%/year, p < 0.001). Poor phys-
ical performance was associated with greater decrease in
central trabecular density and trabecular thickness
(p < 0.001). Compared with men having good physical per-
formance, men with poor physical performance had higher
risk of recurrent falls (≥1 fall/year, n = 65, HR = 2.3, 95%CI:
1.1–5.1, p < 0.05) and of falls requiring hospitalization
(n = 71, HR = 3.9, 95%CI: 1.7–9.0, p < 0.005). Men having
poor physical performance had higher risk of non-spine frac-
ture (n = 61, HR = 2.9, 95%CI: 1.2–7.1, p < 0.05).
Conclusions: In older home-dwelling men, poor physical per-
formance of the lower limbs was associated with greater de-
cline in distal tibia bone microarchitecture, higher risk of fall
and higher risk of non-spine fracture.
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Utility of phase angle as marker of low muscle
mass, impaired muscle function and muscle quality
in colorectal cancer patients
Nilian Carla Silva Souza1,2, Maria Cristina Gonzalez3,
Renata Brum Martucci1,2, Viviane Dias Rodigues2,
Nivaldo Barroso de Pinho2 & Carla Maria Avesani1
1Rio de Janeiro State University – Rio de Janeiro, Brazil, 2Brazilian National Cancer
Institute – Rio de Janeiro, Brazil, 3Catholic University of Pelotas – Pelotas, Brazil
Introduction: Cancer is a catabolic disease that leads to mus-
cle loss, impaired muscle function and quality and, ultimately,
to sarcopenia. Phase angle (PA) is a well-known marker of
muscle mass, but its applicability as a marker of impaired
muscle function and muscle quality in oncologic patients
has not yet been investigated. Therefore, we aimed to inves-
tigate the association between PA with measurements of
skeletal muscle mass, muscle function and muscle quality in
colorectal cancer patients.
Methods: This study included 194 colorectal cancer patients
(age: 60 ± 11 years; 58% men). The skeletal muscle mass
(SMM) and skeletal muscle attenuation were assessed by
computed tomography (CT) at the third lumbar vertebra.
Muscle quality was assessed by skeletal muscle gauge
(SMG) obtained as SMM × skeletal muscle attenuation,
where high SMG indicates good muscle quality. Muscle func-
tion was assessed by handgrip strength (HGS) and gait speed
(GS). The association between PA and the variables studied
were assessed by Spearman/Pearson’s test. In order to inves-
tigate the association between SMM, SMG, HGS and GS with
PA, after adjustments for confounding variables (sex, age and
BMI), linear regression models were constructed.
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Results: Most patients (62%) were overweight and obese
(BMI ≥ 25 kg/m2). The PA was signiﬁcantly associated with
BMI (r = 0.36), with SMM (r = 0.66), SMG (r = 0.68), HGS
(r = 0.53) and with GS (r = 0.32). In the regression models,
the PA remained as a signiﬁcant and independent predictor
(p < 0.05) of SMM (r2 = 0.75), SMG (r2 = 0.70), HGS
(r2 = 0.62) and GS (r2 = 0.16).
Conclusions: PA was independently associated with skeletal
muscle mass, muscle function and muscle quality in colorec-
tal cancer patients. These results suggest that PA is a marker
muscle mass, function and quality in this subset of patients.
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Low muscle radiodensity is associated with
pre-existing comorbidities in early stage colorectal
cancer patients
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Introduction: Comorbidities and computerized tomography
(CT)-measured muscle abnormalities are both common in
cancer patients and evident in diseases such as diabetes
and obesity. This is the ﬁrst study to examine the association
between comorbidities and muscle abnormalities in patients
with colorectal cancer (CRC).
Methods: This cross-sectional study included 3051 patients
with stage I-III CRC. Muscle abnormalities were deﬁned as low
skeletal muscle mass index (SMI) or low skeletal muscle
radiodensity (SMD) quantiﬁed using diagnostic CT images.
Charlson comorbidities were ascertained. Chi-square
tests were used to compare the prevalence of comorbidities
by the presence/absence of each muscle abnormality. Logistic
regression analyses were performed to evaluate which comor-
bidities predicted muscle abnormalities adjusting for age, sex,
body mass index, weight change, stage, race/ethnicity, and
smoking.
Results: Mean age was 63 years; 50% of patients were
male. The prevalence of low SMI and low SMD were
43.1% and 30.2%, respectively. Comorbidities examined
were more prevalent in patients with low SMD than in
those with normal SMD (58.6% vs. 34.4%, p < 0.001), and
most remained signiﬁcant predictors of low SMD, including
myocardial infarction (odds ratio [OR] = 1.82, p = 0.017),
congestive heart failure (OR = 3.34, p < 0.001), peripheral
vascular disease (OR = 2.20, p < 0.001), diabetes with or
without complications (OR = 1.61, p = 0.008; OR = 1.47,
p = 0.003, respectively) and renal disease (OR = 2.23,
p < 0.001). No comorbidities were associated with low
SMI except for diabetes with complication which was asso-
ciated with a lower likelihood of low SMI (OR = 0.64,
p = 0.007).
Conclusions: Prevalence of muscle abnormalities was high in
early stage CRC. Pre-existing comorbidities were most
commonly associated with low SMD, suggestive of a potential
shared mechanism between fat inﬁltration into muscle and
each of these comorbidities.
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Relation between cachexia, patient-generated
Subjective Global Assessment and hand grip
strength in patients with advanced cancer in
palliative care unit in Brazil
Nathália Masiero Cavalcanti de Albuquerque1,2, Juliana Rodrigues1,
Emanuelly Varea Maria Wiegert1, Larissa Calixto-Lima1,
Livia Costa de Oliveira1, Mayane Marinho Esteves Pereira1 &
Wilza Arantes Ferreira Peres2
1Palliative Care Unit, National Cancer Institute José Alencar Gomes da Silva (INCA),
Rio de Janeiro, RJ, Brazil, 2Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro,
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Cachexia is frequently observed in advanced cancer patients,
and it is associated with muscle mass loss and maybe
strength. Therefore, we aimed to correlate cancer cachexia
with Subjective Global Assessment Short Form (PG-SGA SF)
and hand grip strength (HGS) in patients with palliative care.
This is an observational study comprising 525 patients
attended for the ﬁrst time, presenting different locations of
tumor. Cachexia was deﬁned by Fearon et al. (2011) criteria:
1) weight loss >2% in 6 months (A) + body mass index (BMI)
<20 kg/m2; or 2) A + Mid-upper arm muscle area (low mus-
cle mass) <32 cm2 for male and <18 cm2 for female. Low
muscle strength was characterized by HGS <20 kg for female
and <30 kg for male. Associations between clinical and nutri-
tional parameters with cachexia were tested by univariate
and multivariate regressions.
Patients presented a median age of 63 (54;72, IQR) years,
57.5% were female. Half of then presented Karnofsky Per-
formance Status (KPS) < 50% and 60% had albumin
<3.5 g/dl and CRP ≥10 mg/dl. Low BMI and cachexia was
observed in 37% and 61% of the patients, respectively.
Reduced HGS in 79% of women and 74% of men. Patients
with cachexia had worst nutritional status by PG-SGA SF
and lower HGS compared with those without (Figure 1). In
the univariate regression gastrintestinal tract tumor, CRP
and KPS <50%, albumin (<3.5 g/dL), HGS and PG-SGA SF
(≥9) presented an elevated Odds Ratio (OR) for cachexia
(p < 0.02). In the multivariate analysis PG-SGA (≥9) pre-
sented the highest OR (2.43 [CI 95%: 1.52; 3.90]) against
gender, GI tract tumor, and HGS. In conclusion, nutritional
risk by PG-SGA SF, low muscle strength and GI tract tumor,
but not KPS were associated with an increased odds to
present cachexia.
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Association of sarcopenia and survival with
different diagnostic methods in patients with
advanced cancer in Palliative Care Unit in Brazil
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Wilza Arantes Ferreira Peres2
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Sarcopenia has been evaluated by different methods in
patients with advanced cancer. Thus, the objective of this
study is to describe the association of sarcopenia with
survival by different methods in patients with advanced
cancer in palliative care.
This is an observational and prospective study including
342 patients [age: 63 (55; 72, IQR) years; 55.8% female;
65.5% with KPS ≥50%]. Survival time was established by the
time of inclusion until 90 days of follow-up. Sarcopenia was
deﬁne by patients with reduced muscle mass and strength,
where low muscle mass: 1) Mid-upper arm muscle area
(MUAMA) <32 cm2 for male and <18 cm2 for female; 2) Calf
circumference (CC) < 31 cm for both genders; and 3)
Appendicular skeletal muscle mass (ASM) described by
Baumgartner (1998) <7.26 kg/m2 for male and <5.45 kg/
m2 for female. Low muscle strength was deﬁned by hand grip
strength (HGS) <30 kg for male and <20 kg for female.
Kaplan–Meier was used to calculate survival and Log-rank
test to evaluate differences between then. The association
between sarcopenia and survival was evaluated by hazard
ratio (HR) and 95% conﬁdence interval (CI) in a crude
univariate analysis and multivariate COX regression adjusted
for co-founders, including parameters with p-value <0.02 in
the previous analysis.
Prevalence of sarcopenia was 86%, 32.2% and 36.8%, for
ASM, MUAMA and CC, respectively. Patients with sarcopenia
showed shorter survival for those for all three methods. In
the univariate analysis, patients with sarcopenia had a signif-
icant worse survival for ASM (HR [95%CI]: 1.78 [1.29; 2.46]),
MUAMA (1.92 [1.42; 2.60]) and CC (1.89 [1.41; 2.53]). In
the Multivariate analysis, MUAMA (1.55 [1.11; 2.15]) and
CC (1.50 [1.08; 2.07]) remained signiﬁcant. In conclusion,
our data suggest that patients with sarcopenia have reduced
survival, especially, when MUAMA and was used as criteria
method.
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Grip strength as an important part of the
diagnostic criteria for sarcopenia in advanced
cancer
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Background: Patients with advanced cancer are at risk of
developing sarcopenia that can impede a positive outcome
of chemotherapy treatment. In relation to aging, classiﬁca-
tion of sarcopenia should include assessment of both muscle
mass and muscle strength; however, in cancer, classiﬁcation is
usually based on assessment of muscle mass alone. The
Figure 1 Box-plots of abridged Patient-Generated Subjective Global Assessment (aPG-SGA) and Handgrip Strength compared to cancer cachexia in
patients treated at a Palliative Care Unit in the city of Rio de Janeiro- Brazil (n = 525).1122
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addition of muscle strength assessment to classify sarcopenia
also in cancer patients could improve precision of diagnosis
and better predict clinical outcomes. This study aims to deter-
mine prevalence of sarcopenia and examine the association
between low skeletal muscle mass and grip strength in pa-
tients with advanced cancer.
Methods: This is a cross sectional study based on data col-
lected from patients newly diagnosed with advanced stage
lung and pancreatic cancer starting chemotherapy. Muscle
mass was measured from CT-images as cross sectional area
(cm2) of the sum of skeletal muscles at the third lumbar ver-
tebral level. Skeletal muscle index, SMI (cm2/height, m2) was
calculated and cut-offs used were <52.4 cm2/m2 for men;
<38.2 cm2/m2 for women. Grip strength (kg) was assessed
by a handheld dynamometer using the mean value of three
test trials and cut-offs were <40 kg for men and <30 kg for
women.
Results: The sample consisted of 45 patients (26 men; 19
women) aged 35–76 years (mean 60 years) with a perfor-
mance score (Karnofsky) of 80 (range 70–100). SMI (mean
45.5 ± 8.2 cm2/m2) was strongly correlated to low grip
strength in this population (r = 0.567; p < 0.01). The preva-
lence of sarcopenia based on SMI alone was 60%. When grip
strength was used in combination with SMI to diagnose
sarcopenia, the prevalence was 31%.
Conclusions: Assessment of grip strength is a simple tool
that could be considered an important part of the classiﬁ-
cation of sarcopenia in patients with advanced cancer. Fur-
ther studies are warranted to determine cut-offs for grip
strength associated with important clinical outcomes in ad-
vanced cancer.
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(SMM) on changes in quality of life (QoL) in
metastatic colorectal cancer (mCRC) patients
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Introduction: Increasing evidence indicates that low SMM is
associated with poor outcomes in various cancers, including
mCRC. We recently showed, using data of the randomized
phase III CAIRO3 study (Lancet, 2015), that skeletal muscle
loss was associated with poor survival during ﬁrst line mainte-
nance treatment with capecitabine + bevacizumab (CAP-B) or
observation (ASCO, 2017), after induction treatment with
capecitabine + oxaliplatin + bevacizumab. The impact of
SMM change on QoL is not yet known. Here, we investigate
the association between change of SMM and concomitant
QoL changes in mCRC patients.
Methods: Patients were followed during CAP-B or observa-
tion until ﬁrst progression of disease (PD1). Routine CT scans
were analyzed for SMM (from skeletal muscle cross-sectional
area at L3). Change in SMM was measured continuously and
categorized into loss (>2%), stable (≤2% loss- ≤ 2% gain), and
gain (>2%). Multiple linear regression models were applied
to study the association between change in SMM and con-
comitant change in QoL (EORTC-QLQ-C30v.3), adjusted for
relevant confounders.
Results: 221 patients were included (64% male, mean age
63.5 ± 8.4 years). 24% lost, 27% maintained, and 49% gained
SMM, while on average patients gained 0.5 ± 1.7 kg SMM.
Mean QoL at randomization and PD1 was 74.7 ± 18.4 and
74.3 ± 16.8, respectively. One kilogram SMM increase was
signiﬁcantly associated with 2.7 points increase
(95%CI:1.1;4.4) in QoL. Compared to patients who lost
SMM, maintaining or gaining SMM was associated with clin-
ically relevant increase of QoL (9.9 (CI:2.4;17.5) and 14.7
(CI:8.0;21.4), respectively), and role functioning (12.0
(CI:2.2; 21.7) and 17.9 (CI:9.4;26.5)), reduced fatigue (10.0
(CI: –17.4; –2.5) and 15.0 (CI: –21.6; –8.5)), pain (7.4 (CI:
–16.7;2.0) and 16.3 (CI: –24.6; –8.1)), and appetite loss
(12.3 (CI: –22.2; –2.5) and 17.9 (CI: –26.5; –9.2)).
Conclusions: Stable SMM during ﬁrst line CAP-B treatment
or observation was consistently associated with several
clinically relevant increased QoL aspects. In addition,
SMM gain was signiﬁcantly associated with substantially
larger positive QoL changes, underlining the importance
of SMM in mCRC.
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Early detection of skeletal muscle atrophy using a
multiple plasma-free amino acid index in patients
with advanced pancreatic cancer
Shuichi Mitsunaga1,2, Michihiro Takada3, Sachiko Nishikawa3,
Akira Imaizumi3, Makoto Ishii3, N. Tatematsu4, Masafumi Ikeda1 &
Atsushi Ochiai2
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Introduction: Loss of skeletal muscle mass (SMM) is a feature
of both aging and cancer cachexia and can inﬂuence plasma
free amino acid (PFAA) levels via metabolic abnormalities.
The early detection of SMM loss using a multivariate index
composed of PFAAs might be useful for managing patients
with advanced pancreatic cancer (PCa).
Methods: Patients with treatment-naïve advanced PCa were
enrolled. The whole body skeletal muscle index (wSMI) and
cachexia were measured using bioelectrical impedance analy-
sis and the diagnostic criteria for cachexia of the European
Palliative Care Research Collaborative at baseline and one
month later. Each patient was assigned to an atrophy or a
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non-atrophy group based on the change in wSMI after one
month. The concentrations of 19 PFAAs were measured using
liquid chromatography–mass spectrometry. An index
consisting of the PFAAs at baseline was evaluated for its abil-
ity to discriminate atrophy one month later in both younger
(<70 years) and older groups.
Results: Atrophy was observed in 49% of the 161 PCa pa-
tients. The independent risk factors for atrophy were an ad-
vanced age (odd ratio [OR]: 2.1, P = 0.04) and cachexia at
one month (OR: 4.0, P < 0.01). The areas under the curves
(AUCs) based on a receiver operating characteristic (ROC)
curve analysis of the PFAA index for discriminating atrophy
from non-atrophy were calculated using single or multiple
PFAAs. The single PFAA analyses revealed that aging affected
the diagnostic ability of some PFAAs. The best AUCs for the
multiple PFAA indices were 0.85 (95% conﬁdence interval
[CI], 0.74–0.96) for the older group and 0.67 (95% CI, 0.56–
0.77) for the younger group.
Conclusions: SMM atrophy was related to aging and cachexia
in patients with advanced.
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content in skeletal muscle of cancer patients
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Background: Computed Tomography (CT) cross-sectional im-
aging has been recently applied to evaluate muscle area and
radiodensity in cancer patients. Studies of muscle radio-
density, reported in Hounsﬁeld Units (HU)1, reveals an associ-
ation with poor survival in a variety of cancer types.2–5 In
healthy adults, muscle radiodensity inversely associates with
triglyceride content6 but no studies to date have reported
this association in cancer patients. It is also not known
whether lipid is located inside myocytes as lipid droplets or
adjacent to the myocytes within adipocytes.
Methods: Rectus abdominis (RA) muscle biopsies were col-
lected during surgery from patients diagnosed with gastroin-
testinal cancers. Skeletal muscle radiodensity was assessed by
analyzing CT images at the 3rd lumbar vertebra, as well as RA
speciﬁcally. Triglyceride content of muscle was analysed quan-
titatively using gas chromatography. RAmuscles, frozen for his-
tology, were stained for neutral lipid content using Oil Red O
(ORO) to determine location of neutral lipids. Percent area of
pixels with ORO stain was calculated by Volocity6.3 Software.
Results: Mean muscle radiodensity and RA radiodensity were
inversely associated with triglyceride content (μg/mg)
(r = 0.518, p = 0.023 and r = 0.481, p = 0.032, respec-
tively). Of the total percent area of neutral lipid, mean per-
cent area present outside myocytes was 54% compared to
46% mean percent area inside myocytes. There was no signif-
icant difference in percent area of neutral lipids present in-
side (42% vs 54%, p = 0.309) and outside (58% vs 46%,
p = 0.309) myocytes in muscle with low versus high triglycer-
ide content, respectively.
Conclusions: In cancer patients, overall abdominal muscle
and rectus abdominis radiodensity is associated with triglyc-
eride content of the muscle indicating that low muscle
radiodensity is indicative of fatty inﬁltration, which appears
to occur equally inside and outside of the myocyte. Future
studies will enable us to understand effects of high triglycer-
ide content within muscle of cancer patients.
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Introduction: Loss of skeletal muscle mass (SMM) represents
a clinical feature of cancer cachexia. The goal of this study
was to identify the factors associated with the loss of SMM
in advanced pancreatic cancer (PCa) patients receiving ﬁrst-
line chemotherapy.
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Methods: Advanced PCa patients who were scheduled to
receive ﬁrst-line chemotherapy were eligible. The SMM was
measured using the 3rd lumbar vertebral skeletal muscle in-
dex (L3-SMI). Activity, symptoms, and quality of life (QOL)
were prospectively evaluated at baseline and one month
after the start of chemotherapy using Karnofsky Perfor-
mance Status (KPS) and questionnaire (Japanese version of
the M.D. Anderson Symptom Inventory). Each patient was
assigned to atrophy or non-atrophy group on the basis of
the change of the L3-SMI over one month. The differences
in the assessment results between the two groups were
examined at baseline and one month after the start of treat-
ment. Landmark analysis was used for analysis of the overall
survival (OS).
Results: The data of 159 patients (age in mean: 65.3 years,
KPS in mean: 88.7, mean body mass index: 21.7 kg/m2, mean
L3-SMI: 41.8 cm2/m2) were evaluated. There were no differ-
ences in the baseline characteristics between the atrophy
group (n = 78, change of L3-SMI in mean: 3.2 cm2/m2)
and non-atrophy group (n = 81, +0.7 cm2/m2). At 1 month,
the KPS score was lower in the atrophy group than in the
non-atrophy group (83.4 vs. 89.3, P < 0.01). QOL score in at-
rophy group were worsen to be compared with those in non-
atrophy group (3.3 vs. 2.3, P = 0.04). Survival analysis re-
vealed that atrophy group showed poor OS, compared to
non-atrophy group (5.9 vs. 11.9 mo, P < 0.01).
Conclusions: Loss of skeletal muscle mass occurring during
ﬁrst-line chemotherapy is related to the deterioration of ac-
tivity, QOL and poor OS in advanced PCa patients.
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Introduction: Obesity represents a major under-recognized
preventable risk factor for cancer development and recur-
rence, including breast cancer (BC). Obesity is highly preva-
lent in western countries, and it contributes to almost 50%
of BC in older women. However, although high body mass in-
dex (BMI) may indicate overweight and obesity, often low
muscle mass may be present at BC diagnosis, impacting neg-
atively on outcomes.
We aimed at assessing body composition in BC patients at
the moment of cancer diagnosis and the association between
body composition and clinical parameters.
Methods: BC patients were enrolled before undergoing
breast surgery and any other therapy. Clinical characteristics
were collected, including BMI (weight/height2), waist circum-
ference (cm), while muscle mass (MM) (kg) and adiposity (kg)
were assessed by bioelectrical impedance analysis (InBody
770®, InBody Co, Ltd., kindly provided by Caresmed, Italy).
Skeletal muscle index (SMI) was calculated as MM/height
(m)2. Parametric and non-parametric tests were performed,
as appropriate.
Results: A total of 19 consecutive BC patients were studied.
Age (years) was 54.4 ± 11.2. BMI was 25.2 ± 3.8 and MM
was 23.3 ± 3.2. Based on SMI cut-off values for sarcopenia,
we did not ﬁnd this condition in all patients (9.1 ± 1.2).
Eleven patients reported involuntary body weight loss
(between 3 and 6 kilograms) in the previous 6 months,
whose BMI tended to be lower (23.6 ± 2.4) although not
signiﬁcantly different with respect to the patients without
body weight loss (26.3 ± 4.3) (P = 0.07). Patients reporting
body weight loss had a MM signiﬁcantly lower with
respect to patients without body weight loss (P = 0.04)
and a lower phase angle value (P = 0.01), as well as lower
SMI (P = 0.02).
Conclusions: Besides the clinical importance of the anthropo-
metric values, body composition analyses revealed at the mo-
ment of BC diagnosis lower muscularity in patients presenting
involuntary body weight loss in the previous months. These
preliminary results suggest that body composition analysis
should be included in the evaluation of nutritional status,
since BMI and weight loss cannot discriminate the subtle
changes occurring in body compartments in early phases of
disease.
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Background: Preoperative low skeletal muscle mass and den-
sity are associated with increased postoperative morbidity in
patients undergoing curative colorectal cancer surgery.
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However, the long-term effects of low skeletal muscle mass
and density remain uncertain.
Methods: Patients with stage I–III colorectal cancer undergo-
ing surgery, enrolled in a prospective observational cohort
study, were included. Skeletal muscle mass and density were
measured on CT. Patients with high and low skeletal muscle
mass and density were compared regarding postoperative
complications and mortality, disease-free survival (DFS), over-
all survival (OS), and cancer-speciﬁc survival (CSS).
Results: In total, 816 patients (53.9% men, median age 70)
were included; 50.4% had low skeletal muscle mass and
64.1% low density. The severe postoperative complication
rate was signiﬁcantly higher in patients with low versus high
skeletal muscle and density (20.9% versus 13.6%, p = 0.006;
20.0% versus 11.8%, p = 0.003). Low skeletal muscle density
was independently associated with severe postoperative
complications (OR 1.89, 95%CI 1.11–3.23, p = 0.020). Ninety-
day mortality was higher in patients with low skeletal muscle
mass and density compared with patients with high skeletal
muscle mass and density (3.6% versus 1.7%, p = 0.091; 3.4%
versus 1.0%, p = 0.038). No differences in DFS were observed.
After adjustment for covariates such as age and comorbidity,
univariate differences in OS and CSS diminished.
Conclusions: Low skeletal muscle mass and density are asso-
ciated with short-term, but not long-term, outcome in pa-
tients undergoing colorectal cancer surgery. These ﬁndings
recommend putting more emphasis on preoperative man-
agement of patients at risk for surgical complications, but
do not support beneﬁt for long-term outcome.
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Background: Creatinine is exclusively produced by striated
muscle which makes it a reliable surrogate of skeletal muscle
mass under stable conditions. Studies reported that low se-
rum creatinine was associated with increased morbidity and
mortality across different race, age, and disease groups. We
examined the correlations between serum creatinine and
physical function as well as serum creatinine and survival in
patients with glioblastoma.
Methods: 404 consecutive glioblastoma patients who re-
ceived tumor resection between 1/1/2010 and 12/31/2014
were reviewed. Data about treatments (extent of tumor re-
section, radiation therapy, and use of temozolamide), medical
history, vital signs, weight, height, Karnofsky Performance
Status (KPS), and lab tests were collected. Charlson Comor-
bidity Index (CCI) was calculated with ICD-9 codes. Bivariate
associations between baseline KPS and serum creatinine,
and body mass index (BMI) were analyzed using Pearson cor-
relation coefﬁcients. Cox regression for survival analysis was
performed.
Results: The mean age of the population was 58 (+13) years.
64% were male. Death rate was 78%. The correlation coefﬁ-
cients for KPS and creatinine 0.15 (P = 0.003), for KPS and
BMI 0.08 (P = 0.103). Patients with low serum creatinine
(<0.6 mg/dL in female, <0.7 mg/dL in male) had shorter sur-
vival (HR = 1.65 [95% CI = 1.07–2.55], P = 0.023) when ad-
justed for known survival predictors including age, extent of
tumor resection, and treatment strategies.
Conclusions: Serum creatinine positively correlates with func-
tional performance status. Low serum creatinine predicts
mortality in patients with glioblastoma. The unique utility of
creatinine as a marker of muscle mass deserves more re-
search and clinical attention.
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Background: Inﬂammation is a recognized contributor to
muscle wasting1. Gene array analysis in human biopsies has
revealed that immune cell recruitment is a major event oc-
curring in cancer patients experiencing systemic inﬂamma-
tion2. Lymphoid and myeloid cells in the tissue inﬂuence
muscle atrophy through diverse mechanisms3,4; however, lit-
tle is known about the muscle’s immunological environment
and its relationship to muscle loss in conditions of malig-
nancy. Therefore, we hypothesized that features of muscle
atrophy are related to a higher recruitment of immune cells
in the muscle of patients with cancer.
Methods: Rectus abdominis biopsies and computed tomog-
raphy (CT) images were collected from cancer patients
(n = 22) at the University of Alberta Hospital, Edmonton,
Canada, from July 2015 to August 2016. Frozen muscle biop-
sies cut in transverse sections were stained with immunoﬂu-
orescence to evaluate immune cells: T cells (CD8+ and CD4+),
antigen presenting cells (APCs; CD3-CD4+), and granulocytes
(CD11b+). Features of muscle atrophy were explored by eval-
uating histopathological components such as mean muscle ﬁ-
ber area (μm2) and computed CT images to obtain muscle
cross sectional area (CSA; cm2). Spearman’s coefﬁcient was
used to assess correlations.
Results: Muscle with higher CSA (cm2) (r = 0.66, P = 0.001)
and mean ﬁber area (μm2) (r = 0.55, P = 0.008) had a larger
number of T cells (CD4+ and CD8+ combined). CD8+ T cells
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(not CD4+ T cells) maintain a signiﬁcant association with mus-
cle CSA (r = 0.53, P = 0.012) and mean muscle ﬁber area
(r = 0.49, P = 0.021). APCs and granulocytes were not related
to any muscle feature evaluated; however, APCs were posi-
tively correlated to number of CD8+ T cells (r = 0.45,
P = 0.036).
Conclusions: Lymphoid and myeloid cells are present in the
muscle of cancer patients. In particular, T cells seem to be as-
sociated with better muscle condition. Results suggest inter-
action between CD8+ T cells and APCs. Further exploration
will enable understanding the inﬂuence of immune cells
within the muscle of cancer patients.
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Introduction: Despite advanced operative techniques for re-
section surgery, a large number of patients with colon
cancer still suffer from post-operative morbidity. This leads
to delayed subsequent therapy, prolonged hospital stay,
and potentially worse prognosis. Computerized tomography
(CT)-measured muscle abnormalities are of emerging interest
to surgeons due to their potential value for post-operative
risk stratiﬁcation. This study investigated the independent
prognostic effects of muscle abnormalities on surgical
outcomes.
Methods: Patients diagnosed with stages I–III colon cancer
from 2006 to 2011 were included (n = 1,715). Muscle abnor-
malities were deﬁned as a low skeletal muscle index (SMI)
and/or radiodensity (SMD) measured on pre-operative CT im-
ages. Differences in demographic, clinical and surgical
outcomes were compared by each muscle abnormality using
independent t-tests or Chi-squared tests. Logistic regression
was used to evaluate the associations of muscle abnormali-
ties with post-surgical length of hospitalization, any complica-
tion(s) and readmission up to 30 days post-surgery or post-
discharge. Cox proportional hazards regression was per-
formed to examine the effect of muscle abnormalities on
30-day mortality.
Results: Mean age was 64.0 ± 11.2 years and 55.5% were fe-
male. Patients with low SMI (OR = 1.37, 95% CI 1.10–1.72) or
low SMD (OR = 1.50, 95% CI 1.15–1.96) were more likely to
remain hospitalized ≥7 days after surgery, and had higher risk
of 30-day mortality (low SMI: HR = 4.65, 95% CI 1.43–15.06;
low SMD: HR = 3.34, 95% CI 1.08–10.30). Additionally, pa-
tients with low SMI were more likely to have at least one
post-surgical complication (OR = 1.26, 95% CI 1.02–1.55). Re-
admission rate was not associated with any muscle
abnormality.
Conclusions: Muscle abnormalities were associated with
poorer surgical outcomes, including longer hospitalization
and a higher risk of short-term mortality. Low SMI was asso-
ciated with a higher risk of post-surgical complications. Re-
search should evaluate whether targeting potentially
modiﬁable factors preoperatively, such as increasing muscle
mass and/or radiodensity may improve post-operative
outcomes.
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Background: Increasing evidence suggests that severe skele-
tal muscle (SM) loss (sarcopenia) is associated with reduced
overall survival (OS) in mCRC. We recently found that,
using data of the randomized phase 3 CAIRO3 study (Lan-
cet, 2015), SM loss was related to shorter OS during ﬁrst-line
maintenance treatment with capecitabine + bevacizumab
or observation. Subsequently, sarcopenia at start of more
intensive reinduction treatment with oxaliplatin + capecita-
bine + bevacizumab (CAPOX-B) was associated with shorter
time to progression and OS (ASCO, 2017). As a potential
risk factor for reduced survival we explored whether
sarcopenia was associated with DLT during CAPOX-B
reinduction treatment.
Methods: CAIRO3 patients were included who received
CAPOX-B reinduction treatment. DLT were deﬁned as any
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dose delay/reduction/discontinuation of systemic treatment
because of reported CTCAE(v3.0) toxicities at start or during
treatment. Poisson regression models, adjusted for con-
founders, were used to study the association between
sarcopenia and DLT.
Results: 254 patients received CAPOX-B reinduction treat-
ment. 39% of patients were sarcopenic and compared to nor-
mal SM patients we found no statistically signiﬁcant
differences in age and sex (sarcopenic vs normal SM: mean
age 63.6 ± 9.1 vs 61.9 ± 8.5 years, p = .20 and 39% vs 31%
women, p = .31). BMI was signiﬁcantly lower in sarcopenic
patients, but patients were on average still overweight
(25.9 ± 3.8 vs 27.2 ± 3.8 p = .01). Overall, 67% experienced
≥1 DLT. At start of CAPOX-B, 25% already received a dose re-
duction and the risk of dose reduction at start was signiﬁ-
cantly higher for sarcopenic patients compared to normal
SM (RR 1.8 (CI:1.08–2.90)). Despite more frequent dose re-
ductions at start, sarcopenic patients did not have a signiﬁ-
cantly lower risk of DLT during CAPOX-B (RR sarcopenia vs
normal SM 0.86 (CI: 0.46–1.45)).
Conclusions: Sarcopenia was signiﬁcantly associated with
dose reductions at start of CAPOX-B reinduction treatment,
and not with DLT during CAPOX-B reinduction treatment.
Possible explanations for dose reductions at start might be
more frequent toxicities during previous treatment including
neuropathy.
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Introduction: Muscle atrophy is frequently encountered in
diseased patients. It contributes to patient’s frailty and is as-
sociated with an increased risk of death. Studies using animal
models suggest the involvement of the Ubiquitin Proteasome
System (UPS) in renal failure-induced muscle atrophy. How-
ever, this remains to be established in humans. Another im-
portant goal is to detect markers that may help ﬁghting
against muscle atrophy through nutritional or pharmacologi-
cal strategies. Indeed, it is very difﬁcult to counteract the in-
creased proteolysis when it is established. Our objectives
were (i) to identify the proteolytic systems activated in
chronic hemodialysis (HD) or lung cancer (LC) patients, i.e.
pathologies having a different etiology and (ii) to identify
markers speciﬁc to the activation of muscle atrophy pro-
cesses independently of the pathology per se.
Methods: Muscle biopsies (n = 7 per group) were obtained
upon programmed surgery. mRNA and protein levels were
determined using qRT-PCR, immunoblotting and proteomic
approaches.
Results: We found that the UPS and autophagy were acti-
vated in both HD and LC patients. Mass spectrometry analysis
identiﬁed >1700 proteins. Main component analysis re-
vealed 3 distinct protein expression proﬁles corresponding
to the 3 groups studied. We identiﬁed 106 proteins that were
signiﬁcantly modiﬁed (decreased or increased) in both HD
and LC patients compared to controls (CT). Hierarchical clus-
ter analysis showed that expression levels of these proteins
distinguished diseased (HD or LC) vs. CT patients. Orthogonal
partial least square discriminant analysis conﬁrmed these
results.
Conclusions: We demonstrated that the UPS and autophagy
were activated during long-term disease in humans. We also
found a set of proteins whose expression levels may be spe-
ciﬁc of the atrophying process. These proteins constitute po-
tential biomarkers witnessing the activation of muscle
atrophy and/or potential therapeutic targets.
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Background: The occurrence of dysphagia is a well-known
feature of oesophageal cancer that may reduce caloric intake.
Body composition alterations and prevalence of sarcopenia in
patients with oesophageal cancer before and after surgery
are not well known, and their possible consequences have
been debated. The aim was to describe biometric measures
including body composition, and sarcopenia, physical perfor-
mance, dysphagia, as well as quality of life (QoL) in a cohort
of patients with oesophageal cancer before surgery with cu-
rative intent. In addition, we aimed to investigate alterations
in body composition as a consequence of the surgery at 1 and
3 months post-operatively. Moreover, to investigate if pre-
operative biometric measures, or sarcopenia, are correlated
to morbidity, length of stay, QoL or mortality.
Methods: An observational study was performed in a cohort
of 76 patients who had oesophageal or cardia cancer and
were planned for open surgery with curative intent. Demo-
graphic data and data on body composition measured with
bioimpedance, working capacity (cardiac stress test), grip
strength and QoL (EORTC QLQ-C30 version 3.0) were pro-
spectively collected from the patient history database. Data
regarding dysphagia was derived from the oesophagus-
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related QoL form EORTC QLQ-OES18. Data on tumour stage
and type, complications, length of stay, weight loss and nutri-
tional state were also collected.
Results: Pre-operatively the patients displayed normal BMI
despite that almost 20% were sarcopenic, 86% had a lowered
physical performance level and 37% of the patients were
judged severely malnourished. All body composition variables
except fat mass were declined up to 3 months after surgery.
No pre-operative biometric measure or QoL item was corre-
lated with risk for complications. BMI was positively corre-
lated to length of stay at the intensive care unit. Female sex
and malnourishment showed signiﬁcantly fewer ICU days.
High physical performance, female sex and high global QoL
score positively predicted overall survival.
Conclusions: Severe malnourishment was common in pa-
tients planned for oesophageal resection due to cancer in
spite of normal BMI. Neither pre-operative malnutrition
(SGA C) nor sarcopenia were independent risk factors for
morbidity or overall mortality in patients judged suitable for
surgery. However, oesophageal resection surgery caused long
lasting catabolic effects, highlighting the importance of opti-
mal peri- and post-operative nutrition.
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Introduction: This explorative retrospective study investigated
the relation between skeletal muscle measurements (muscle
mass, muscle quality and sarcopenic obesity), and postopera-
tive morbidity and survival after neoadjuvant chemoradiation
followed by non-laparoscopic resection for rectal cancer.
Methods: Ninety-nine consecutive patients who underwent
neoadjuvant chemoradiation and surgery between January
2007 and May 2012 were identiﬁed. Skeletal muscle mass
was measured as total psoas area and total abdominal muscle
area at three anatomical levels using the patient’s preopera-
tive computed tomography scan. Skeletal muscle quality was
measured using corresponding mean Hounsﬁeld Units for to-
tal abdominal muscle area. Sarcopenic obesity was deﬁned as
body mass index above 25 kg·m2 combined with skeletal
muscle mass measures below the sex-speciﬁc median. Postop-
erative complications were graded according to the Clavien-
Dindo classiﬁcation.
Results: Twenty-ﬁve patients (25.3%) developed a severe
complication. Lower skeletal muscle quality was indepen-
dently associated with overall (p = 0.007) and severe compli-
cations (p = 0.002). Sarcopenic obesity was associated with
overall complications (all p < 0.05). No signiﬁcant relations
were found between skeletal muscle measurements and
survival.
Conclusions: Skeletal muscle quality is associated with overall
and severe postoperative morbidity after neoadjuvant che-
moradiation and non-laparoscopic resection for rectal cancer.
Sarcopenic obesity is associated with overall complications.
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Introduction: Decreased muscle mass and muscle strength
are independent predictors of postoperative complications
and poor postoperative recovery in patients with esophageal
cancer. The association between muscle mass and muscle
strength is not self-evident. If the association between mus-
cle mass and muscle strength in preoperative patients with
esophageal cancer is known, physiotherapists are able to
measure functional muscle strength as an early predictor
for the consequences for functional performance due to de-
creased muscle mass and eventually sarcopenia.
Objectives: To investigate the association between muscle
mass and functional muscle strength in patients with esoph-
ageal cancer awaiting esophagectomy before neoadjuvant
chemoradiation.
Methods: In patients with resectable esophageal cancer eligi-
ble for surgery between March 2012 and October 2015, Com-
puted Tomography scans were used to assess muscle mass
and compared with functional strength measures (hand grip
strength, inspiratory- and expiratory muscle strength, 30 sec-
onds chair stands test). Pearson correlation coefﬁcients were
calculated, and associations were determined by multivariate
linear regression analysis.
1019
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 999–1080
DOI: 10.1002/jcsm.12255
Results: 126 subjects were referred to physiotherapy from a
tertiary referral center and were eligible for the study; 94
subjects were ﬁnally included for statistical analysis. Multi-
ple backward regression analysis showed that gender (95%
CI –32.4, 2.2), weight (95% CI 0.4, 1.0), age (95% CI –
0.9, 0.7), non-dominant handgrip strength (95% CI 0.2,
1.5) and inspiratory muscle strength (95% CI 0.1, 0.4) were
all independently associated with muscle surface area at L3.
All these variables together explained 65% of the variability
(R2) in muscle surface area at L3 (p < 0.001).
Conclusions: This study shows an independent association
between aspects of functional muscle strength and muscle
mass in patients with esophageal cancer awaiting surgery,
and the results could be used by physiotherapists to predict
muscle mass based on functional muscle strength in preoper-
ative patients with esophageal cancer.
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The addition of sarcopenia does not surpass the
MELD score in predicting waiting list mortality in
cirrhotic liver transplant candidates
Jeroen L.A. van Vugt1, Louise J.M. Alferink2, Stefan Buettner1,
Marcia P. Gaspersz1, Daphne Bot3, Sarwa Darwish Murad2,
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Herold J. Metselaar2 & Jan N.M. IJzermans1
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Groningen, University Medical Centre Groningen, Groningen, The Netherlands,
6Department of Surgery, University of Groningen, University Medical Centre
Groningen, Groningen, The Netherlands, 7Department of Gastroenterology and
Hepatology, Leiden University Medical Center, Leiden, The Netherlands,
8Department of Gastroenterology and Hepatology, University of Groningen
University Medical Center Groningen, Groningen, The Netherlands
Background: Frail patients with low MELD scores may be
underprioritized. Recently, low skeletal muscle mass (i.e.
sarcopenia) has been identiﬁed as a risk factor for waiting list
mortality and a study proposed to include sarcopenia in the
MELD score (i.e. MELD-Sarcopenia score). We aimed to inves-
tigate the association between sarcopenia and waiting list
mortality and to validate the MELD-Sarcopenia score
(MELD + 10.35*Sarcopenia).
Patients and methods: Using the Eurotransplant registry,
consecutive patients with cirrhosis listed for liver trans-
plantation between 2007 and 2014 were identiﬁed. Sur-
vival of patients with and without sarcopenia was
compared using Fine and Gray Competing Risks Analysis.
Performance of the MELD, MELDNa and MELD-Sarcopenia
score was investigated using concordance (c) indices after
bootstrapping crossvalidation. Variables in the multivariable
analysis were selected based on the Akaike Information
Criterion.
Results: In total, 588 patients were included with a median
MELD of 14 (IQR 9–19), of which 225 (43.4%) were identiﬁed
as having sarcopenia. Median waiting list survival was
5 months. Both the sarcopenia cut-offs according to Carey
and according to Martin were not signiﬁcantly associated
with survival in univariable analysis. The discriminative per-
formance of the MELD-Sarcopenia score for 5 months (c-in-
dex 0.668) was comparable to the MELD score alone (c-
index 0.663) and the MELDNa score (c-index 0.666). Apart
from the MELD score with or without sarcopenia, other inde-
pendent predictive variables were occurrence of hepatic en-
cephalopathy before listing, and recipient albumin at the
time of listing.
Conclusions: Sarcopenia as an addition to the MELD score did
not improve prognostic ability when analysed using compet-
ing risks regression in a Dutch national cohort. Other mea-
sures of sarcopenia did not reach signiﬁcance in univariable
analysis.
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Resting Energy Expenditure (REE) of children with
End Stage Liver Disease (ESLD)
Eirini Kyrana1, Jane E. Williams2, Jonathan C.K. Wells2 &
Anil Dhawan1
1King’s College Hospital, London, UK, 2Institute of Child Health, London, UK
Introduction: Hypermetabolism has been described in pa-
tients with ESLD, as measured REE (mREE) ≥ 120% of pre-
dicted REE (pREE).
Methods: REE was quantiﬁed by indirect calorimetry. Seven-
teen children (mean age 7.6 yrs/ median 6.9 yrs) with ESLD
had their mREE prior to having a liver transplant. Valid results
were in sixteen. pREE was calculated from the Henry 2005
equations. REE was measured and predicted for thirteen
healthy children (mean age 8.3 yrs/ median 8 yrs). Twelve
had valid results. Children over 4 years of age from both
groups had fat free mass (FFM) determined with air displace-
ment plethysmography (BOD POD).
Results: The differences in mean age, mean mREE/kg of body
weight (BW) and RQ between the patients and healthy con-
trols were not signiﬁcant (NS). Seven of the 16 patients
(44%) were hypermetabolic, and 9/16 were normometabolic
(56%). Mean RQ for both groups was 0.77.
6 of the 12 (50%) healthy controls were hypermetabolic. The
mean RQ for the hypermetabolic healthy children was 0.75
and for the normometabolic 0.79 (NS). Differences of mean
SD scores for BW, height and BMI between hypermetabolic
and normometabolic groups of patients and healthy children
did not achieve statistical signiﬁcance. 8 patients and 10
healthy controls had FFM measured with BOD POD. Mean
mREE/kg of FFM for the patients was 57.53 Kcal/kg and for
the healthy controls 59.5 Kcal/kg (NS). Nine of the patients
had their liver transplant and had mREE at a median of
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10.8 months post-transplant. The differences in mean REE/kg
and RQ before and after liver transplantation were not statis-
tically signiﬁcant. REE/kg pre transplant correlated signiﬁ-
cantly with REE/kg post-transplant (r = 0.832, p = 0.005).
Conclusions: mREE and the presence of hypermetabolism
was not different between children with ESLD awaiting liver
transplant and healthy controls. mREE/kg after transplant
correlated signiﬁcantly with mREE/kg before transplant.
2-50
Six-minute walk distance is superior to Karnofsky
Performance Status to predict mortality in
candidates for liver transplantation
Elizabeth J. Carey1 & Bridgette McNally2
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Background: Poor functional status is associated with in-
creased mortality in cirrhosis patients awaiting liver trans-
plantation; however, the optimal assessment of functional
status remains unknown. This study sought to determine
the relationship between six-minute walk distance (6MWD)
and Karnofsky Performance Status (KPS) and their association
with waitlist mortality (WLM) in liver transplant (LT)
candidates.
Methods: Two hundred seventy-eight consecutive patients
listed for LT at a single institution were included. KPS and
6MWD were assessed at the time of LT evaluation. KPS scores
were recorded as a percentage from 0 to 100, with 0
representing death and 100 representing no presence of dis-
ease. Patients were followed from time of listing until trans-
plantation, death, removal from the waitlist or end of the
study period (study period: 01/2014–03/2017).
Results: The mean KPS and 6MWD were 77.4 ± 13.5 and
323.6 ± 163.9 m, respectively. A mild correlation between
6MWD and KPS was demonstrated (Spearman ρ = 0.4317,
p< 0.0001). KPS score was signiﬁcantly lower in patients with
6MWD<250 meters (p< 0.0001). In univariate and multivar-
iate logistic regression, there was no signiﬁcant relationship
between KPS score and waitlist mortality. In contrast, the
6MWD was signiﬁcantly lower in patients who suffered
waitlist mortality (266.1 vs 331.8, p = 0.05) and was the only
signiﬁcant predictor of WLM in multivariate logistic regres-
sion. HCC patients were shown to be less likely to die on the
waitlist compared to other liver disease etiologies.
Conclusions: In conclusion, 6MWD is a better predictor of
waitlist mortality than KPS score in candidates for LT. The ad-
dition of 6MWD as a standard assessment may help to iden-
tify patients at risk of dying on the waitlist.
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Amyloidotic Polyneuropathy (FAP): the relevance
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Introduction: Loss of muscle mass and function is a common
occurrence in liver transplant Familial Amyloidotic
Polyneuropathy (FAP) patients. Sarcopenia is associated with
morbidity and mortality before and after liver transplanta-
tion. However, the ability of skeletal muscle mass to recover
after transplant remains questionable and thus the impor-
tance of clinical exercise prescription.
Methods: Participants were 39 FAP patients aged 23–
59 years, who had been submitted to a liver transplant (Tx)
(22 men) between 2 and 4 months post-tx. Sarcopenia was
deﬁned according to the International Working Group on
Sarcopenia and Society of Sarcopenia, Cachexia and Wasting
Disorders. Whole-body dual x-ray absorptiometry was used
to measure body fat and lean-soft tissue. Skeletal Muscle In-
dex (SMI) was calculated adjusting the value of appendicular
skeletal mass to the squared height. Functional aerobic ca-
pacity was assessed using the 6 min walk test (6MWT), and
handgrip strength was measured on the dominant hand using
a hand dynamometer.
Results: The prevalence of sarcopenia using SMI was 45.5% in
men and 41.2% in women. A fat mass higher than 16% for
men and 26% for women was found in 54.5% of men and
52.9% of women. Also 27.3% of men and 17.6% of the
women could be classiﬁed as having sarcopenia with low mo-
bility (distance < 400 m).
Discussion and Conclusions: Sarcopenia is common in FAP
patients and a liver transplant seems to increase the preva-
lence, also because an aggressive medication with impact
on muscle metabolism should be made longtime. More data
are needed on the long-term effects of sarcopenia after
transplant, especially in light of the high rate of metabolic
syndrome.
A clinical exercise prescription seems to be necessary for
these patients but more studies are needed (e.g. longitudinal
studies).
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Luiz Augusto Carneiro D’Albuquerque1, Rosa Maria R. Pereira4,
Valéria F. Caparbo4, Steven B. Heymsﬁeld3 & Dan L. Waitzberg1
1Department of Gastroenterology (LIM 35), Surgical Division, Faculdade de
Medicina da Universidade de São Paulo, Brazil, 2Postgraduate program in Health
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Background: Ascites limit skeletal muscle mass assessment.
We propose that sarcopenia diagnosis in cirrhosis can be im-
proved by using dual-energy X-ray absorptiometry to calcu-
late the appendicular skeletal muscle index (DXA-ASMI), as
it bypasses the abdominal compartment.
Objective: We evaluated whether DXA-ASMI is inﬂuenced by
ascites or lower limb edema (LLE) and can be applied to diag-
nose sarcopenia with prognostic value for mortality, alone or
combined with non-dominant handgrip strength (ND-HGS).
Design: DXA-ASMI and ND-HGS values were obtained and
36 months mortality recorded in 144 male cirrhotic patients.
DXA-ASMI was calculated pre- and post-paracentesis in 20
patients with ascites and compared with data from 20
matched volunteers. DXA-ASMI values obtained from pa-
tients with and without LLE were compared. Prognostic value
of DXA-ASMI and DXA-ASMI + ND-HGS was tested in a ﬁnal
survival model adjusted for MELD and age. Survival probabil-
ities were obtained for sarcopenia diagnosed by standard cut-
offs for DXA-ASMI and ND-HGS values (EWGSOP) and a new
cutoff calculated from our DXA-ASMI + ND-HGS tertiles.
Results: DXA-ASMI did not differ pre- and post-paracentesis,
were lower in cirrhotic patients than in volunteers
(p < 0.001), and were not inﬂuenced by LLE (mean differ-
ence = 0.30 kg/m2, p = 0,068; R2 = 2.40%). Mortality was in-
ﬂuenced by DXA-ASMI and ND-HGS (pinteraction = 0.028).
Sarcopenia diagnosed by EWGSOP was also diagnosed by
our new cutoff; both predicted mortality, but the latter was
more sensitive for mortality risk prediction (p = 0.011).
Conclusions: In cirrhosis, DXA-ASMI estimates are not inﬂu-
enced by ascites or LLE and can identify low skeletal muscle
mass for diagnosing sarcopenia with prognostic value for
mortality, mainly when combined with ND-HGS.
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listed for liver transplantation
Jeroen L.A. van Vugt1, Stefan Buettner1, Louise J.M. Alferink2,
Niek Bossche3, Ron W.F. de Bruin1, Sarwa Darwish Murad2,
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Introduction: Low skeletal muscle mass (sarcopenia) is asso-
ciated with increased morbidity and mortality in liver trans-
plant candidates. We investigated the association between
sarcopenia and hospital costs in patients listed for liver
transplantation.
Methods: Consecutive patients with cirrhosis listed for liver
transplantation between 2007 and 2014 in a Eurotransplant
center were identiﬁed. The skeletal muscle index ([SMI],
cm2/m2) was measured on CT performed within 90 days from
waiting list placement. The lowest sex-speciﬁc quartile repre-
sented patients with sarcopenia.
Results: In total, 224 patients were included. Median time on
the waiting list was 169 (IQR 46–306) days, and median
MELD-score was 16 (IQR 11–20). The median total hospital
costs in patients with sarcopenia were €11,294 (IQR 3,570–
46,469) compared with €6,878 (IQR 1,305–20,683) in patients
without sarcopenia (p = 0.008). In multivariable regression
analysis, an incremental increase in SMI was signiﬁcantly as-
sociated with a decrease in total costs (€458 per incremental
SMI, 95%CI 14–902, p = 0.043), independent of the total time
on the waiting list.
Conclusions: In conclusion, sarcopenia is independently asso-
ciated with increased health-related costs for patients on the
waiting list for liver transplantation. Optimizing skeletal mus-
cle mass may therefore lead to a decrease in hospital expen-
diture, in addition to greater health beneﬁt for the transplant
candidate.
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Body composition in extreme small stature adults:
the case of mucopolysaccharidosis
Bhawna Sharma1,2, Boyd Strauss2, Christian Hendriksz1,3 &
Gisela Wilcox1,2
1Mark Holland Metabolic Unit, Salford Royal NHS Foundation Trust, UK, 2Faculty of
Biology, Medicine and Health, University of Manchester, UK, 3Steve Biko Academic
Unit, University of Pretoria, South Africa
Background: The mucopolysaccharidoses (MPS) are a group
of rare inherited metabolic disorders due to the accumulation
of glycosaminoglycans (GAGs) within lysosomes. Accumula-
tion of GAGs in different tissues causes signiﬁcant multi-
systemic complications, associated with, in many cases,
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extreme short stature. Hydrophilic GAGs may alter body com-
position, but measurement has not yet been explored in the
literature.
Aims: We aimed to assess if patients with MPS have a differ-
ent body composition to that of the general population and
to investigate in which body composition compartment GAGs
accumulate predominantly.
Methods: Eleven MPS patients attending the adult inherited
metabolic medicine clinic at Salford Royal Foundation Trust
were measured using the multifrequency segmental SECA
BIA 515. These data were compared to data from healthy Eu-
ropean individuals.
Results: In the 11 patients with MPS, weight was signiﬁcantly
correlated with fat mass, but not percentage fat. Weight was
also highly correlated with fat-free mass and skeletal muscle
mass, even after correction for height. Height was signiﬁ-
cantly correlated with fat-free mass and skeletal muscle
mass.
Patients with MPS have a signiﬁcantly reduced stature,
mass and phase angle, and signiﬁcantly increased resistance
to current ﬂow, when compared to the general population.
Conclusions: The question of whether or not extreme small
stature affects body composition is not yet resolved. The cor-
relation between both weight and height, and skeletal mus-
cle mass, could be accounted for by GAG accumulation in
skeletal muscle; other body composition techniques, espe-
cially for muscle mass, need to be applied to this group and
methods for estimating tissue GAG mass developed. This
group challenges conventional deﬁnitions of sarcopenia.
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Introduction: Phase angle (PA) has been considered as a
prognostic factor for several clinical conditions, probably be-
cause of its relationship to fat-free mass and function. More
recently, decreased muscle mass and functional assessment
were used to deﬁne sarcopenia. The purpose of this work
was to identify the relationship of PA, sarcopenia and its
components in cancer patients.
Methods: Fifty-nine cancer patients hospitalized for elective
surgery were studied. Bioelectrical impedance analysis (BIA
Quantum II, RJL Systems®) was performed in all patients
and skeletal muscle index, using Janssen equation, and PA
and Standardized Phase Angle (SPA) were estimated, using
reference values from this population. The handgrip strength
was obtained using Jamar® hydraulic dynamometer, and gait
speed was assessed by using 4-m test. The diagnosis of
sarcopenia was performed according the European Working
Group on Sarcopenia in Older People. Malnutrition was
assessed by Patient-generated Subjective Global Assessment.
The outcomes evaluated were postoperative complications
(Clavien–Dindo classiﬁcation) and length of stay (LOS).
Results: Sarcopenia was present in 17% of the patients and
malnutrition in 30.5%. SPA was signiﬁcantly lower in mal-
nourished (0.20 vs. 0.62 p = 0.028) and sarcopenic patients
(0.39 vs. 0.59 p = 0.010). Patients with a lower handgrip
strength (0.31 vs. 0.69 p = <0.001) and slower gait speed
(0.30 vs. 0.60 p = 0.016) also showed a lower SPA. SPA
and PA from non-sarcopenic patients with impaired functions
also showed a lower SPA and PA than those with normal
function. Patients with serious postoperative complications
(0.71 vs. 0.41 p = 0.007) and longer LOS (0.16 vs. 0.64
p = 0.030) presented lower SPA. The same results were found
when PA (adjusted for sex and age) was used.
Conclusions: PA was decreased in all the sarcopenia compo-
nents, and it has been associated with impaired nutritional
and functional status in this sample.
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Introduction: The purpose of the present study was to trans-
late into French the SARC-F questionnaire, a simple and easy
screening tool for sarcopenia, and then to validate this
translated/French version on behalf of the EUGMS Special In-
terest Group (SIG) on Sarcopenia.
Methods: The translation process has been divided into two
consecutive parts: 1) the translation of the questionnaire
from English to French and its language validation (inter-rater
reliability and test–retest reliability); 2) the clinical validation
of the French SARC-F in order to assess its performance (sen-
sitivity, speciﬁcity, predictive positive value and predictive
negative value) in a cohort of Belgian elderly subjects, against
seven existing deﬁnitions of sarcopenia.
Results: The translation from English to French has been per-
formed without any difﬁculties and demonstrated an excel-
lent inter-rater reliability with an ICC of 0.90 (95% CI: 0.76–
0.96) as well as an excellent test–retest reliability with an
ICC of 0.86 (95% CI: 0.66–0.94). Afterwards, 306 subjects took
part in the clinical validation of the French version of the
SARC-F questionnaire. Results showed that the sensitivity of
the tool ranged from 22.1% to 75.0%, depending on the def-
inition used for the diagnosis of sarcopenia, and the speciﬁc-
ity ranged from 84.9% to 87.1%. Moreover, all PPVs were
below 50%; the lowest PNV was 68.1% and the best one
reached around 99%.
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Conclusions: The results are in line with the performance
established in the initial English validation of the SARC-F
and seem to indicate that this screening tool can detect with
precision the absence of sarcopenia but seems less precise in
afﬁrming the presence of this geriatric syndrome.
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The SarQoL®, a speciﬁc quality of life questionnaire
for sarcopenia, is adapted to identify 1-year
decrease in quality of life related to muscle
function
Charlotte Beaudart, Médéa Locquet, Laura Delandsheere,
Jean-Yves Reginster & Olivier Bruyère
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University of Liège, Liège, Belgium
Background: Our aim was to assess the impact of 1-year
change in musculoskeletal health on quality of life (QoL)
using the SarQoL® questionnaire, a quality of life question-
naire speciﬁc for sarcopenia.
Methods: Three QoL questionnaires (the SarQoL® and two
generic QoL questionnaires, the EQ-5D and the SF-36) have
been completed by 301 subjects from the SarcoPhAge study
(Sarcopenia and Physical impairments with advancing Age, a
cohort developed in Belgium). Muscle mass (ALM/h2,
assessed with DXA), grip strength (assessed with hydraulic dy-
namometer) and gait speed were evaluated. Sarcopenia was
diagnosed according to the EWGSOP algorithm.
Results: After one year of follow-up, the QoL of the general
population (75.0 ± 5.97 years, 59% women) decreased
(p < 0.001 with the SarQoL®, p = 0.03 with the EQVAS,
p < 0.001 with the EQ-5D). The ALM/h2 was not signiﬁcantly
modiﬁed but a decrease in muscle strength, and gait speed
was observed (p < 0.001 for both). A signiﬁcant correlation
was found between 1-year decrease in gait speed and 1-year
decrease in QoL only when using the speciﬁc questionnaire
SarQoL®, but not when using the generic EQ-5D or EQVAS
tools. Results indicated a correlation of r = 0.21 (p < 0.001)
for the whole cohort population and r = 0.41 (p = 0.013) for
the sarcopenic elders (n = 38). These associations were not
observed for muscle mass (p = 0.65) or muscle strength
(p = 0.06). Using a multivariate regression the association be-
tween decreased gait speed and decreased QoL, assessed
with the SarQoL®, was signiﬁcant, independently of age,
sex, number of comorbidities and number of drugs
(p < 0.001 for both whole cohort and sarcopenic subjects).
Conclusions: Our ﬁndings suggest that a decrease in physical
performance and more speciﬁcally in gait speed is associated
with a decrease in QoL in elders and more speciﬁcally in
those suffering from sarcopenia. The speciﬁc SarQoL® seems
better adapted than generic tools to identify decrease in QoL
related to muscle function.
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Introduction: SARC-F + CC was recently proposed as a varia-
tion of the SARC-F questionnaire, combining its questions
(which evaluate muscle function) with an anthropometric
measurement (calf circumference (CC), as a surrogate for
muscle mass]. However, SARC-F + CC still lacks validation.
Objective: Evaluating SARC-F + CC’s performance as a
sarcopenia screening tool.
Methods: Cross-sectional study including elderly women
(≥60 years old) who performed bone densitometry for clinical
purposes. Sarcopenia was deﬁned by the EWGSOP’s recom-
mended criteria: muscle mass evaluation through dual-
energy X-Ray absorptiometry (DXA), muscle strength evalua-
tion by handgrip strength and muscle performance evalua-
tion through the 4-m gait speed test. Speciﬁc cut-off
reference values for the Brazilian population were used to
deﬁne low Appendicular Skeletal Muscle Mass Index (ASMI)
from DXA (5.62 kg/m2) and CC (≤33cm). The Brazilian version
of SARC-F was applied, and 10 points were added to the
SARC-F score if the subjects had a low CC. Subjects with a ﬁ-
nal score ≥11 were considered as at sarcopenia risk.
Results: A total of 205 elderly women (mean age:
67.3 ± 5.9 years) were included in the study. The majority
of the sample lived in rural areas (65.9%) were Caucasian
(71.2%), had 4–8 years of schooling (47.3%), lived with a part-
ner (61.5%) and were retired (92.2%). Applying EWGSOP
criteria, the prevalence of sarcopenia was 2.4% of the total
sample (5 subjects). Through SARC-F + CC, 37 women (18%)
were identiﬁed as in risk for sarcopenia. Although SARC-
F + CC presented low sensitivity (40%) and positive predictive
value (5.4%), it performed well in identifying healthy partici-
pants (speciﬁcity: 82.5%) and had an excellent negative pre-
dictive value (98.2%).
Conclusions: This study conﬁrms previous published ﬁndings
which suggest that the combination of SARC-F + CC, using
speciﬁc regional cut-off values for CC, can be used to rule
out healthy subjects from further testing, improving
sarcopenia screening in clinical practice.
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Introduction: The mean value of appendicular lean mass
(ALM) in Saudi young men has been recently determined
and was different from those of other ethnicities. Whether
ALM is associated with increased metabolic syndrome among
Saudis has not been examined.
Aim: The aim was to determine the association between
ALM, muscle strength and metabolic syndrome in Saudi men.
Methods: Participants included 497 Saudi men aged between
20 and 77 years. Hand grip and thigh strength was measured,
and lean muscle mass was assessed using dual-energy X-ray
absorptiometry (DXA). Venous blood samples were collected
to assess metabolic syndrome markers.
Results: There were 14.9% of participants who had low
ALM/Ht2 (2SD below reference value of Saudi young men).
Handgrip and thigh strength were signiﬁcantly lower among
sarcopenic group (37.9 ± 7.1 vs 43.4 ± 7.5, p < 0.001 and
63.5 ± 24.3 vs 76.6 ± 23.5, p < 0.001, respectively). Metabolic
Syndrome was 17.7% of participants, and 8.1% of them were
classiﬁed as sarcopenic. There were no signiﬁcant differences
between sarcopenic and normal group in metabolic syn-
drome factors, but there was correlation between total cho-
lesterol and ALM/Ht2 in sarcopenic group (r = 0.24). 63.9%
of participants were obese (BMI > 30 kg/m2). Sarcopenic
group had signiﬁcantly lower level of fat compared with nor-
mal group, and the decrease was found in trunk and arms,
but not legs (p = 0.27).
Conclusions: There was no association between low lean
mass and metabolic syndrome in Saudi men. Socioeconomic
factors that interact with current data have to be examined.
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Prevalence of sarcopenia in patients with cachexia
and disease-related malnutrition
Igor Khoroshilov1 & Sergei Ivanov2
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Aim: The sarcopenia prevalence assessment in patients with
cachexia and disease-related malnutrition.
Methods: 44 patients (16 men, 28 women) with undernutri-
tion (BMI less than 18.5 kg/m2) held the treating in 2012–
2016 years were included into retrospective analyze.
Sarcopenia was identiﬁed by criteria suggested G. Biolo,
T. Cederholm and M. Muscaritoli (2014): fat-free mass index
(FFMI) less than 17 kg/m2 for men and less than 15 kg/m2
for women. Bioimpedance analysis and dual energy X-ray ab-
sorptiometry were used for FFMI evaluating.
Results: It has been found that FFMI in the patients with ca-
chexia and precachexia with inﬂammation (cancer, Crohn’s
disease, ulcerative colitis, sepsis etc.) were 13.96  1.4 kg/
m2, particularly 13.5  0.47 kg/m2 in 7 women and 14.3 
0.49 kg/m2 in 9 men. Sarcopenia was found at all of 16 pa-
tients with cachexia and precachexia (100%). At 28 patients
with chronic and acute disease-related malnutrition (without
inﬂammation) FFMI were 13.7  0.4 kg/m2, particularly 13.7 
0.46 kg/m2 in 21 women and 13.7  1.2 kg/m2 in 7 men. In
patients without inﬂammation sarcopenia had been observed
in 19 persons (68%). Signiﬁcant differences in FFMI were
found between patients with sarcopenia but without inﬂam-
mation (FFMI was 12.68  0.49 kg/m2) and patients with
sarcopenia combined with cachexia (P < 0.05).
Conclusions: Sarcopenia is observed at all of patients with ca-
chexia and precachexia. Among patients with undernutrition
without inﬂammation the sarcopenia was observed at 68%
of them.
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Muscle thickness measured by A-mode ultrasound
in prediction of total lean body mass in apparently
healthy adults
Renata M. Bielemann, Mariana O. Xavier, Arele R. Nunes,
Rafaela B. Bergmann, Silvana P. Orlandi, Thiago G. Barbosa-Silva,
Maria Cecília Assunção & Maria Cristina Gonzalez
Federal University of Pelotas, Brazil, Catholic University of Pelotas, Brazil
Introduction: In the last decades, ultrasound (US) has
emerged as a promising tool to assess body composition, es-
pecially in situations where the assessment of muscle mass
should be done at bedside. To evaluate the relationship be-
tween muscle thicknesses in various body regions and total
lean soft tissue in adults.
Methods: Cross-sectional study with 208 individuals between
20 and 59 years from Pelotas, Brazil. Muscle thicknesses of bi-
ceps, triceps, thigh and calf regions were measured by A-
mode ultrasound (BodyMetrix®). Arm, thigh and leg circum-
ference and length were also measured. Lean soft tissue in-
dex (LSTI) (kg/m2) was obtained by total lean body mass
from DXA divided by squared height. The highest muscle
thickness from eight ultrasound measurements in each re-
gion was used in the analyses. Pearson correlation coefﬁ-
cients were obtained between muscle thickness of regions
of the upper and lower limbs and LSTI. Adjusted coefﬁcients
of determination (R2) were described to show the explained
variance in LSTI promoted by addition of each anthropomet-
ric information from linear regression.
Results: Muscle thickness from thigh showed the highest cor-
relation coefﬁcient with LSTI in both men (r = 0.68) and
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women (r = 0.52). Correlation coefﬁcients of sum of muscle
thickness from the four regions and LSTI was 0.78 in men
and 0.58 in women. Around 62% and 36% of variance in LSTI
was explained by the sum of muscle thickness in the four re-
gions. Arm, thigh and leg length did not increase the R2, but
arm, thigh and leg circumference increased the R2 to around
69% and 44% in men and women, respectively. Body weight
did not add explanation in LSTI after use of all other anthro-
pometric measurements.
Conclusions: The results demonstrated that the A-mode ul-
trasonography has shown good predictive value of LSTI in ap-
parently healthy men, mainly in set with other
anthropometric information.
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Introduction: The European Working Group on Sarcopenia in
Older People (EWGSOP) considered muscle mass loss to iden-
tify sarcopenic (S) or pre-sarcopenic (PS) patients. However,
loss of function without muscle mass loss, here called “func-
tionally impaired with normal muscle mass” (FINMM), may
determine a different prognostic risk. The objective of this
study is to use Phase angle (PA), a prognostic marker in sev-
eral clinical situations, and compare its values between
FINMM and patients with normal muscle mass and function
in non-sarcopenic (NS) patients.
Methods: Sarcopenia was assessed according to EWGSOP
criteria. The muscle mass was evaluated through the calf cir-
cumference (CC), using validated cut-offs for this population.
Muscle strength and performance were assessed by handgrip
strength and 4-m gait speed test. PA was assessed with a Bio-
electrical impedance analysis device, using resistance and re-
actance from 50 kHz.
Results: A sample of 82 patients with a mean age of
53.9 ± 16.9 years were studied. PS was present in 4.9% of
the sample, and sarcopenia in 32.9% (27 patients). There
were no signiﬁcant differences in PA values among NS
(5.91° ± 1.31°), PS (6.65° ± 1.54°) and S patients
(5.38° ± 1.27 ). Only severe sarcopenic patients had PA values
signiﬁcantly lower than NS and PS patients. From the 51 pa-
tients identiﬁed as NS, 34 patients were considered FINMM.
When normal and FINMM patients were compared, it was
found that PA values from FINMM patients were signiﬁcantly
lower than normal patients (5.46° ± 1.11°× 6.82° ± 1.22°,
p = 0.003), and they were not signiﬁcantly different from
PA values found in PS or S patients.
Conclusions: The lower PA values found in FINMM patients
may suggest that they should be identiﬁed as a special risk
group among non-sarcopenic patients. Longitudinal studies
may show the increased morbidity and mortality in this
group.
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SARA-data platform: clinical trials novel
methodologies and big data to evaluate
SARconeos in Age-related sarcopenia
Susanna Del Signore1,2, Gianluca Zia1, Stefania Del Signore1 &
Waly Dioh2
1Bluecompanion ltd, London, UK, 2Biophytis, Paris, France
Introduction: SARA clinical development program encom-
passes one observational study and two randomized, placebo
controlled clinical trials for evaluating the candidate drug
SARconeos (BIO101) in sarcopenic and obese sarcopenic pa-
tients Aged ≥65 years.
Methods:We deployed an integrated Information & Commu-
nication Technology (ICT) platform, SARA-data, to monitor on
real-time different source clinical, imaging (DEXA), laboratory
and physical activity data generated at investigation sites,
centralised lab and by the patients via wearable devices and
auto-evaluation questionnaires.
Standard designed clinical trials may be inadequate for
collecting informative long-term clinical data in older adults.
Rigid scheduling of visits and investigations negatively affects
compliance and retention rate while increasing the risk of bi-
ased results. Little is knownabout intercurrent changes inphys-
ical function between protocol scheduled visits at the clinic.
A novel approach, including systematic and continuous use of
wearable devices, allows to collect and integrate in one single
web-based portal all different data sources: electronic Case
Report Form clinical data, imaging DEXA scans,
biochemistry-haematology results from a centralised labora-
tory and disease related biomarkers. Of note, continuous
physical activity recording is enabled during the whole clinical
trial duration by providing each older participant with a wrist-
worn accelerometer. The device transmits anonymised activ-
ity data to SARA platform via a non-intrusive, unattended,
home-centred machine-to-machine technology. This kind of
high volume data, directly generated by the patient during
several months, fulﬁls the deﬁnition of Health-related Big
Data, and will constitute an important resource for addi-
tional, supportive analyses complementing standardised
muscular function assessments. These data are generated in
a real-life context and could provide answers to speciﬁc ques-
tions by regulators and payers.
Conclusions: SARA-data is an adapted ICT, real-time data
platform for conducting long-term clinical trials in older
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patients. The potential impact of using Big Data in geriatric
clinical research represents a further advantage, and enables
secondary research.
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Background: Computed tomography (CT) is an assessment of
body composition offering high precision and speciﬁcity. In
cancer patients, CT measurements of muscularity are corre-
lated with dose limiting toxicity, hospital length of stay, sur-
gery infections/complications and overall survival (OS).
Skeletal muscle compartment is one determinant of these ad-
verse outcomes. Small sample sets to date have hampered
our ability to understand the shape of the relationship be-
tween muscularity and outcomes. We sought to deﬁne the
sex-speciﬁc relationships between muscularity and mortality
in a large international data set including patients from
Canada and Europe.
Methods: Skeletal area (cm2) (SMA) and skeletal muscle in-
dex (SMI, cm2/m2) were assessed by CT at the 3rd lumbar
vertebra (L3) in advanced solid tumor patients. Data were
stratiﬁed into 10 equal groups (deciles), to explore relation-
ships to OS.
Results: Male patients (n = 2751) were 64 (±11.5) years, tu-
mor sites were colorectal (29.8%), other GI (22.3%) and lung
(17.4%) cancers that were mostly stage 4 (60.9%). Median of
OS was 20.7 (95% CI 19.1–22.3) months and mean SMI
49.5 ± 9.2 cm2/m2 and SMA 150.7 ± 29.27 cm2. Survival by
deciles of SMI (univariate) are shown (Table ). SMI was con-
tinuously related to OS, with the longest OS in the most
muscular individuals. SMI was independently prognostic of
OS in a model adjusted for age, cancer site, stage & perfor-
mance status (p = 0.021). Stratiﬁcation on SMA gave similar
results. Women (n = 1981) have a smaller range of muscular-
ity than men. Stratiﬁcation of SMI and SMA by deciles also
showed a continuous relationship with OS. In men and
women of equal muscularity, survival in women was signiﬁ-
cantly longer.
Conclusions: Muscularity is continuously related to OS in
male and female cancer patients. Prior research used statisti-
cal tests to identify threshold values of SMI associated with
survival (i.e. “sarcopenia” thresholds); this bivariate approach
oversimpliﬁes the relationship with OS.
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Skeletal muscle capillary density predicts insulin
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Introduction: Aging induces a substantial decrease in
muscle capillarization, reducing the transport of nutrients,
oxygen and hormones, such as insulin, into muscle ﬁbers.
Thus, muscle capillarization could be critical not only for
muscle growth but also for glucose intolerance and insulin
resistance. It is known that physical activity can improve
muscle perfusion by increasing capillary density in young
adults; however, its role in older adults is still
controversial.
The aim of this study was to investigate the association be-
tween muscle capillary density and indices of muscle hyper-
trophy and insulin sensitivity before and after 12 weeks of
progressive resistance exercise training (RET).
Table 1 Patient characteristics in male sex: skeletal muscle index and median overall survival
SMI (cm2/m2)
Overall Survival (months)
mean ± sd Median 95% CI HR 95% CI P
Male(n = 275)
Deciles0-10 34.2 ± 3.7 5.9 4.3–7.5 3.22 2.6–4.0 0.000
Deciles10-20 40.1 ± 1.1 12.8 10.6–15.0 2.17 1.7–2.7 0.000
Deciles20-30 43.2 ± 0.7 15.2 12.3–18.1 1.93 1.5–2.4 0.000
Deciles30-40 45.6 ± 0.7 17.7 13.9–21.5 1.78 1.4–2.2 0.000
Deciles40-50 47.9 ± 0.7 22.4 16.9–27.9 1.44 1.1–1.8 0.000
Deciles50-60 50.3 ± 0.6 24.4 18.8–30.0 1.36 1.0–1.7 0.010
Deciles60-70 52.7 ± 0.9 26.1 22.4–29.8 1.42 1.1–1.8 0.000
Deciles70-80 55.5 ± 0.8 32.3 27.2–37.5 1.10 0,9–1.4 0.420
Deciles80-90 58.9 ± 1.2 36.7 29.6–43.7 1.05 0.8–1.3 0.710
Deciles90-100 66.6 ± 4.9 36.8 28.5–45.0
*Kruskal–Wallis test * p < 0.000 between all deciles groups.
**Kaplan–Meier method—Log-rank (Mantel–Cox) analysis and Cox proportional hazards model.
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Methods: 19 subjects (71.1 ± 4.3 years; 27.6 ± 3.2 BMI) were
studied before and after 12 weeks of RET. Pre- and post-
training measurements of muscle mass, strength and OGTT
were obtained. Insulin sensitivity was assessed with Matsuda
index and OGIS index. In addition, pre and post study days
also included percutaneous biopsies from the vastus lateralis
muscle. Immunohistochemical analysis was used to quantify
capillary density, myosin heavy chain (MyHC) isoform expres-
sion and cross-sectional area (CSA).
Results: Basalmuscle capillarizationwas highly correlatedwith
leanbodymass, sarcopenic index (SMI) anddaily physical activ-
ity level (p< 0.05). Muscle capillary density was also positively
associated (p< 0.05) with ﬁber type I frequency and ﬁber size
(CSA).Moreover, higher basal capillarizationwaspositively cor-
related (p<0.05)with a higher improvement in the insulin sen-
sitivity index and muscle ﬁber CSA. RET increased muscle
capillary density (p< 0.05), which was also correlated with an
increase in ﬁber CSA and MyHC type II ﬁber frequency.
Conclusions: Muscle ﬁber capillarization at baseline may be a
predictive factor for improving insulin sensitivity in response
to RET in older adults. Increases in muscle ﬁber perfusion fol-
lowing RET are correlated with muscle growth.
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3 days of human skeletal muscle disuse promote
fatty inﬁltrations development
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Introduction: Fatty inﬁltrations, or intermuscular adipose
tissue (IMAT), are currently well-recognized components
of muscle deconditioning. Although IMAT is present in
healthy human skeletal muscle, its increase and accumula-
tion are linked to muscle dysfunction. Although IMAT de-
velopment has been largely attributable to inactivity, the
precise mechanisms of its establishment are still poorly un-
derstood. Because the sedentary lifestyle that accompanies
age-related sarcopenia may favor IMAT development,
deciphering the early processes of muscle disuse is of
great importance before implementing strategies to limit
IMAT deposition.
Methods: Here, we took advantage of the dry immersion
(DI) model of severe muscle inactivity to induce rapid mus-
cle deconditioning during a short period. Skeletal muscle
biopsies were obtained from the vastus lateralis of healthy
men (n = 12; age: 32 ± 6) before and after 3 days of DI.
Results: We showed that DI for only 3 days was able to de-
crease myoﬁber cross-sectional areas (10.6%). Protein ex-
pression levels of two key markers commonly used to
assess IMAT, perilipin and FAPB4 were upregulated. We ob-
served an increase in the C/EBPα and PPARγ protein
expression levels, indicating an increase in late adipogenic
processes leading to IMAT development. While many stem
cells in the muscle environment can adopt the capacity to dif-
ferentiate into adipocytes, ﬁbro-adipogenic progenitors
(FAPs) appear to play a major role in IMAT development. In
our study, we showed an increase in the protein expression
of PDGFRα, the speciﬁc cell surface marker of FAPs, in re-
sponse to 3 days of DI. It is well recognized that an unfavor-
able muscle environment drives FAPs to ectopic adiposity
and/or ﬁbrosis.
Conclusions: This study is the ﬁrst to emphasize that during a
short period of severe inactivity, muscle deconditioning is as-
sociated with IMAT development. Our study also reveals that
FAPs could be the main resident muscle stem cell population
implicated in ectopic adiposity development in human skele-
tal muscle.
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women are in part secondary to signals originating
in persistently denervated muscle ﬁbers
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Carole Spake1, Kathryn J. Wright3, Anna Perez2,
Jose A. Morais3, Tanja Taivassalo4 & RussellT Hepple5
1Department of Kinesiology and Physical Education, McGill University, Montreal,
QC, Canada, 2Meakins Christie Laboratories and Research Institute of the McGill
University Health Centre, Montreal, QC, Canada, 3Research Institute of the McGill
University Health Centre, Montreal, QC, Canada, 4Department of Physiology and
Functional Genomics, University of Florida, Gainesville, FL, USA, 5Department of
Physical Therapy, University of Florida, Gainesville, FL, USA
Introduction: Mitochondrial impairment is implicated in the
age-related decline in skeletal muscle, but whether the mito-
chondrion represents a therapeutic target depends upon
whether the changes in function of this organelle are primary
organelle defects or secondary responses to other changes in
the aging milieu. Whereas we recently showed that mito-
chondrial function changes in octogenarian men are at least
partly secondary to muscle ﬁber denervation, this has not
been addressed in pre-frail/frail elderly women.
Methods: Mitochondrial respiratory capacity by high-
resolution respirometry and reactive oxygen species (ROS)
emission by Amplex Red was determined in saponin
permeablized myoﬁbers obtained from Vastus lateralis mus-
cle biopsies of prefrail/frail elderly (FE; 79.6 ± 4.9y) and
healthy young inactive (YI; 23.1 ± 2.5y) women. The effect
of denervation on mitochondrial function during the ROS as-
say was assessed pharmacologically upon inhibition of cPLA2
with arachadonyl triﬂuoromethyl ketone (AACOCF3). The
presence of denervated myoﬁbers was assessed morphologi-
cally by histochemistry.
Results:Muscle respiratory capacity was reduced in FE due to
lower mitochondrial content, whereas FE exhibited higher
ROS emission even after normalizing for mitochondrial con-
tent compared to YI group. The reduction in ROS production
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compared to ethanol vehicle control in FE (Ethanol:
1.3 ± 0.5 pmol/min/mg vs AACOCF3: 0.8 ± 0.4 pmol/min/
mg; p < 0.001) reveals a modulating impact of denervation
on mitochondrial function in FE women, as seen previously
in octogenarian men. Consistent with this, there was a signif-
icant accumulation (15.9%) of very small ﬁbers (deﬁned as a
size ≤1505 μm2) exhibiting histological evidence of denerva-
tion (high non-speciﬁc esterase activity) in FE.
Conclusions: We can conclude that denervation plays a mod-
ulating role in skeletal muscle mitochondrial function in
prefrail/frail elderly women, suggesting therapeutic strate-
gies in advanced age should focus on the causes of persistent
denervation.
3-04
Relationships between the branched chain amino
acid transporter LAT 3 and Myosin Heavy Chain
proteins in human skeletal muscle
Britt-Marie Iresjö, Cecilia Engström & Kent Lundholm
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Introduction: Recent studies indicate participation of amino
acid transporter proteins in activation of mTOR signaling
and down-stream increase in muscle protein synthesis. In a
previous study we identiﬁed amino acid transporter LAT 3,
a transporter of BCAA, met, phe, as signiﬁcantly altered in re-
sponse to provision of total parenteral nutrition (TPN)
(p < 0.01). Here we investigate if alterations in LAT3 mRNA
and protein concentrations reﬂect altered gene transcription
of myosin proteins.
Methods: 22 patients (mean weight loss 6 ± 2%) scheduled
for upper GI-surgery received either a continuous standard
TPN infusion (0.16 gN kg1 day1, 30 kcal kg1 day1) or sa-
line infusion for 12 hours overnight before operation. Biop-
sies from the rectus abdominis muscle were taken at start
of operation. LAT 3 mRNA and mRNA of Myosin heavy chain
(MHC) isoforms MHC1, MHC2A and MHC2X were analyzed by
real-time PCR. LAT3 transporter protein content was quanti-
ﬁed by western blot in a subgroup of patients (n = 18). Linear
regression was used for analyses of relationships.
Results: MHC2A mRNA concentrations showed a positive re-
gression with LAT 3 mRNA (r = 0.56; p = 0.007), while there
were no relationship between MHC1 or MHC2X and LAT3
mRNA concentrations. There were a negative relationship be-
tween MHC2A mRNA and LAT 3 protein content (r = 0.62;
p = 0.007) while MHC2X mRNA showed a positive linear rela-
tionship with LAT3 protein content (r = 0.53; p = 0.02). No re-
lationship was found between MHC1 mRNA and LAT3 protein
content.
Conclusions: Both mRNA and protein concentrations of
the branched chain amino acid transporter LAT 3 showed
a signiﬁcant relationship with Myosin Heavy Chain 2A
mRNA concentrations in muscle cells. The lack of relation-
ship with other Myosin Heavy chain isoforms and LAT3
may suggest speciﬁc regulation of individual MHC tran-
scripts. These ﬁndings deserve further nutritional evalua-
tions to understand the control of myoﬁbrillar protein
translation.
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Introduction: Mitochondrial dysfunction in skeletal myocytes
has been proposed as a major factor contributing to the de-
velopment and progression of sarcopenia. Hence, the quanti-
tation of mitochondrial DNA (mtDNA) abundance and mtDNA
deletion mutation load may help clarify the role of mtDNA in-
stability in muscle aging.
Methods: We applied real-time PCR-based approaches to to-
tal DNA puriﬁed in muscle samples obtained from young
adults, sedentary older adults, classiﬁed as high- and low-
functioning based on the Short Physical Performance Battery
(SPPB), in order to examine the effect of aging on key quan-
titative alterations of mtDNA and how this relates to physical
performance.
Results: Muscle volume, as quantiﬁed via 3D-NMR, was de-
creased by 38% and 30% in low- (LFE) and high-functioning
elderly (LFE) participants, respectively, when compared to
young and high-functioning elderly participants, respec-
tively, and positively correlated with physical performance.
The content of mtDNA was found to be signiﬁcantly re-
duced in both groups of elderly participants, regardless of
the SPPB score, relative to their younger counterparts.
The age-associated decrease in mtDNA abundance was
paralleled by an increase in the mtDNA deletion in HFE
and LFE participants, with no differences between the two
groups. Further investigations will probe alterations in
mtDNA encoding genes: NADH dehydrogenase 1 (ND1/
Complex 1), Cytochrome b (Complex III), and cytochrome
c oxidase (COI/Complex IV).
Conclusions: This study shows altered mitochondrial ho-
meostasis in muscles of aged human. The decline in
myocyte mitochondrial mass and the accumulation of
mtDNA deletions may therefore represent critical steps
to muscle aging and possible targets for interventions
against sarcopenia.
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Background: Unraveling the complexity of aging is crucial for
understanding its mechanisms and why aging is the risk fac-
tor for most chronic conditions. The advancements marked
by genome-wide association studies (GWASs) have sparked
interest in gene cataloguing in the context of aging and
age-related conditions. Here, we used GWAS to explore
whether single nucleotide polymorphisms (SNPs) were asso-
ciated with functional and anthropometric parameters in a
cohort of old community-dwellers enrolled in the ilSIRENTE
aging study.
Methods: Analyses were carried out in men and women
aged 80+ years enrolled in the ilSIRENTE Study (n = 286)
and replicated in the inCHIANTI Study (n = 1055).
Genotyping was accomplished on Inﬁnium Human610-
QUAD version 1.
Results: In the ilSIRENTE population, genetic variants in
ZNF295 and C2CD2 (rs928874 and rs1788355) on chromo-
some 21q22.3 were signiﬁcantly associated with the 4-meter
gait speed (rs928874, p = 5.61 × 108; rs1788355,
p = 5.73 × 108). This association was not replicated in the
inCHIANTI population.
Conclusions: Our ﬁndings suggest that speciﬁc SNPs may be
associated with a key measure of physical performance in
older adults. GWASs using larger samples are needed to con-
ﬁrm these preliminary results to enhance our comprehension
of complex age-associated phenomena.
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Introduction: Cancer-associated cachexia is a metabolic syn-
drome characterized by weight loss and systemic inﬂamma-
tion. Exacerbated inﬂammation seems to cause protein and
energy disorders leading to reduced survival and quality of
life. Furthermore, systemic inﬂammation may be involved in
muscle wasting and impaired myogenesis. Therefore, the
present study aimed to evaluate satellite cells markers and
cell signaling proteins in skeletal muscle of gastrointestinal
cancer patients.
Methods: Patients with gastrointestinal cancer were re-
cruited after signature of the informed consent form. Rectus
abdominismuscle biopsies were collected in surgery. Patients
were separated into Weight-Stable Cancer (WSC) and Cachec-
tic Cancer (CC) groups (WSC n = 13 and CC n = 16) according
to criteria described by Evans et al. (2008). Muscle mRNA was
extracted and real-time PCR gene expression was analysed
using 2-ΔΔCT. Cell signalling proteins and CX3CL1 were quanti-
ﬁed with Luminex®xMAP technology.
Results: mRNA relative levels of two transcription factors
expressed mainly by satellite cells, PAX7 and MYF5, were in-
creased in CC patients (p = 0.004 and p = 0.003 respectively).
Furthermore, CC muscle biopsies showed decreased JNK
(p = 0.006) and p53 protein content (p = 0.03) and an increase
in those of ATF-2 (p < 0.03), cJUN (p = 0.04) and mitogen-
and stress-activated protein kinase (MSK1) (p = 0.038) in rela-
tion to WSC patients. CX3CL1, a chemokine that may be in-
volved in muscle regeneration, was decreased in CC
patients (p = 0.0004).
Conclusions: Changes in satellite cells markers seems to indi-
cate an attempt towards myoblasts proliferation and differ-
entiation; however, this process may be compromised as
suggested by the lower p53 protein content. Sustained sys-
temic inﬂammation may impair myocyte differentiation and
consequently decrease muscle regeneration capability in CC
patients. Further analysis of muscle differentiation markers
are required to corroborate these ﬁndings.
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Introduction: Low muscle mass is a deﬁning feature of cancer
cachexia. Methods for measuring muscle mass exist, but
these are often too time-consuming and expensive for the
routine evaluation of patients in clinic. Several different circu-
lating markers of muscle mass have been proposed but to
date, none have been validated.
Methods: Repeated measurements of body composition (CT
cross-sectional imaging or DEXA) were performed and simul-
taneous blood samples were collected, on up to 4 occasions,
from patients with cancer. Serum assays for nine different
candidate markers of muscle mass were measured. The cor-
relation between each serum marker and muscularity (ap-
pendicular skeletal muscle mass index (ASMI (kg/h2)) was
assessed. In addition, comparison of values of each serum
marker in those with and without low muscle mass was
performed.
Results: 43 patients (67% men), mean (SD) age 62(12) yr were
recruited at two sites. 60% had lung cancer and 91% had ad-
vanced (stage III/IV) disease. Serum levels of Creatinine Ki-
nase, Myoglobin, Ghrelin, Testosterone (men), Insulin,
Growth Hormone, Cortisol and C-reactive protein did not cor-
relate with ASMI. However, insulin-like growth factor-1 (IGF)
levels did correlate with ASMI (e.g. visit 1: R = 0.38,
P = 0.02). Furthermore, using sex-speciﬁc cut-offs for ASMI,
IGF levels was the only marker which was signiﬁcantly differ-
ent in sarcopenic individuals (Sarcopenia N vs Y: 24.9 vs
17.3 nmol/l, P = 0.04). Lower IGF levels were also associated
with greater loss of muscle mass (e.g. IGF < 17 nmol/l: 0.8 kg
loss vs 0.2 kg gain, P = 0.02).
Conclusions: Of the serum markers tested, only IGF ap-
pears to be useful to identify advanced cancer patients
who have low muscle mass. Furthermore, low circulating
IGF may also help predict which patients are most at risk
of further muscle loss.
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TNF-α-mediated inﬂammatory apoptosis and
angiogenesis in physical inactivity-induced muscle
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Introduction: Skeletal muscle atrophy can result from physi-
cal inactivity, space ﬂight and chronic bed rest associated
with ageing. Hind-limb unloading (HU) is an accepted rodent
model of muscle disuse to simulate physical inactivity. We in-
vestigated the roles of tumor necrosis factor-alpha (TNF-α) in
apoptosis and angiogenesis pathways using HU-induced mus-
cle atrophy model.
Methods: HU was performed in 8-week-old ICR mice for 14
consecutive days. We compared muscle mass, muscle
strength, morphology, and blood ﬂow, reactive oxygen spe-
cies (ROS), TNF-α, vascular endothelial growth factor (VEGF),
endothelial NOS (eNOS), cytochrome C (Cyto-C), B-cell lym-
phoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-9,
and caspase-3 between HU vs. control mice.
Results: As compared to control mice, HU mice were signif-
icantly lower in muscle mass and strength (p < 0.01), with
their muscle ﬁbers arranged more loosely along a different
direction. HU mice had signiﬁcantly higher levels of blood
ROS, expressions of TNF-α, VEGF, and caspase-3 in the skel-
etal muscle (p < 0.01), and the blood ﬂows in the hind-
limb and whole body were signiﬁcantly higher (P < 0.05).
No signiﬁcant differences were found in the expressions
of other biomarkers between the two groups. TNF-α was
highly correlated with both caspase 3 (r = 0.725,
P < 0.01) and VEGF (r = 0.725, P < 0.01) in the hind-limb
muscles in response to HU.
Conclusions: TNF-α is involved in both the caspase 3-mediated
apoptosis pathway and the VEGF-mediated angiogenesis
pathway in HU-induced muscle atrophy. Development of
future treatments for physical inactivity-induced muscle atro-
phy should take into consideration the ﬁndings of this study.
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†Denotes co-ﬁrst authors.
Introduction: Although colon cancer has the second highest
cancer mortality rate, targeted treatments are improving sur-
vival. 5-Fluoroucil (5-FU) is a common chemotherapeutic
used to treat colon cancer. Cancer therapy can adversely af-
fect many tissues and processes including skeletal muscle.
However, 5-FU’s effects on skeletal muscle quality and func-
tion are not known.
Purpose: Therefore, we examined the effect of a 5-FU
treatment regime on indices of skeletal muscle wasting in a
pre-clinical model of colon cancer.
Methods: At 12 weeks of age, after intestinal and colon
polyp development, male ApcMin/+ mice were treated with
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PBS (n = 10) or 5-FU (n = 10) once every two weeks for six
weeks. At 18 weeks of age muscles were examined for in-
ﬂammation, protein turnover, and mitochondrial signaling as-
sociated with wasting.
Results: Both PBS (6 ± 2%) and 5-FU (4 ± 1%) mice lost
bodyweight and were initiating cachexia. Absolute grip
strength and triceps surae muscle mass were higher with 5-
FU treatment. Muscle inﬂammatory signaling (p-STAT, p-65)
was suppressed by 5-FU. Protein turnover regulation was im-
proved by 5-FU (increased p70S6K, decreased Atrogin-1), and
5-FU also increased quadriceps muscle ribosomal capacity.
Additionally, 5-FU treatment rescued muscle metabolic sig-
naling associated with AMPK, DRP-1, and PGC-1α.
Autophagy-related signaling (LCB II: I, BNIP3, p62) was de-
creased by 5-FU.
Discussion: Collectively, we report that the 5-FU treatment to
tumor bearing mice improved indices of muscle quality re-
lated to the wasting phenotype. Future studies will need to
delineate the potential mechanisms regulating 5-FU’s protec-
tive effects on muscle metabolic and functional capacities in-
dependent to cancer-induced body weight loss.
Acknowledgements: Supported by NCI R01-CA121249 and
NIGMS 5P30GM103336.
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Introduction: In the fatal X-linked skeletal muscle wasting dis-
ease, Duchenne Muscular Dystrophy (DMD), the progressive
degeneration of skeletal muscle coincides with impaired mi-
tochondrial function, alterations in structural networking,
the inability to respond to metabolic stress signaling and
the decline of cellular energy stores1. Similar metabolic signa-
tures are observed in other skeletal muscle wasting
phenotypes such as cachexia2, diabetic myopathy3, chronic
obstructive pulmonary disease4 and sarcopenia.5 We have in-
vestigated whether the purine nucleotide, adenylosuccinic
acid (ASA), a mitochondrial and purine nucleotide cycle
stimulant, can be used to enhance mitochondrial dynamics,
cellular bioenergetics and attenuate skeletal muscle wasting
in the mdx mouse model of DMD.
Methods: Four-week-old control (C57Bl/10; CON) and dystro-
phic mdx mice were treated with 3000 μg·mL1 ASA in drink-
ing water (~350 mg·kg1 day1) for 8 weeks. Skeletal muscle
mitochondrial density, viability, oxidative function and
superoxide (O2) content, alongside metabolic stress re-
sponse signaling (adenosine monophosphate protein-
activated kinase (AMPK) and peroxisome proliferator-
activated receptor gamma coactivator-1α/β (PGC1α/β) and
histopathology, including ﬁber cross-sectional area,
damage/regeneration, pseudohypertrophy and fat and ﬁ-
brotic tissue inﬁltration, were assessed.
Results: ASA treatment increased mitochondrial density (by
>200% in isolated ﬂexor digitorum brevis (FDB) ﬁbers
(p < 0.01) and ~50% in tibialis anterior (TA) cross-sections
(p < 0.0001) and viability (by ~20% in FDB ﬁbers; p < 0.05),
as well as the bioenergetical proﬁle of TA muscles, including
phosphocreatine (p < 0.01) concentration. ASA also reduced
O2 production by ~25% (p < 0.05). These changes were in-
dependent of AMPK and PGC1α/β activation in mdx quadri-
ceps. ASA treatment signiﬁcantly attenuated skeletal muscle
damage (p < 0.01) and wasting (p < 0.05) in mdx TA, as well
as downstream histopathological features including
pseudohypertrophy (p < 0.05), centronucleated ﬁbers
(p < 0.01), lipid accumulation (p < 0.05) and connective tis-
sue inﬁltrate (p < 0.001).
Conclusions: Our data highlight a protective effect of ASA on
skeletal muscle-wasting phenotypes by stimulating unknown
molecular pathways to enhance mitochondrial density and vi-
ability, as well as cellular bioenergetics.
References:
1. Timpani et al., Med Hypoth; 2015
2. Der-Torrosian et al., J Cachexia Sarcopenia Muscle; 2013
4(2):145–155.
3. Ohlendiek, J Nutrition Metabolism, 2012
4. Gea et al., J Thorac Dis, 2015 7(10): E418-E438.
5. Garvey et al., Biogerentology, 2014 15(3): 214–232.
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Introduction: Chronic tobacco smoke (TS)-related diseases,
such as cancer, cardiovascular disease and Chronic Obstruc-
tive Pulmonary Disease, are associated with common ele-
ments of skeletal muscle deterioration (fast ﬁber shift,
erosion of oxidative capacity and atrophy) that worsen clini-
cal outcomes, including increasing the risk of death. Although
chronic TS exposure is an exacerbating factor in conditions
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involving neuromuscular junction degeneration, including ag-
ing and amyotrophic lateral sclerosis (ALS), there are as of yet
no data addressing the impact of chronic TS exposure on the
neuromuscular junction and how this relates to the muscle
alterations induced by TS. Furthermore, although chronic ac-
tivation of the aryl hydrocarbon receptor (AHR) is linked to
neurotoxicity, and the AHR responds to multiple compounds
in TS, no studies have considered the role of the AHR in me-
diating the adverse impact of chronic TS exposure on muscle.
Methods: In the ﬁrst set of experiments, we exposed 8-
month-old C57Bl6 male mice to 60 minutes of TS exposure
twice daily, 5 days per week, for 16 weeks. Following the ﬁnal
TS exposure, we examined muscle mass, neuromuscular junc-
tion morphology by confocal microscopy, and oxidative ca-
pacity by high-resolution respirometry. In the second set of
experiments, we determined whether whole body knockout
of the AHR would attenuate the neuromuscular junction im-
pact of 8 weeks of TS exposure in 3-month-old male mice.
Results: 16 weeks of TS induced mild atrophy of limb muscle
that was associated with neuromuscular junction degenera-
tion and mild erosion of oxidative capacity. Strikingly, AHR
knockout completely prevented the TS-induced neuromuscu-
lar junction degeneration and reduced indices of stress in ho-
mogenates of spinal cord tissue.
Conclusions: Chronic TS exposure induces neuromuscular
junction degeneration that is dependent upon the AHR, pro-
viding novel insights into the mechanisms by which chronic
TS adversely impacts skeletal muscle.
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parameters to molecular signaling
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Introduction: Inactivity is the main factor during aging lead-
ing to physical alterations, such as muscle atrophy, strength
reduction, balance and coordination impairment, and aerobic
ﬁtness decrease. Muscle atrophy and strength decrease can
be explained by an impairment of muscle protein balance
characterized by a decreased protein synthesis and an
increased proteolysis. Also, a decrease in mitochondria con-
tent and functions are involved in the impairment of aerobic
ﬁtness observed during aging. These mechanisms are af-
fected by numerous upstream factors including a decrease
in the release of anabolic hormones, increased pro-
inﬂammatory cytokines production and an increase in muscle
oxidative stress. Each of these adaptations could turn to seri-
ous health deterioration during aging. Beta-hydroxy-beta-
methylbutyrate (HMB), a leucine metabolite, has been
described in normal condition to increase aerobic ﬁtness
and prevents muscle atrophy during cancer through
enhanced mitochondria functions, anti-catabolic and anabolic
mechanisms. We hypothesized that HMB could be used as a
nutritional countermeasure to prevent physical decon-
ditioning due to inactivity.
Methods: Mature C56Black6J male mice were hindlimb-
unloaded (HU) or kept ambulatory for 14 days. Mice were
provided either HMB (250 mg/kg body mass per day) or dis-
tilled water by oral gavage for 21 days. Aerobic ﬁtness was
evaluated and a multiple static rod test assessed coordination
and balance. Histological and molecular analyses were done
on soleus muscle and plasma.
Results and Discussion: HMB treatment counteracted soleus
slow and fast-twitch ﬁbers atrophy. Aerobic ﬁtness, coordina-
tion and balance were also counteracted in HU treated mice.
These results can be explained by a better protein balance in
treated mice compared to placebo mice as shown by higher
protein synthesis and lower proteolysis in mice receiving
HMB. According to our results, lower oxidative stress and
inﬂammation could explain the better protein balance in
treated mice.
Conclusions: HMB could thus be envisaged as an efﬁcient
nutritional countermeasure.
Our work is supported by grants from the French “Centre
National d’Etudes Spatiales” (CNES).
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Introduction: Frailty is a clinical syndrome associated with
the aging process, which leads to a decreased physical func-
tion. The damages induced by reactive oxygen species (ROS)
in cells accentuate this process. The antioxidant system is
largely based on the reducing power of NADPH, whose levels
are mainly determined by the enzyme glucose-6-phosphate
dehydrogenase (G6PD).
Material and methods: Using a speciﬁc model of Tg-mice
overexpressing G6PD, we measured oxidative stress parame-
ters, cross-sectionnal area (CSA) of muscle ﬁbers, markers
regulating protein synthesis, mitochondrial dynamics and
apoptosis. We used a cohort of WT and G6PD-Tg old female
mice (from 18 to 26 months old) to evaluate the evolution
of 5 functional parameters and establish a score for frailty
based on the construct described by Linda Fried. CSA and
molecular markers were measured on 21 months old mice.
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Results: Our results relative to functional test demonstrated
that 18–20 and 23–24 months old G6PD-Tg animals per-
formed better in the motor coordination test than the WT.
At the age of 23–24 months, 45% of WT-mice were consid-
ered frail for maximal strength vs 4.8% in the G6PD-Tg group.
Taking into account the 5 different parameters, we founded
that the percentage of mice considered as frail is higher in
the WT than in the G6PD-Tg group. G6PD-Tg mice exhibited
higher muscle ﬁber CSA, levels of reduced glutathione
(GSH), lower levels of apoptosis and our results suggest a
higher protein synthesis in muscle tissue.
Conclusions: Finally, overexpression of G6PD in mice prevents
frailty in 18 to 26 months old mice acting on muscle mass and
metabolism (protein balance, oxidative stress, mitochondria
and apoptosis).
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of heart failure with preserved ejection fraction
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Introduction: Despite normal left ventricular ejection fraction
(LVEF), patients with heart failure and preserved left ventric-
ular ejection fraction (HFpEF) present exercise intolerance
which can be attenuated by exercise training. Alterations in
skeletal muscle have been described in HFpEF, yet the under-
lying mechanisms involved as well potential beneﬁts
mediated by exercise training remain unknown. The present
study, therefore, used a cardiometabolic rat model of HFpEF
to further elucidate: 1) the skeletal muscle alterations
induced; and 2) the effects of aerobic exercise training during
secondary prevention.
Methods: After 20 weeks, obese Zucker diabetic
fatty/spontaneously hypertensive heart failure F1 hybrid
(ZSF1) rats (n = 12) were compared to their lean counterparts
(n = 8), with a further 3 groups of obese ZSF1 rats assessed
8 weeks later following sedentary behavior (n = 15),
moderate-continuous training (MCT; n = 11) or high-intensity
interval training (HIIT; n = 11) on a treadmill.
Results: Obese rats evidenced HFpEF: diastolic dysfunction,
LV hypertrophy, and exercise intolerance were present
(P < 0.05) with LVEF preserved. HFpEF rats demonstrated
~20% reduction (P < 0.05) in both ﬁber cross-sectional area
and capillary-to-ﬁber ratio in the extensor digitorum longus
(EDL) skeletal muscle, which were not reversed by exercise
training. These alterations were further associated with a re-
duction in absolute maximal force by ~30% and greater fati-
gability by ~20% in all HFpEF groups compared to controls.
Conclusions: A cardiometabolic obese rat model of HFpEF
was associated with skeletal muscle atrophy, impaired
capillarity, and functional deﬁcits, yet these alterations could
not be reversed by aerobic exercise training. Whether these
ﬁndings translate to patients, whereby exercise training has
limited efﬁcacy in treating skeletal muscle impairments in
HFpEF, requires further investigation.
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Introduction: Diaphragm weakness is a risk factor leading to
prolonged mechanical ventilation, increased morbidity and
death for patients in intensive care units. Muscle dysfunc-
tion is related to an unbalance between protein synthesis
and breakdown. Glucocorticoids and pro-inﬂammatory cyto-
kines such as TNF-α and IL-6 play an important role in the
activation of calpain and ubiquitin proteasome system.
Since few years, myostatine, a member of TGF-β family,
seems to strongly trigger activation of protein breakdown.
The aim of this study was to investigate the potent beneﬁt
effect of a TGF- β receptor inhibitor in muscle function
during chronic sepsis.
Methods: Chronic sepsis was induced by cecal ligation and
puncture (CLP) and carried out during 7 days. Three groups
were realized: sham group, septic group, and septic group
with daily intra peritoneal injection of TGF-βRI inhibitor
(LY364947 at 1 mg/kg) starting 24 h after sepsis induction
(LY group). Rats were sacriﬁced 7 days after sepsis induction,
and the diaphragm was removed for muscle contraction re-
cordings then weighted. Mean values are compared to sham
group.
Results: Chronic sepsis led to a signiﬁcant decrease of 20% of
diaphragm mass (176.7 ± 15 g vs. 221.1 ± 12.4 g in sham
group) but with inhibitor treatment, the mass was not signif-
icantly modiﬁed (218.1 ± 20.8 g). Concerning muscle contrac-
tion, absolute force was decreased in septic group by
approximatively 35% (75 ± 16 g vs. 115.4 ± 9 g in sham
group), and in LY group the maximal force was restored to
109.7 ± 8 g. In the same manner, the speciﬁc force was de-
creased by 32% in septic group (92.3 ± 21 g/cm2 vs.
135.2 ± 8 g/cm2 in sham group) whereas there was no differ-
ence in LY group (140.7 ± 10 g/cm2).
Conclusions: This work demonstrates that the inhibition of
TGF-β pathway can protect muscle such as diaphragm from
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weakness and proteolysis during chronic sepsis. This could be
of a major importance in the care of septic patients.
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Effects of β hydroxy-β-methylbutyrate on liver
regeneration, skeletal muscle protein balance, and
amino acid concentrations in partially
hepatectomized rats
Milan Holeček & Melita Vodeničarovova
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Introduction: Beta-hydroxy-beta-methylbutyrate (HMB) is a
leucine metabolite used as a nutritional supplement for pres-
ervation of muscle mass in elderly and muscle wasting disor-
ders, and as an ergogenic aid in exercise. Although most of
the HMB is produced in the liver, there are no reports of
the effects of HMB in subjects with liver injury. We examined
the effects of HMB on liver regeneration, muscle protein bal-
ance, and amino acid concentrations in rats after partial
(68%) hepatectomy (PH).
Methods: HMB (200 mg/kg/day) or saline were administered
using osmotic pumps to PH or laparotomized rats for 7 days.
The animals were then sacriﬁced by exsanguination and the
liver, m. soleus (SOL, slow-twitch, red muscle), and m. exten-
sor digitorum longus (EDL, fast-twitch, white muscle) were
quickly removed and weighed. Blood plasma and tissue sam-
ples were kept in 80 °C until analyses. ANOVA and
Bonferroni multiple comparisons procedure were used for
statistical analysis of the results.
Results: In PH animals we found lower concentrations of glu-
cose, triglycerides and urea, and higher concentrations of cre-
atinine, bilirubin, alanine, and ketoisovalerate in blood
plasma, lower weights and protein contents in EDL, and lower
weights and protein and DNA contents in the liver when com-
pared with laparotomized animals. In PH rats treated by HMB
we found higher concentrations of urea, triglycerides,
branched-chain amino acids (BCAA; valine, leucine, isoleu-
cine) and branched-chain keto acids, and lower concentra-
tions of glucose and creatinine in blood plasma, higher
BCAA concentrations in muscles and in the liver, and higher
DNA contents in the liver than in saline treated animals.
The effect of PH on muscle weights and protein contents
was in HMB treated rats insigniﬁcant.
Conclusions: The results indicate that HMB administration af-
fects metabolism of the BCAA and has favourable effects on
protein balance in muscles and liver regeneration in PH
animals.
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Introduction: Macrophages play different roles in tissue ho-
meostasis, as they are involved in defense from pathogens,
debris removal as well as in tissue repair. Their effects are re-
lated to their activation/polarization state, which depends on
the stimuli they receive. Two major MF phenotype can be dis-
tinguished; M1, a proinﬂammatory phenotype, and M2, a
pro-tolerogenic and tissue repair-favoring proﬁle.
On regenerating skeletal muscle, M1 inhibit myogenic pre-
cursor cell fusion while M2 promote satellite cell differentia-
tion to form mature myotubes. It has been demonstrated
in vivo—included in humans—that macrophages sequentially
orchestrate adult myogenesis during regeneration of dam-
aged skeletal muscle where differentiating myogenin-positive
myogenic precursor cells preferentially couple to anti-
inﬂammatory macrophages.
Interestingly, the activation and polarization of macro-
phages is associated to a well-deﬁned metabolic repro-
gramming and a robust association between the metabolic
state and the phenotype of macrophages exists. In particular,
M1 obtains energy mainly by glycolysis while M2 relies
mostly on the oxidative metabolism. Several drugs, deﬁned
metabolic modulators, have been extensively studied in
cardiology and their ability to reprogram the metabolism of
the myocardium and to optimize the production of energy
has been assessed.
Methods: Here, we treated un-stimulated and M2-stimulated
macrophages with metabolic modulators, in vitro. Moreover,
we administered trimetazidine (TMZ), an MM also used in
clinical practice, to mice recovering from skeletal muscle
damage due to cardiotoxin.
Results: We showed that metabolic modulators are capable
to enhance M2 polarization in vitro, inducing the expression
of M2-related genes both in M2-stimulated macrophages
and in un-stimulated macrophages. We also observed that
in injured muscle of TMZ treated mice there is a decrease
in the number of muscle inﬁltrating macrophages.
Conclusions: Taken together, these preliminary data suggest
that metabolic modulators can be used to modulate macro-
phage polarization, which might be useful to sustain tissue
regeneration.
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Mineralocorticoid Receptor activation.
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Background and aims: Mineralocorticoid Receptor (MR)
modulation affects adipocyte function, and MR antagonism
has been shown to improve glucose metabolism in a mouse
model of diet-induced obesity. Moreover, there is evidence
that MR inhibition affects insulin signaling pathway in
skeletal muscle. Here, we aim at elucidating the role of MR
in regulating skeletal muscle homeostasis.
Methods: We analysed MR activation in a murine myoblast
cell line (C2C12), and in parallel, we characterized the impact
of MR activation on signaling pathways involved in skeletal
muscle metabolism in obese mice.
Results:We observed an increase in MR protein expression in
C2C12 myotubes during differentiation in vitro. Treatment of
myotubes with aldosterone induced an increase in
serum/glucocorticoid-regulated kinase1 (SGK1) protein
phosphorylation. In addition, aldosterone increased activa-
tion of AMP-activated protein kinase (AMPK), a key regulator
of muscle metabolism, and Acetyl-CoA carboxylase (ACC), a
downstream target of AMPK signaling. Importantly,
spironolactone was able to revert these effects, suggesting
that MR affects muscle ﬁbers energy metabolism.
We also evaluated gastrocnemius expression of MR and
metabolic proﬁle in ob/ob mice. Reduction in glucose
transporter type 4 (GLUT4), peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC1
alpha) and mitochondrial transcription factor A (mtTFA)
protein levels in skeletal muscle of obese mice suggested
the occurrence of metabolic alterations in glucose uptake
and mitochondrial function. Surprisingly, SGK1 and AMPK
protein phosphorylation were reduced in obese mice, thus
indicating downregulation of MR activity. This hypothesis
was conﬁrmed by real-time qPCR, which revealed a
reduction in MR and SGK1 mRNA levels in obese mice
gastrocnemius.
Conclusions: Our data indicate a downregulation of MR activ-
ity in skeletal muscle of obese mice concomitant with im-
paired muscle metabolism and suggest a causal role of
reduced MR activity in metabolic alterations of skeletal mus-
cle ﬁbers in obesity.
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Genes differentially expressed during reversion of
androgen-dependent skeletal muscle atrophy
Flavia A. Guarnier1†, Priscila de O. Coelho2†, Leonardo Bruno
Figueiredo3, Livia S. Zaramela2, Rosely O. Godinho3 & Marcelo D.
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1Laboratory of Pathophysiology and Muscle Adaptation, State University of
Londrina, Brazil, 2Department of Biochemistry and Immunology, Ribeirao Preto
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†Equal contributed ﬁrst author
Muscle wasting or atrophy is a condition associated with ma-
jor human systemic diseases including, diabetes, cancer, and
kidney failure, among others. There is accumulating evidence
from comparison of transcriptional proﬁles that a common
set of genes, termed atrogenes, are modulated in atrophyi
ng muscles. However, the transcriptional changes that trigger
reversion or attenuation of muscle atrophy have not been
characterized at the molecular level. To identify key factors
involved in the recovery of skeletal muscle mass, we have
used cDNA microarrays to investigate genes differentially
expressed during the atrophy reversion of the androgen-
sensitive levator ani muscle (LA), in the well-established
model of castration and testosterone replacement. The data
obtained in microarray assay showed that 310 genes were
differentially expressed in LA muscles 24 hours after hor-
mone replacement. The statistical analysis of the p value
allowed the selection of some targets to be validated through
qPCR. As expected, most of them behave as atrogenes and
responded to castration-induced atrophy. Strikingly, 7 genes
(APLN, DUSP5, IGF1, PIK3IP, KLHL38, PI15, and MKL1) did
not respond to castration but exclusively to the hormone re-
placement. We therefore proposed to name these genes
antiatrogens. Considering that almost all proteins encoded
by these genes may function as regulators modulators of cell
proliferation/growth, our results open new perspectives in
signaling pathway on atrophy-related syndromes ﬁeld, bring-
ing to light also a new perspective for therapeutic
approaches.
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In vitro assessment of postnatal myonuclear
accretion
Anita E.M. Kneppers1, Lex B. Verdijk2, Chiel C. de Theije1, Luc J.C. van
Loon2, Annemie M.W.J. Schols1 & Ramon C.J. Langen1
1Departments of Respiratory Medicine, 2Human Biology and Movement Sciences;
NUTRIM School of Nutrition and Translational Research in Metabolism,
Maastricht University Medical Centre, Maastricht, the Netherlands
Introduction: Postnatal myogenesis is essential for skeletal
muscle regeneration and relies on satellite cell proliferation,
differentiation and subsequent fusion with muscle ﬁbers
(i.e., myonuclear accretion). Ex vivo, myogenesis is primarily
studied using the formation of syncytia during myoblast
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differentiation, which represents aspects of developmental
myogenesis, but may incompletely portray postnatal
myogenesis. We aimed to develop an in vitro model that bet-
ter reﬂects postnatal myonuclear accretion (PNMA) and eval-
uated the effects of known modulators of muscle plasticity.
Methods: Mononuclear C2C12 myoblasts were added to dif-
ferentiated myotubes and co-cultured for 3 days. Postnatal
myonuclear accretion (PNMA) was assessed by live cell
time-lapse imaging, and cell tracing by cell labelling with
Vybrant® DiD and DiO. Furthermore, a Cre/LoxP-based cell
system was developed to quantitatively assess PNMA, by
the conditional expression of luciferase upon myoblast–
myotube fusion, which was detected using luminometry.
Results: Live cell time-lapse imaging, staining-based cell trac-
ing, and recombination-dependent luciferase activity, re-
vealed PNMA in vitro. Treatment of co-cultures with the
myogenic factor IGF-I (p < 0.001) and the cytokines IL-13
(p < 0.05) and IL-4 (p < 0.001) increased PNMA, while the
myogenic inhibitors Cytochalasin D (p < 0.001), Myostatin
(p < 0.05), and TNFα (p < 0.001) decreased PNMA. Further-
more, PNMA was increased upon recovery from contraction-
induced myotube damage (p = 0.052) and LY29004-induced
atrophy (p < 0.001). Moreover, siRNA mediated knockdown
of Myomaker in myoblasts (p < 0.001), but not in myotubes,
decreased PNMA.
Conclusions: We developed a sensitive model system for
quantitative assessment of in vitro postnatal myonuclear ac-
cretion for the study of physiological and pathological modu-
lators of myogenesis, which allows distinction between cell
type speciﬁc roles of signals and responses in the regulation
of postnatal myogenesis.
3-26
The overexpression of PGC-1α in the skeletal
muscle affects myogenesis
Marc Beltrà, Fabrizio Pin, Riccardo Ballarò, Ambra Iannuzzi, Fabio
Penna & Paola Costelli
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Introduction: Peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1α) is a master regulator of mitochon-
drial biogenesis. In skeletal muscle, PGC-1α expression is in-
duced by exercise. Along this line, transgenic MCK-PGC-1α
mice, which overexpress this transcription factor speciﬁcally
in the skeletal muscle, are characterized by enhanced exer-
cise performance in comparison with wild-type animals; this
is mainly due to increased myoﬁber mitochondrial content
that results in markedly improved energy metabolism. In ad-
dition to an increased proportion of oxidative ﬁbers vs glyco-
lytic ones, we found a high number of ﬁbers with centrally
located nuclei, which is indicative of muscle regeneration.
Moreover, myogenic stem cells are more abundant in
transgenic mice compared to wild-type animals. When cul-
tured in differentiating medium, cells isolated from PGC-1α
mice form myotubes larger than those generated by cells de-
rived from wild-type animals. Starting from this point, the
aim of the study was to investigate if stem cells from MCK-
PGC-1α mice can improve myogenesis.
Methods: Muscles from male wild-type and MCK-PGC-1α
mice were subjected to mild digestion, and mononuclear cells
were isolated by ﬁltration. These cells were then
transplanted into the tibialis anterior muscle of female wild-
type mice, either injured (BaCl2 i.m. injection 8 hours before
cell transplantation) or not. The animals were euthanized
12 days after BaCl2 injection.
Results: Hematoxylin/eosin staining of muscles transplanted
with WT-derived cells shows improved regeneration. On the
contrary, all the muscles injected with MCK-PGC-1α-derived
cells show an increase of centrally located nuclei, altered
myoﬁber cross-sectional area distribution and marked SDH
staining. The expression of molecular markers of
regeneration (Pax7, MyoG) and mitochondrial content
(Tom20, COX-IV) is consistent with the histological pattern.
Conclusions: The results obtained in the present study
suggest that cells isolated from MCK-PGC-1α donor mice are
able to fuse with recipient muscle myoﬁbers partially
inducing a shift towards oxidative metabolism and affecting
regeneration.
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Resistance exercise prevents cancer-induced
muscle wasting in Ehrlich tumor-bearing mice
Rafael Deminice1, Mayra J. Testa1, Camila S. Padilha1, Fernando T.
Frajacomo1, Poliana C. Marinello1,2, Paola S. Cella1, Felipe A. Moura1,
Jose A. Duarte3, Rubens Cecchini2 & Flávia A. Guarnier2
1Department of Physical Education, State University of Londrina, Brazil,
2Department of Pathology, State University of Londrina, Brazil, 3CIAFEL, Faculty of
Sport, University of Porto, Porto, Portugal
Background and aim: Resistance exercise training (RET) is
known to stimulate protein synthesis and skeletal muscle hy-
pertrophy in health subject. However, RET effects on tumor-
induced cachexia and muscle wasting are poorly known. We
aimed to evaluate cachexia and skeletal muscle plasticity
responses to RET after Ehrlich tumor cell inoculation.
Methods: Swiss mice were divided randomly into 4 groups:
control (C), tumor-bearing (T), exercised (E) and tumor-
bearing exercised (TE). Animals were inoculated with Ehrlich
tumor cells (1 × 106 suspension in PBS) before RET that was
performed for the following 4 wks. RET protocol consisted
of climbing a ladder apparatus with progressive load weights
tied to the animal’s tail in E and TE groups, while the physical
activity of C and T rats was conﬁned to the space of the cage.
Results: Ehrlich tumor grew progressively (P < 0.05) reaching
15% of animal’s body weight after 4 wks. Tumor growth
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promoted muscle wasting demonstrated by decreased gas-
trocnemius CSA (28%, P < 0.05), body weight loss (15%,
P < 0.05) and decreased fat content. Increased (P < 0.05)
systemic leukocytes and pro-inﬂammatory interleukins were
also demonstrated in T animals compared to C. In contrast,
RET was able to mitigate the reduced body weight and mus-
cle wasting by the attenuation of systemic inﬂammatory
markers. RET also prevented loss of muscle strength and
locomotor capacity associated with tumor development in
both experiments. Pro-inﬂammatory panel attenuation may
down-regulates protein degradation pathways in skeletal
muscle and contributes to the preventive anti-atrophy effects
of RET. In addition, the Erlich tumor microenvironment
analysis demonstrated RET reduced the proliferation of
tumor cells and increases the necrotic tumor area without
change tumor volume.
Conclusions: RET prevented muscle wasting by attenuating
tumor-induced systemic pro-inﬂammatory. Our data also
suggest RET reduces tumor proliferation cells and tumor
aggressiveness.
Supported by Capes-PVE #88881.068035/2014-01
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Walker-256 tumour growth affects the 1H-NMR
based metabolomic proﬁle of skeletal muscle more
severely in young-host compared to adult rats
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Luiz Alberto Ferreira Ramos1 & Maria Cristina Cintra Gomes-
Marcondes1
1Laboratory of Nutrition and Cancer, Department of Structural and Functional
Biology, Biology Institute, University of Campinas (UNICAMP), Brazil, 2Université
d’Angers, Angers, France
Introduction: Cancer cachexia is an important clinical prob-
lem, which reduces the life expectancy, mainly due to the
marked body weight loss. The tumour evolution leads to
skeletal muscle mass wasting, mediated by the proteolysis
and/or reduced protein synthesis. We aimed to evaluate, by
a time-course study, the tumour growth correlation to the
cachectic state and also to muscle tissue metabolomic proﬁle
in Walker-256 tumour-bearing rats.
Methods: Adult Wistar rats (A; 90 days) and young (Y;
21 days) were submitted to tumour implant (2 × 106 viable
cells). The animals euthanasia occurred at a different time
of tumour evolution (7th, 9th and 14th day for young; 7th,
14th and 21st day for adults) and compared to non-tumour-
bearing rats. The carcass, muscle and tumour weights were
measured at each euthanasia day. The metabolomic analysis
of skeletal muscle samples were accessed by using high-
resolution 1H-NMR spectroscopy.
Results: We observed that young tumour-bearing rats had an
increase in carcass-to-initial body weight ratio (58% higher;
P = 0.0003), associated with a higher liver-to-carcass weight
(67%; P < 0.0001) when compared to A group. The cachexia
index was bigger in young than adult group (Y > A, 2.4×;
P = 0.0001). Even though, the muscle-to-carcass weight ratio
was similar in Y and A groups, as well as the tumour weight
rate. The 1H-NMR analysis of muscle tissue showed differ-
ences mainly in the content of methylhistidine (Y > A, 10×
higher; P = 0.0186), succinate (Y > A, 4.2×; P = 0.0255),
dimethylglycine (Y > A, 12×, P < 0.0001), and other metabo-
lites. These differences showed some impacted metabolic
pathway such as nitrogen metabolism (P = 0.0128);
alanine/aspartate/glutamate metabolism (P = 0.0339), and
citrate cycle (TCA cycle; P = 0.0283) (analysed using http://
www.metaboanalyst.ca).
Conclusions: The tumour evolution reduced the survival time
in young rats (14 days) comparing to the adult group
(21 days), leading to severe damage effects mainly related
to muscle wasting, showing substantial implications in a
young host.
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Akt-mTOR pathway contribution to the skeletal
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exercise in Walker 256 tumor-bearing rats
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Cecchini1, Flávia A. Guarnier1 & Rafael Deminice1
1State University of Londrina, Londrina, PR, Brazil, 2Federal University of Mato
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Introduction: Resistance exercise (RE) is known to up-
regulate Akt-mTOR signaling for protein synthesis in skeletal
muscle; however, RE effect on tumor-induced muscle wasting
is poorly known. We aimed to investigate the Akt-mTOR
pathway contribution to the skeletal muscle wasting preven-
tion promoted by resistance exercise in tumor-bearing rats.
Methods: Thirty-seven Wistar rats were divided into 4
groups: control (C,n = 9), tumor-bearing (T,n = 9), exercised
(E,n = 9), and tumor-bearing exercised (TE,n = 10). Walker-
256 tumor cells were implanted in the right ﬂank of T and
TE groups. Forty-eight hours after tumor implantation the an-
imals started a four-week period of RE. RT protocol consisted
of climbing a ladder apparatus with weights tied to the ani-
mal’s tail in E and TE groups, while the physical activity of C
and T rats was conﬁned to the space of the cage.
Results: The Walker-256 tumor grew progressively (P < 0.05)
reaching 4% of animal’s body weight after 4 wks. Tumor
growth caused a reduced body weight gain (9.85%) and
muscle weight loss. Tumor growth also decreased muscle
strength (11.09%), promoted skeletal muscle atrophy
(P75 = 24%) and increased skeletal muscle collagen deposit
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(+87.5%). In addition, elevated systemic leukocytes (+150%),
TNF-α (+30.3%) and mRNA muscle levels of Atrogin-1
(+204%), but not changed mTor skeletal muscle mRNA level
were demonstrated in T rats compared to C. In contrast, RE
was able to attenuate loss of body weight (+6.35%) and skel-
etal muscle weight (+12.5%). However, no changes in Akt-
mTOR were demonstrated in tumor-bearing rats after RE.
Exercised tumor-bearing animals presented attenuated mus-
cle atrophy (P75 =1.12%) and collagen deposition, probably
by attenuating elevated systemic leukocytes (31.5%) inﬂam-
matory interleukins and elevated mRNA Atrogin-1 levels
(44.6%) caused by tumor growth.
Conclusions: RE attenuates cachexia development and mus-
cle wasting, by downregulating tumor-induced systemic in-
ﬂammation and proteolysis signaling, but not to enhances
Akt-mTOR signaling.
Supported by Capes-PVE #88881.068035/2014-01
3-30
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Introduction: Cancer cachexia is a wasting syndrome
characterised by involuntary weight loss caused mainly by
skeletal muscle loss associated or not with mobilisation of ad-
ipose tissue. Additionally, muscle function could be severely
jeopardised leading to a bad quality of life and poor treat-
ment outcomes. Few preclinical studies evaluate the loss of
muscle function in experimental models of cancer cachexia.
Therefore, the aim of this study was to evaluate whether
CatWalk test (natural gait evaluation) could be used to mea-
sure muscle function in cancer cachexia preclinical studies.
Methods: As preclinical model of cancer cachexia, Wistar rats
were subcutaneously injected in the right ﬂank with Walker
256 carcinoma (2.5 × 106 viable cells). Animals performed
CatWalk test previously (health) and posterior (pre-agonic
state) of tumour inoculation. For CatWalk analysis, we
considered maximal contact area (cm2), print area (cm2)
and maximal intensity of hind limb and forelimb paws. We
also evaluate muscle mass (g), muscle ﬁber cross sectional
area (cm2) and fat mass using Dual-Energy X-Ray
Absorptiometry (DEXA).
Results: Walker-256 tumour growth led to cachexia state
manifested by signiﬁcant weight loss (P = 0.001) due to loss
of skeletal muscle mass (18.7%, P = 0.03), decreased muscle
ﬁber cross section area (43.5%, P = 0.0001) and also by fat
loss (35.8%, P < 0.0001). CatWalk measurements at pre-
agonic state showed a signiﬁcant reduction in the maximal
contact area and the print area of hind limb paws (46.9%,
P = 0.0196 and 46.1%, P = 0.0112) and the maximal paw foot-
print intensity decreased in both fore and hind limb (5.83%,
P = 0.0024 and 6.8%, P = 0.0143).
Conclusions: The high sensitivity of the motor dynamic func-
tion analysis by the CatWalk method was able to characterise
the loss of muscle function in this experimental model of
cachexia and also showed that these functional parameters
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Introduction: Cancer cachexia is a syndrome characterized by
profound cardiac and diaphragm muscle wasting, which in-
crease the risk of morbidity in cachectic patients due to fail-
ure of the cardiorespiratory system. In this regard, muscle
relies greatly on mitochondria to meet energy requirements
for contraction and mitochondrial dysfunction can result in
muscle weakness and fatigue. In addition, mitochondria are
a major source of reactive oxygen species (ROS) production,
which can stimulate increased rates of muscle protein degra-
dation. Therefore, it has been suggested that mitochondrial
dysfunction may be an underlying factor that contributes to
the pathology of cancer cachexia.
Methods: To determine if inhibition of mitochondrial
dysfunction is sufﬁcient to prevent cancer-induced muscle
dysfunction, colon 26 (C-26) tumor-bearing mice were admin-
istered either saline or the mitochondrial peptide SS-31 daily
(3 mg/kg/day). Speciﬁcally, SS-31 is a multifunctional peptide
that has been demonstrated to preserve mitochondrial func-
tion during atrophic conditions by inhibiting cardiolipin
peroxidation and reducing ROS production.
Results: C-26 mice treated with saline demonstrated greater
rates of ROS emission and mitochondrial uncoupling
compared to C-26 mice receiving SS-31 in both the heart
and diaphragm muscle. In addition, SS-31 administration to
C-26 mice attenuated both cardiac and diaphragm muscle
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dysfunction. Indeed, cancer cachexia-induced alterations to
the myocardial performance index and the percentage
fractional shortening were signiﬁcantly rescued in C-26
mice treated with SS-31. In the diaphragm, muscle ﬁber
cross-sectional area of C-26 mice treated with saline was
signiﬁcantly reduced, and force production was impaired
compared to C-26, SS-31 treated animals. Finally, ventila-
tory deﬁcits were also attenuated in tumor-bearing
animals treated with SS-31, compared to those treated
with saline.
Conclusions: These data demonstrate that cancer promotes
severe cardiac and respiratory myopathy and that prevention
of mitochondrial dysfunction is sufﬁcient to preclude cancer
cachexia-induced cardiorespiratory dysfunction.
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Multitargeted tyrosine kinase inhibitors imatinib,
sorafenib and sunitinib perturb energy metabolism
and cause cytotoxicity to C2C12 murine skeletal
muscle cell line
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Sawyer1,2
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Introduction: Tyrosine kinase inhibitors (TKIs) have improved
cancer treatment and prognosis but have also resulted in side
effects that include fatigue, diarrhea, hypothyroidism, and
other toxicities. Because TKI effects on mitochondrial func-
tion are thought to play a role in cardiac myocyte dysfunc-
tion, we investigated TKI effects on skeletal muscle as a
possible explanation of TKI fatigue. Mitochondrial dysfunc-
tion can result from inhibition of oxidative phosphorylation
complexes and superoxide generation. It is also likely that in-
hibition of key transporters involved in uptake of glucose
and/or nucleosides could also result in alteration of energy
metabolism or mitochondrial mass. In this work, we investi-
gated these processes in cultured C2C12 murine skeletal
muscle cells.
Methods: We studied imatinib, sorafenib and sunitinib ef-
fects in C2C12 cells grown under conditions that result in for-
mation of myotubes by measuring mitochondrial complex
activity, ATP production, caspase activation, mitochondrial
membrane potential, reactive oxygen species (ROS) genera-
tion and nucleoside and glucose uptake.
Results: Imatinib was cytotoxic and inhibited complex V activ-
ity. Imatinib had negligible effects on ATP levels, ROS genera-
tion or membrane potentials, but stimulated glucose uptake.
Sunitinib caused cytotoxicity, ATP level depletion, apoptosis
activation, increase in ROS, and decrease in mitochondrial
membrane potential and nucleoside and glucose uptake.
Sorafenib was cytotoxic with rapid activation of caspase 3/7
activity. Sorafenib inhibited complex III and V quite potently,
but there was no increase in generation of mitochondrial
superoxide, although depolarization of mitochondrial mem-
branes occurred very rapidly with complete loss at 5–10 μM
sorafenib.
Conclusions: Imatinib, sunitinib and sorafenib through differ-
ent mechanisms caused changes in mitochondrial complex
activities, glucose and nucleoside uptake leading to de-
creased energy production and decreased mitochondrial
function in a skeletal muscle cell model, suggesting that these
effects play a role in fatigue, one of the most common TKI
side effects.
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helping recovery
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Introduction: Muscle growth and post-injury regeneration
are supported by muscle satellite cells (mSCs) that reside be-
neath the myoﬁber basement membrane in close proximity
to capillaries. We previously showed that pericytes play a
key role in the microvascular niche of mSCs during post-natal
stages of muscle growth, by promoting post-natal
myogenesis through IGF-1 and inducing mSC quiescence end-
ing the accretion phase through Angiopoietin-1. Since 90% of
capillaries have pericyte coverage at the end of muscle
growth, we investigated the role of pericytes in the adult
mSC niche.
Material et methods: We used TNAP-CreERT2 mice crossed
with R26RDTRstoploxP/stoploxP, Angiopoietin-1loxP/loxP, and
R26RmTloxPmG/loxPmG animals to generate respectively
conditional models for diphteria toxin-induced muscle
depletion of microvascular cells, ablation of microvascular
Angiopoietin-1 and ﬂuorescent tracing of microvascular cells.
Results: Conditional muscle pericyte depletion could not be
used due to extensive, presumably ischaemic, muscle necro-
sis. In contrast, selective Cre recombinase ablation of
Angiopoietin-1 gene in TNAP+ pericytes induced release of
adult mSCs from quiescence. Following chemical injury, the
ablation caused delayed muscle regeneration with persis-
tently cycling Pax7+ mSCs. Selective Type 2 ﬁber hypotrophy
was observed consistently with prominent association of
TNAP-expressing microvessels with type 2 ﬁbers observed in
TNAP-GFP reporter mice.
Conclusions: We conclude that pericytes associated with
endothelial cells exert paracrine effects on adjacent myo-
genic cells that are essential to maintain adult muscle homeo-
stasis and during muscle repair.
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Background: Cancer Cachexia is a devastating and multifacto-
rial syndrome involving changes in several metabolic path-
ways, in many tissues and organs. It is deﬁned as a muscle-
wasting syndrome, with or without adipose tissue atrophy.
Anorexia, fatigue, asthenia, anaemia, insulin resistance and
systemic inﬂammation are symptoms commonly related to
the syndrome, leading to a poor prognosis and reduced sur-
vival. Furthermore, circulating hormones and neuropeptides,
directly related to peripheral signals from the Central Ner-
vous System, could play a key role contributing in the regula-
tion of energy homeostasis and inﬂuencing food intake.
Aim: To evaluate circulating hormones and neuropeptides
and to elucidate possible modiﬁed pathways related to appe-
tite regulation and weight control in cancer cachexia patients.
Methods: Patients with colorectal cancer were divided into
Weight-Stable Cancer (WSC, n = 42) and Cachectic Cancer
(CC, n = 44) groups. Blood sampling was performed after sig-
nature of the informed consent form. Hormones and neuro-
peptides were quantiﬁed with Luminex® xMAP technology.
Results: Serum samples from cachectic patients presented
signiﬁcant lower levels of circulating amylin and insulin, com-
pared to WSC (p < 0.0004 and p < 0.0001, respectively).
Moreover, Leptin (p < 0.0002) and gastric inhibitory polypep-
tide (GIP) (p < 0.0009) were both signiﬁcantly decreased in
CC patients. Finally, no differences were observed between
WSC and CC for the other hormones (Glucagon, C-Peptide,
pancreatic polypeptide (PP), Peptide YY (PYY); glucagon-like
peptide-1 (GLP-1); Ghrelin). Finally, the neuropeptides Orexin
A (p < 0.0195) and Oxytocin (p < 0.004) were decreased in
CC patients, maybe contributing to the behavioural changes
generally related to the syndrome.
Conclusions: The results show robust modulation by cachexia
of patient circulating hormone and neuropeptides, factors di-
rectly related to appetite regulation, energy homeostase and
food intake. For that reason, the results point out to a possi-
ble beneﬁcial effect of hormone therapy. Furthermore, neu-
ropeptide changes might be related with behavioural
changes, a major problem in cachexia that remains poorly
investigated.
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TAPT: its role in tumoral microenvironment
Nelson Inácio Pinto Neto1, Diego Alexandre Cavalaro2, Valter Tadeu
Boldarine1, Ana Claudia Losinskas Hachul1, Joanna Darck Carola
Correia Lima2, Marilia Seelaender2, Claudia Oller do Nascimento1 &
Lila Missae Oyama1
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Introduction: The adipose tissue is an endocrine organ that
secretes a wide range of molecules, including the adipokines.
Adipocytes also produce angiogenic and growth factors that
contribute to progression of solid tumors such VEGF and
TGF-β, respectively. These adipokines and the peritumoral ad-
ipose tissue may have an important role in cancer biology and
carcinogenesis, considering the possible crosstalk between
the peritumoral adipose tissue and tumour.
Methods: 16 patients enrolled in this study was divided as
follows: patients with cancer without cachexia-WSC (n = 7)
and patient with cancer cachexia-CC (n = 9). The study was
approved by the Ethics Research Committee (972.914). Sam-
ples of peritumoral adipose tissue were removed for determi-
nation of TNF-α, IL-1β, STAT-1, STAT-3, RANTES, IL-1Ra, IOp-
10, IL-15, MCP-1, IFN-α, GCSF, FADD, and TGF-β concentra-
tion. Also, correlation between these proteins and cytokines
was analyzed.
Results: TNF-α and FADD, factors involved with apoptosis,
were signiﬁcantly higher in CC as compared to WSC. Also,
IL-1β and STAT-1 were signiﬁcantly lower in CC as compared
to WSC. In the TAPT of CC, a signiﬁcant positive correlation
of RANTES with IL-1Ra and IP-10 and a negative correlation
(RANTES/IFN-α) were found. Analysis of correlation of GCSF
with the protein content of IL-1Ra, IP-10, IL-15 and MCP-1
showed a signiﬁcant negative relationship and a positive cor-
relation with IFN-α. In TAPT of WSC no signiﬁcant correlations
were detected between RANTES, GCSF, IL-3, FADD and STAT-
1 and cytokines/chemokines analyzed.
Conclusions: These results indicate that inﬂammatory and tu-
morigenic pathways are altered in peritumoral adipose tissue
during cancer cachexia. Furthermore, we demonstrate that in
peritumoral adipose tissue of cachectic patients, inﬂamma-
tory cytokines are correlated with growth factors, pointing
to a modulation of the proliferative environment in close
proximity to the tumor by inﬂammatory cytokines.
4-03
Sexual dimorphism in human cancer cachexia: a
preliminary study into miRNA/mRNA expression in
human skeletal muscle
Ashok Narasimhan1, Russell Greiner1, Oliver F. Bathe2, Vickie
Baracos1 & Sambasivarao Damaraju1
1University of Alberta, Edmonton, Canada, 2University of Calgary, Calgary, AB,
Canada
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Introduction: Cancer cachexia (CC) is a multifactorial syn-
drome characterized by severe depletion of skeletal muscle,
with or without fat loss. Gene expression studies have identi-
ﬁed several genes associated with CC; however, sex-speciﬁc
expression differences have never been studied.
Aim: To proﬁle microRNAs (miRNAs) and differential gene ex-
pression at the isoform level (DEI) in human skeletal muscle
biopsies to understand the sex-speciﬁc expression differences
in CC and mRNA isoform regulation by miRNAs.
Methods: 42 cancer patients were classiﬁed into cachectic
cases based on International diagnostic consensus frame-
work for CC, and non-cachectic controls—cancer patients
who were weight stable for six months compared to
pre-illness weight. While 9 men and 13 women were
cachectic cases, 9 men and 11 women were non-cachectic
controls. Next generation sequencing and Affymetrix
Human Transcriptome array 2.0 were used to identify
miRNAs and DEI, respectively. Representative miRNAs and
DEI were validated using qRT-PCR. Differentially expressed
(DE) miRNAs and DEI were identiﬁed at 1.4 FC at
p < 0.05 using Partek genomics suite 6.6.
Results: 10 DE miRNAs (9 in autosomes and 1 in X chromo-
some) were identiﬁed in men, and 3 DE miRNAs (autosomal)
were identiﬁed in women, and none were common between
the two sexes. 1324 and 372 DEI were identiﬁed in men and
women respectively and showed limited overlap (3%). qRT-
PCR results showed cross-platform concordance for both
miRNA and DEI. Validation of DE miRNAs in an independent
dataset conﬁrmed these ﬁndings. While skeletal muscle atro-
phy associated pathways were prominent in men, adipogen-
esis pathways were seen in women. TGFB1 was identiﬁed
as a common upstream regulator in both sexes. However,
their downstream targets were different.
Conclusions: The preliminary study identiﬁes sex-speciﬁc
expression in CC at the miRNA, DEI and at the pathway levels.
Functional characterization of these molecules is warranted
to delineate their mechanisms in CC pathophysiology.
4-04
Displaced myonuclei in cancer cachexia suggest
altered innervation
Dario Coletti1,2, Hassani Medhi1,2, Nissrine Daou1, Matos Emidio3,
Raquel Galvao Figueredo3, Gabriela Salim De Castro3, Viviana
Moresi2, Adamo Sergio2, Li Zhenlin1 & Marilia Seelaender3
1Dept. of Biological Adaptation and Ageing B2A (CNRS UMR 8256 - INSERM ERL
U1164 - UPMC P6), Pierre et Marie Curie University Paris 6, France, 2DAHFMO
Unit of Histology and Medical Embryology, and Interuniversity Institute of
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Introduction: Central nuclei are considered a hallmark of
skeletal muscle ﬁber regeneration and a sign of myopathy.
We and others have previously observed central myonuclei
in both pre-cachectic patients and animal models of cancer
cachexia, in striking contrast with the reduced regenerative
potential characterizing cachectic muscles.
Methods: To elucidate the mechanisms underlying these
divergent observations we further characterised the nature
of central nuclei, and the muscle ﬁber involved, in both pre-
and cachectic cancer patients, as well as in C26-tumor-
bearing mice. Muscle with different physiological properties,
the Rectus abdominis and the Tibialis anterior, was analysed
in search of denervation and regeneration markers.
Results: We observed rare though measurable, non-
peripheral myonuclei. The latter consisted of two distinct
population: bona ﬁde central nuclei and nuclei that are nei-
ther central nor subsarcolemmal, which we named
«displaced» myonuclei. Displaced and central nuclei were de-
tected in all types of muscle ﬁbers. However, displaced
myonuclei were the only ones to vary between control and
cachectic muscles, suggesting a link with the pathological
condition. Non-peripheral myonuclei were observed in the
absence of muscle regeneration molecular markers, such as
embryonic or fetal myosin expression. The analysis of longitu-
dinal sections revealed that displaced myonuclei are clus-
tered as it occurs upon denervation, and that the number
of nuclear clusters increases in cachexia, coincident with N-
CAM upregulation, another denervation marker. Additional
denervation markers were upregulated in both human and
murine cachectic muscles.
Conclusions:We observed a novel phenomenon in cancer pa-
tients and animal models of cachexia: the presence of
displaced nuclei consistent with motor neuron loss or NMJ
perturbation. This phenomenon could underlay a previously
neglected phenomenon of denervation rather that myoﬁber
damage and regeneration in cachexia. Like in aging,
denervation-dependent myoﬁber atrophy could contribute
to the atrophic process leading to muscle wasting.
4-05
Cachexia mechanisms in cancer through the lens of
transcriptomics
Sarah Kolitz, Kevin D. Fowler, Jason M. Funt, Jenny Zhang, Matthew
Ung, Renan Escalante-Chong, Andrew C. Lysaght, Gregory Koytiger,
Yoonjeong Cha & Benjamin Zeskind
Immuneering Corporation, Cambridge, MA, USA
Introduction: Cachexia is a major clinical complication that
affects up to 80% of patients with advanced cancer, and by
some estimates is responsible for 20% of cancer deaths 1.
Despite its role in cancer mortality, no approved therapies
are yet available, and the mechanisms underlying cachexia
remain to be fully elucidated.
Methods: Gene expression proﬁling provides a quantitative
means to systematically assess biological differences be-
tween tissue from patients who develop cachexia and from
those who do not. Here, we report cachexia-related ﬁndings
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from computational analysis of publicly accessible gene ex-
pression datasets from various biological contexts, including
a dataset with adipose tissue from cancer patients with and
without cachectic weight loss (E-GEOD-51931) 1.
Results: Genes and pathways identiﬁed by these analyses in-
clude currently known cachexia mechanisms, and also emerg-
ing mechanisms that have not historically been emphasized
in cachexia research. Some of these emerging mechanisms
may help to more fully explain the consequences of the
well-known association between inﬂammation and cachexia
and support the previously described importance of Pax7 in
cachexia 1.
Conclusions: Transcriptomics is a powerful approach for dis-
secting the molecular underpinnings of cancer cachexia and
prioritizing areas for drug development. Our ﬁndings suggest
new avenues for experimental follow-up and highlight new
possibilities for the treatment of cachexia in cancer patients.
4-06
Blocking adipose tissue lipolysis does not prevent
muscle wasting in an experimental cancer cachexia
model
Sílvia Busquets1,2, Marta Castillejo1, Cristina Moreno1, Ecem Tuna1,
Marina Bantulà1, Tessa van Daalen1, Francisco J. López-Soriano1,2 &
Josep M. Argilés1,2
1Cancer Research Group, Departament de Bioquímica i Biomedicina Molecular,
Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, 2Institut de
Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain
Introduction and Purpose: A previous study through genetic
ablation of adipose triglyceride lipase (ATGL) concluded that
blocking the lipolytic machinery prevented the loss of muscle
wasting in mouse models of cancer cachexia (Lewis lung carci-
noma and B16 melanoma). Bearing this in mind, the objective
of the present study was to block all the lipolytic enzimes pres-
ent in adipose tissue (using chemical inhibitor) to see if muscle
wasting could be avoided using this pharmacological strategy.
Methods: We used Acipimox to block lipolysis, Atglistatin to
inhibit ATGL, and Compound 12 to inhibit hormone sensitive
lipase (HSL).
Results: The results obtained clearly show that, despite the
decrease in circulating free fatty acids caused by the inhibi-
tion of lipolytic enzymes, no changes in the muscle loss
associated with cancer cachexia were observed.
Conclusions: It is therefore concluded that preventing adi-
pose tissue wasting does not inﬂuence muscle atrophy asso-
ciated with cancer.
Reference:
1. Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-
associated cachexia. Science. 333, 233–8 (2011).
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Long non-coding RNA proﬁling in human skeletal
muscle and their role in Cancer Cachexia
Bhumi Bhatt1, Ashok Narasimhan1, Oliver Bathe2, Vickie E. Baracos1
& Sambasivarao Damaraju1
1University of Alberta, Edmonton, 2University of Calgary, Calgary, AB, Canada
Introduction: lncRNAs (long non-coding RNAs, >200 BP) reg-
ulate gene expression by transcriptional, post-transcriptional
and epigenetic mechanisms. lncRNAs originating in gene re-
gions may regulate the coding genes. lncRNAs act as decoys
and scaffolds for miRNAs and transcription factors, respec-
tively, to regulate gene expression. lncRNAs are known to
be dysregulated in a tissue- and disease-speciﬁc context.
Expression and regulation of lncRNAs in human skeletal
muscle under conditions of cancer cachexia remains to be
elucidated.
Aim: i) To proﬁle lncRNAs from human skeletal muscle biop-
sies from cachectic and non-cachectic cancer patients; ii) to
identify differentially expressed (DE) lncRNAs; iii) to identify
muscle-speciﬁc transcription factor gene expression to
explain transcriptional regulation of lncRNAs.
Methods: Study subjects (n = 40) were classiﬁed as cachectic
cases and non-cachectic controls based on international con-
sensus diagnostic criteria (high %weight loss with sarcopenia
or low BMI). Total RNA was extracted from muscle biopsies
and mRNA and lncRNAs were proﬁled using Human Tran-
scriptome Array-2.0. Data were analysed using Partek Geno-
mics Suite. DE analysis was done using one-way ANOVA,
and lncRNAs were annotated using Gencode database.
Annolnc database was used for functional insights into
lncRNAs.
Results: 62 lncRNAs were identiﬁed as DE (fold change range
1.2 to 1.58 and p< 0.05), of which 13 were down-regulated
and 49 were up-regulated in cachectic cases. Reciprocal ex-
pression of the DE representative lncRNA-nearest mRNA pairs
noted were RP11-420G6.4-SERPINB9P1; CTA-292E10.6-001-
XBP1; RP11-587D21.4-001-BDNF; and RP11-196G18.22-
HIST2H2BC, suggestive of transcriptional regulatory
mechanisms.
We predicted transcription factor binding sites in the
lncRNAs and a subset of these also showed DE in muscle:
e.g. ZNF143, CHD1/2, SMC3, HDAC2, NFYB, MEF2C; these
need to be validated in functional assays.
Conclusions: We identiﬁed DE lncRNAs associated with can-
cer cachexia. Our current efforts are also to identify how
lncRNAs act as decoys to sequester miRNAs and contribute
to the pathophysiology of cachexia.
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3. He et al, J Clin Invest (2013) 123:4821–4835
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Blood cells in cancer cachexia: it is easy to spot the
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Background: Cachexia is a multifactorial syndrome whose
hallmark is weight loss and systemic inﬂammation. Despite
the relevance of cachexia as a health system burden, ﬁnding
feasible diagnostic methods remains a challenge.
Aim: Characterization of blood cellularity and biochemical pa-
rameters in cancer cachexia.
Methods: Non-cancer patients (CONTROL), weight stable
(WSC) and cachectic gastrointestinal cancer (CC) patients par-
ticipated in the study approved by the University of São Paulo
Biomedical Sciences Institute (CEP 788/07) and University
Hospital Ethics Committee (CEP 752/07, SISNEP CAAE:
0031.0.198.019.07). Informed consent was obtained from
all participants. Patient group division was based on the
criteria proposed by Evans et al., 2008. Blood samples were
collected to evaluate the protein expression of CCL-2 and
CCL-3 using Multiplex Magpix® technology. The numbert of
lymphocytes, neutrophil, platelets and MDSCs (Myeloid De-
rived Suppressor Cells) was assessed by ﬂow cytometry.
Results: The number of lymphocytes was decreased in CC,
whereas that of platelets, neutrophils, the neutrophil-
lymphocyte ratio (NLR) and the PLR (Platelets Lymphocytes
Ratio) were increased in CC when compared to CONTROL
and WSC. In CC, the concentration of circulating chemokine
CCL-2 was higher than that of WSC patients.
Conclusions: Our results demonstrate increased NLR and PLR
ratios as systemic inﬂammatory parameters in cancer ca-
chexia. The easy evaluation of NLR, PLR makes them promis-
ing diagnostic tools. The increased platelets levels and the
higher number of circulating MDSCs also seem to be speciﬁc
for the immune phenotype of CC patients.
5-01
The TGF-b family cytokine MIC-1/GDF15 has
differential effects on lean mass in normal and
obese mice
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Introduction: MIC-1/GDF15 is a physiological appetite
regulator, which when markedly overproduced in some
disease states, such as advanced cancer, causes an
anorexia/cachexia syndrome mediated, at least in large part,
by its actions on appetite control centres in the brain. Anti-
bodies to MIC-1/GDF15 have been proposed as therapeutics
for patients with some anorexia cachexia syndromes and
recombinant MIC-1/GDF15 protein as an obesity therapeutic.
Methods: In order to better understand how prolonged ele-
vation of MIC-1/GDF15 might impact animals with differing
adiposity, we have infused normal chow fed mice and those
with diet induced obesity, with either vehicle or highly puri-
ﬁed, yeast derived, recombinant murine MIC-1/GDF15
(0.5 ug/gBW/day), delivered over 28 days, by an osmotic
minipump.
Results: Steady-state serum MIC-1/GDF15 levels in these
mice reached an average of about between 10 and
12 ng/ml, levels that are commonly reached in patients with
advanced cancer. Over this time, both groups of mice experi-
enced a substantial reduction in body weight in association
with a reduction in energy intake (13–15%) that was similar
in both groups. The reduction in body weight was signiﬁ-
cantly greater in obese than in lean mice (15.54 ± 1.5% vs
10.28 ± 1.12%). Moreover, weight loss in obese mice was
due exclusively to loss of fat mass, with no signiﬁcant loss
of lean mass. In contrast, the normal mice showed signiﬁcant
reductions in both lean and fat mass. MIC-1/GDF15 effec-
tively corrected the pro-inﬂammatory metabolic abnormali-
ties that frequently accompany obesity in both this mouse
model and as is well known to occur in humans.
Conclusions: The differential effects of MIC-1/GDF15 on lean
and obese mice may explain the relative protection from the
anorexia/cachexia syndrome afforded by having an increased
BMI or obesity.
5-03
Identiﬁcation of tumor-borne mediators secreted
via exosomes triggering alterations in fat and
muscle tissues in cancer cachexia
Victor Laurent, Sören Fisker-Schmidt, Maria Rohm, Stephan Herzig &
Mauricio Berriel Diaz
Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, Neuherberg,
Germany, and Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg Uni-
versity Hospital, Heidelberg, Germany
Introduction: Cancer cachexia is strongly associated with dif-
ferent types of tumors and negatively affects quality of life,
efﬁcacy of tumor treatment and survival of cancer patients.
Despite its clinical importance, the identity of tumor-borne
signals inducing wasting and their impact on speciﬁc periph-
eral organ systems remain mostly unknown. Exosomes have
been shown to be key mediators of the crosstalk between
tumor cells and their microenvironment. Nevertheless, only
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very few studies have focused on the role of tumor cells
derived-exosomes on cancer cachexia.
Methods: In an unbiased differential secretome analysis of
colon cancer cells-derived exosomes combined with high-
throughput adipocytes and myotubes phenotyping, we de-
ﬁned a list of exosomal proteins which potentially had
cachexia-inducing properties.
Results: By using overexpression strategy in HEK293 cells, dif-
ferent mouse models for both colorectal and pancreatic can-
cer and human serum samples, we conﬁrmed that tumor-
derived exosomal proteins contributed to skeletal muscle at-
rophy and adipose tissue wasting in vitro and in vivo.
Conclusions: Our study suggests that tumor cell-derived
exosomes are important mediators of different components
of cancer cachexia, which could potentially provide novel op-
portunities for diagnostic and therapeutic measures to allevi-
ate cachexia, thereby contributing to improved disease
outcomes.
5-04
Comparison of whole genome gene expression in
(cancer) cachectic muscles of animal models and
human patients
Rogier L.C. Plas1, Guido J.E.J. Hooiveld1, Renger F. Witkamp1 & Klaske
van Norren1,2
1Division of Human Nutrition, Wageningen University and Research, Wageningen,
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Background: Different animal models are used to study
mechanisms and treatment options of (cancer) cachexia.
Next to this, experimental conditions may vary for the same
model. In some studies, whole genome gene expression of
muscle tissue is measured using micro array analysis. Upon
publication of these gene expression studies, raw data are of-
ten made available via the NCBI Gene Expression Omnibus
database. By comparing these datasets, differences and sim-
ilarities between models and experimental conditions can be
examined. Moreover, knowledge can be gathered on underly-
ing processes causing muscle wasting and possible differ-
ences between animal models for cancer cachexia and
human cancer cachexia. We are currently comparing differ-
ent datasets containing muscle gene expression of animal
models and human tissue (on-line available) and one of our
own new and unpublished datasets containing microarray
data of heart muscle and m. extensor digitorum longus and
m. soleus of mice from a C26 model.
Aims:
1. Examine differences and commonalities in whole genome
gene expression between different muscle tissues in
(cancer) cachexia mouse models.
2. Examine differences and commonalities in whole genome
gene expression between (cancer) cachexia mouse
models and muscle from cachectic colon cancer patients.
Methods: All datasets (our own and those online available)
are quality checked, normalised and annotated using the
latest CDF available. Comparisons are made both on gene
and on pathway level.
Hypotheses: We hypothesise that main differences exist
between different models and that smaller differences occur
due to different muscle types analysed for a certain model.
Moreover, we hypothesise that these smaller differences
are due to different effects of cachexia on speciﬁc muscle
ﬁbre types. We also hypothesize that some models mimic
the human situation better than others.
Currently, analysis is ongoing. At the conference the data
on comparison of different animal models and human
samples will be available and presented.
5-05
The effect of n-3 fatty acid-derived amines and
gut-derived bacterial compounds on excretion of
tumour-derived inﬂammatory mediators
Klaske van Norren, Mieke Poland, Rogier Plas, Frouwkje Politiek,
Milena Banic, Jocelijn Meijerink & Renger Witkamp
Nutrition & Pharmacology group, Wageningen University, Wageningen, The
Netherlands
Aim: To investigate the role N-3-derived-acyl-amines on the
release of cachexia-inducing inﬂammatory-mediators by co-
lon adenocarcinoma (C26) cells.
Background: N-3 fatty acids have been reported to be able to
reduce the cachectic inﬂammatory response. The effectivity
of the anti-cachectic response on N-3 fatty acids, however,
seems to vary between patients and study populations. We
hypothesize that the diversity of the response to N-3 fatty
acids might be due to the ability of an individual to form
speciﬁc endogenous metabolites (acyl-amines) from these
fatty acids.
Methods: C26 cells were incubated for 24 h in the presence
and absence of Docosahexaenoic acid (DHA), doco-
sahexaenoyl ethanolamide (DHEA) and docosahexaenoyl
serotonin (DHA-5-HT). To stimulate IL-6 release, cells were
incubated with lipopolysaccharide (LPS) and Pam3CysSerLys4
(Pam3CSK4). Interleukin (IL)-6 and PGE2 release were mea-
sured using enzyme-linked immunosorbent assays (ELISAs).
Data represent the average of n = 3 independent experi-
ments. Statistical analysis was performed using one-way
analysis of variance (ANOVA) and Dunnett’s post hoc testing.
A p-value <0.05 was considered statistically signiﬁcant.
Results: PGE2 excretion was inhibited by both DHEA and DH-
5-HT, but not signiﬁcantly by DHA. Incubation with 0.5 μg/ml
LPS or Pam3CSK4 was needed to induce IL-6 excretion, which
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was not measurable in unstimulated cells. 1 μM DHA-5-HT
reduced the LPS- and Pam3CSK4-induced IL-6 release. Both
DHA and DHEA had no effect on IL-6 release.
Conclusions: Unstimulated cells produced PGE2, but did not
produce IL-6. This is surprisingly because the C26 mouse
model shows an IL-6-dependent development of cachexia.
We therefore hypothesize that passage of bacterial com-
pounds through the gut-barrier might trigger the excretion
of tumour-derived cachexia-inducing inﬂammatory mediators
in this model. Acyl-amine-derivatives of DHA were far more
effective than DHA in inhibiting the excretion of PGE2 and
IL6. These results suggest that the metabolic fate of food de-
rived n-3 fatty acids might inﬂuence the anti-cachectic prop-
erties of these fatty acids.
5-06
Tumour growth changed the serum metabolomic
proﬁle in ageing rats
Rafaela Rossi Rosolen, Lais Rosa Viana, Rogerio Willian Santos &
Maria Cristina Cintra Gomes-Marcondes
Laboratory of Nutrition and Cancer, Department of Structural and Functional
Biology, Biology Institute, University of Campinas (UNICAMP), Brazil
Introduction: The neoplasia development promotes host’s
biochemical and metabolic alterations that culminate in the
involuntary weight loss mainly due to spoliation of muscle
protein. This process results in a severe syndrome called ca-
chexia, which reduces the quality of life and survival in cancer
patients. This study aimed to analyse the tumour evolution
and the alterations in metabolic pathways during the ageing
process in Walker-256 tumour-bearing rats.
Methods: Ageing Wistar rats (400 days old) were distributed
into six different groups: Ageing control (CS); Walker-256
tumour-bearing rats euthanized in various days of tumour
evolution: group euthanized at 11th (W11); 14th (W14);
17th (W17); 21st (W21) and 25th (W25) days. The tumour im-
plant occurred by a single inoculation of 2 × 106 viable neo-
plastic cells in the right ﬂank subcutaneous. These all
groups were also compared with adult control (CA; 90 days
old). The animals’ serum samples were collected, ﬁltered
and processed to access the metabolomic proﬁle analysis by
using high-resolution 1H-NMR spectroscopy to evaluate the
metabolites/pathways that may be involved in the process
of cancer cachexia.
Results: The tumour evolution showed an exponential growth
curve, associated with marked loss of body weight. The ef-
fects of tumour growth led to an crescent increase in concen-
tration of allantoin (W25 > S, 1.8-fold; P = 0.0047), 2-
hydroxybutyrate (W25> S, 10.7-fold; P = 0.0108), tryptophan
(W25 > S, 2.6-fold; P = 0.0011) and n-methylhistidine
(W25 > S, 12.2-fold; P = 0.0027), associated with marked re-
duction of serum glutamine (W25 80% lower; P = 0.0317) and
glutamate (W25 34% lower; P = 0.0112). These changes led to
impacted metabolic pathways such as glutamine/glutamate
metabolism (P = 0.00001), nitrogen metabolism (P = 0.0128)
and alanine/aspartate/glutamate metabolism (P = 0.0339).
Conclusions: These results show that tumour evolution re-
quires energy and structural substrates such as glucose and
glutamine and promotes intense host spoliation, such as pro-
tein degradation leading to an intense muscle mass waste
(higher methylhistidine), inducing a severe weight loss, which
culminates in host cachectic state.
5-07
The mitochondrial metabolic reprogramming
agent trimetazidine as an ‘exercise mimetic’ and
myogenesis promotor in cachectic C26-bearing
mice
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Introduction: Mitochondrial metabolism reprogramming
might enhance metabolic efﬁciency. We investigated the abil-
ity of the metabolic modulator trimetazidine (TMZ), which
partially inhibits mitochondrial free fatty acid β-oxidation
while enhancing glucose oxidation, to counteract skeletal
muscle dysfunctions and wasting occurring in cancer
cachexia.
Methods: For this purpose we used mice bearing the C26
coloncarcinoma as a model of cancer cachexia. Mice received
5 mg/kg TMZ (i.p.) once a day for 12 consecutive days. A fore-
limb grip strength test was performed, and tibialis anterior
and gastrocnemius muscles were excised for analysis. Ex vivo
measurement of skeletal muscle contractile properties was
also performed. Moreover, satellite cells and C2C12 myo-
blasts were treated with TMZ during differentiation.
Results: Our data showed that TMZ induces some effects
achieved through exercise, among which is grip strength in-
crease, an enhanced fast-to-slow myoﬁber phenotype shift,
reduced glycemia, PGC1α up-regulation, oxidative metabo-
lism and mitochondrial biogenesis. TMZ also partially restores
the myoﬁber cross-sectional area in C26-bearing mice, while
modulation of autophagy and apoptosis were excluded as
mediators of TMZ effects. Moreover, TMZ enhances the myo-
genic potential of skeletal muscle progenitor cells leading to
MyoD, Myogenin, Desmin over-expression and, similarly to
exercise, stimulates the phosphorylation of AMPK and up-
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regulates PGC1α, both of which enhancing mitochondrial bio-
genesis necessary for myoblast differentiation. Finally, we
found that TMZ is able to stimulate myogenesis in vivo both
in the C26 mice model of cancer cachexia and upon
cardiotoxin damage.
Conclusions: In conclusion, our data show that TMZ acts like
an “exercise mimetic” and is able to promote myogenesis,
enhance regenerative capacity and trigger some mechanisms
of adaptation to stress in cancer cachexia. This makes the
modulation of the metabolism by TMZ a suitable candidate
for a therapeutic rehabilitative protocol design and for
regeneration-impaired disorders, particularly considering
that TMZ has already been approved for clinical use.
5-08
Cancer and chemotherapy-induced cachexia yield
distinct metabolic perturbations
Fabrizio Pin1,2, Rafael Barreto3, Marion E. Couch4,5,6, Thomas M.
O’Connell3,4,5,6 & Andrea Bonetto1,2,3,4,5,6
1Department of Anatomy and Cell Biology, Indiana University School of Medicine,
Indianapolis, IN, USA, 2Indiana Center for Musculoskeletal Health, Indiana
University School of Medicine, Indianapolis, IN, USA, 3Department of Surgery,
Indiana University School of Medicine, Indianapolis, IN, USA, 4Department of
Otolaryngology - Head and Neck Surgery, Indiana University School of Medicine,
Indianapolis, IN, USA, 5Simon Cancer Center, Indiana University School of
Medicine, Indianapolis, IN, USA, 6IUPUI Center for Cachexia Research Innovation
and Therapy, Indiana University School of Medicine, Indianapolis, IN, USA
Advanced cancer patients frequently suffer from cachexia, a
severe wasting condition characterized by depletion of both
muscle and adipose tissue. Work from our laboratory and
others have shown that chemotherapy, one of the primary
treatment options for cancer can also lead to cachexia. In this
study, we employed a comprehensive metabolomics ap-
proach to elucidate the similarities and differences in the
metabolic perturbations of these two drivers of cachexia.
Our study design included four sets of mice: (1) mice im-
planted with C26 colorectal tumor cells, (2) mice given che-
motherapy Folﬁri (5-FU, leucovorin, irinotecan) for ﬁve
weeks, (3) C26 tumor bearing mice treated with Folﬁri, and
(4) vehicle treated mice. The multi-platform metabolomics
approach utilized both NMR and mass spectrometry analyses
on serum, muscle and liver tissue. The data highlighted
several striking differences between the metabolic pheno-
types of the C26 tumor and chemotherapy groups. The
C26 group displayed reduced levels of TCA cycle
intermediates, branched chain amino acids and short chain
acylcarnitines while those same metabolites were
unchanged in the Folﬁri group. The number of low density
lipoprotein particles (LDL-P) increased by more than ﬁve-
fold in the C26 group while a more modest two-fold
increase was observed in the Folﬁri group, suggesting differ-
ences in lipid and cholesterol metabolism. In muscle, the
ATP levels were more signiﬁcantly reduced in the Folﬁri
group compared with the C26 perhaps, suggesting a more
dramatic impact on oxidative metabolism. In the C26 group
treated with Folﬁri, the effects of each treatment were
sometimes additive and sometimes appeared to be
dominated by one condition over the other.
Overall, our results show that cancer- and chemotherapy-
induced cachexia are characterized by clearly different meta-
bolic perturbations indicating different pathophysiological
mechanisms. New therapeutic interventions to treat cachexia
will have to account for these differences in order to provide
effective treatment.
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The current literature correlates the proteolysis-related atro-
phy (which usually occurs in later stages of cachexia syn-
drome) to oxidative damage of proteins. Fast-twitch ﬁbers
are more affected during the muscle waste induced by cancer
cachexia. In the present study, we investigated oxidative
modiﬁcations, ultrastructural modiﬁcations in mitochondria
and sarcoplasmic reticulum (SR), and the correlation with
muscle loss in EDL and Soleus muscles (respectively fast-
and slow-twitch muscles) in pre-cachexia. Male Wistar rats
were subcutaneously inoculated with a suspension of
Walker-256 tumor cells and divided into 2 groups: tumor-
bearing rats (T), and tumor-bearing rats treated with N-
acetylcisteine (T-NAC; NAC 1% ad libitum in drinking water),
a drug known to promote increased antioxidant capacity in
tissues. After 5 days, pre-cachexia was characterized in T an-
imals according to the criteria pre-established by Fearon et al.
(2011; Lancet Oncol). Tumor implantation caused decrease in
general body weight (2.77%), followed by a signiﬁcant
weight loss in EDL muscle (15.33%), contrasting with the
small mass loss of soleus (5.14%). We measured both pro-
tein and membrane oxidation and found that only membrane
oxidation was signiﬁcantly increased in EDL from tumor-
bearing mice. Soleus presented a discrete alteration on redox
balance. As a result, we found that the volume of intracellular
membrane organelles such as SR and mitochondria was sig-
niﬁcantly decreased (18.89% and 22.41%, respectively)
compared to group C. In addition, in the EDL of tumor-
bearing rats, the fusion:ﬁssion ratio was altered in favor of
the former. Interestingly, all differences were signiﬁcantly res-
cued in T-NAC group, suggesting a central role of oxidative
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stress in the modiﬁcations of membrane compartments.
These data suggests that in pre-cachectic stages: 1) glycolytic
muscles are already more prone to mass waste, but indepen-
dently of protein oxidation, and 2) loss of membrane organ-
elles could play an important role early in these initial stages.
This study was supported by the following grants:
a) Brazilian Ciências Sem Fronteiras: CNPq 233892/2014-1
and Brazilian Continuous Flow Program to support special
projects (973/2013) to FAG;
b) MIUR Future in Research: RBFR13A20K to SB.
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Introduction: Currently, there are no mechanism-based tools
for the early detection & diagnosis of cachexia, a debilitating
condition that typically progresses through three phases,
namely, pre-cachexia, cachexia and refractory cachexia.
Unfortunately, the classically emaciated patient is often in
the refractory stage where the decline is irreversible.
Methods: In this study we employed a comprehensive, multi-
platform metabolomics including untargeted high ﬁeld NMR,
targeted LC/MS and NMR-based lipoprotein analysis. Our
study design involved implanting mice s.c. with C26 colorectal
tumor cells and sampling serum and muscle tissue every
other day for two weeks. In this model the mice generally de-
velop signiﬁcant weight loss starting day 10.
Results: The metabolomics analyses of serum revealed that
the trajectories of several biomarkers, among which the
branched-chain amino acids (BCAAs), signiﬁcantly diverged
from controls in advance of detectable weight loss. In partic-
ular, leucine levels signiﬁcantly dropped by day 6, well in ad-
vance of detectable weight loss and even in advance of a
palpable tumor. Interestingly, previous studies have sug-
gested that reductions in BCAAs are correlated with in-
creased muscle amino acid oxidation. Other metabolic
markers that diverged at or before day 10 include low density
lipoprotein particles, taurine and GlycA (an inﬂammatory
marker associated with acute phase response).
Conclusions: These initial biomarkers represent a set of criti-
cally altered pathways in the development of cancer cachexia
including protein catabolism, lipolysis/dyslipidemia, oxidative
stress and inﬂammation. This work provides the foundation
for the development of a biomarker panel that would provide
early detection and stratiﬁcation of cachexia based upon the
unique constellation of metabolic disturbances that may af-
ﬂict individual patients. Further studies will be conducted
on different cancer models and eventually in human cohorts.
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Introduction: Doxorubicin (DOX) is a widely used
anthracycline chemotherapeutic agent,1 which has emerged
as a signiﬁcant and independent promoter of cachexia during
anticancer therapy.2 To characterise its muscle-speciﬁc
effects, DOX has typically been administered in cancer-free
animal models as a single high bolus dose or with prolonged
periods between dosages.2 However, in the clinical setting,
metronomic DOX administration is common since it is gener-
ally of greater therapeutic beneﬁt.3 Thus, the aim of our study
was to assess the cachectic signature of metronomic low,
moderate and high dose DOX treatment over either one
(short) or two (long) week schedules, in cancer-free mice.
Methods: 6-week old Balb/C mice were treated with DOX
using three different schedules: (1) 6 × 2mg/kg dosages over
14 days (low-long (LL)); (2) 3 × 4mg/kg dosages over 7 days
(moderate-short (MS)); and (3) 6 × 5mg/kg dosages over
14 days (high-long (HL)). Mice were weighed and body
composition analysis was performed using pre- and post-
treatment EchoMRI. Thereafter, muscles and organs were
harvested, weighed and functional and structural analyses
were performed.
Results: DOX treatment induced cachexia in a dose-
dependent and anorexia-independent manner (LL = 14%;
MS = 17%; HL = 28%; p < 0.0005), and this was mostly at-
tributable to a loss of fat mass (LL = 47%; MS = 39%;
HL = 55%; p < 0.0005). Lean mass wasting was only ob-
served for the HL schedule (11%; p < 0.05). Regardless of
dosage, cachexia was most severe after day 5 of treatment.
On the MS schedule, extensor digitorum longus (fast-twitch
muscle) mass was reduced by 28% (p < 0.05), while soleus
(slow-twitch muscle) mass was unaffected.
Conclusions: Our data highlight that cumulative dosage is
more impactful than treatment duration, but that dose repe-
tition is a factor in cachexia progression. While overall lean
mass was unaffected at lower dosage schedules, the loss of
fast-twitch muscle mass (i.e. EDL) was still observable, sug-
gesting ﬁbre-type-speciﬁc effects which likely account for
the muscle weakness reported by patients.
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1. Jamieson & Boddy, Expert Opin Drug Metab Toxicol, 2011;
7(10):1201–10.
2. Sorensen et al., Cancer Chemother Pharmacol, 2016;
78(4):673–683.
3. Scharovsky et al., Current Oncol, 2009;16(2):7.
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Introduction: The majority of patients with pancreatic ductal
adenocarcinoma (PDAC) develop cachexia. Serum activin cor-
relates with cachexia and mortality in PDAC, and Activin over-
expression causes cachexia. We studied Activin expression in
PDAC cachexia.
Methods: Data mining, immunohistochemistry, qRT-PCR, cell-
based studies, and mouse modeling were used.
Results: In meta-analysis of 9 studies of human PDAC, INHBA,
encoding Activin A, was among the top 1–10% of over-
expressed. INHBB, encoding Activin B, was not. In the pan-
creas TCGA, high INHBA conferred increased mortality (HR
1.218, P = 0.003), while INHBB was not signiﬁcant. Immuno-
histochemistry detected Activins in human PDAC in both tu-
mor and stromal cells. Next, we characterized three novel
orthotopic and the genetic LSL-KrasG12D;LSL-p53R172H;
Pdx1-Cre (KPC) mouse PDAC models. All developed cachexia,
with KPC cell lines expressing more INHBA causing more rapid
cachexia. (INHBB was not detected in cell lines.) Tumors from
KPC lines expressed both INHBA and INHBB, with expression
in both tumor and stromal cells. Notably, in both genetic
and orthotopic models, Activin expression was not conﬁned
to tumors. Immunohistochemistry detected Activins in mus-
cle, heart, kidney, and liver. RT-qPCR indicated that tumors
expressed mostly INHBA, while organs expressed both INHBA
and INHBB, with the latter more dynamically regulated. KPC
tumors likely induce Activin and wasting directly, because
KPC cell line conditioned medium-induced INHBA expression
and atrophy in C2C12 myotubes. The Activin trap ACVR2B/
Fc showed reduced efﬁcacy against cachexia in models
expressing higher levels of Activin and did not affect activin
expression in organs, suggesting that circulating Activin was
not responsible for systemic Activin expression.
Conclusions: PDAC induces a systemic Activin response. Given
the differential transcriptional regulation of INHBA and
INHBB and the differing efﬁcacy of ACVR2B/Fc on endocrine
versus autocrine Activin signaling, our results suggest that
speciﬁc targeting and/or upstream targeting of each tumor-
released and tumor-induced Activin would offer more
effective therapy.
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Heart failure is a frequent comorbidity of cachectic rheuma-
toid arthritis in humans (RA). Adults with RA have about two-
fold higher risk of cardiovascular disease even without
enhanced of traditional risk factors. Inﬂammatory cytokines
are supposed to be implicated in this pathogenesis. Central
role in cardiac heart failure plays β-isoform of myosin heavy
chain (β-MHC) by reducing cardiomyocyte contractility. The
β-MHC production is regulated by Foxo1 transcription factor
which is controlled by insulin signaling cascade, and/or by
triiodothyronin-T3/thyroid hormone receptor (TR) complex
which negatively regulates β-MHC transcription.
The aim of our study was to ﬁnd out whether adjuvant ar-
thritis in rats (AA)—a model of human RA affects cardiac β-
MHC expression and to elucidate the mechanisms involved.
AA was induced to male Lewis rats by complete Freund’s
adjuvant. On day 18 of maximum inﬂammatory score the ex-
periment was terminated. The hearts were perfused in situ
with heparinized saline, and the tissues around left ventricles
were dissected and extracted for total RNA. After a reversed
transcription the relative cDNA for each transcript was mea-
sured by real-time PCR using the SYBER green mix and the
primer sequences for rat TNF-α, IL-6, β-MHC, insulin receptor
substrates IRS1, IRS2, Foxo1, Foxo4, TRβ1, TRβ2. As reference
gene the expression for HPRT was used.
The expression of β-MHC in AA-rats was enhanced against
nontreated controls (p < 0.01) and against pair fed rats
(p < 0.05). The cytokine expressions were low at the detec-
tion limit. None of the molecules of the insulin signaling path-
way, neither of the Foxo expressions were changed. However,
in AA group the signiﬁcant downregulation of TRβ1, TRβ2 was
found, indicating desinhibition of β-MHC and thus contribut-
ing to its overexpression.
These results show that chronic inﬂammation during AA
may cause cardiac contractility dysfunction by activating of
β-MHC expression whereby downregulation of TRs plays a
role.
Supported by: grant P34, Czech Republic and grants VEGA
2/0174/17 and APVV-15-0229, Slovak Republic.
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Background: Sarcopenia adversely affects prognosis in
metastatic NSCLC. However, the pattern of changes and dis-
tribution of muscle- and adipose tissue mass during chemo-
therapy and their relation to overall survival (OS) is unclear.
Therefore, we analyzed changes in muscle cross-sectional
area (CSA), intramuscular adipose tissue (IMAT), subcutane-
ous adipose tissue (SAT) and visceral adipose tissue (VAT)
on CT-images after the ﬁrst cycle of chemotherapy.
Methods: In this post-hoc analysis of the randomized
controlled NVALT12 trial (NCT01171170), body composition
was characterized in 117 patients at the third lumbar level
on CT-images obtained before start of treatment and after
1 cycle of chemotherapy. Changes in body composition were
related to OS with Kaplan Meier and log-rank test. Cox
multivariate analysis assessed the relative contribution of
muscle and adipose tissue CSA and distribution to OS.
Results: Changes in muscle- and IMAT SCA were an indepen-
dent predictor for OS while change in SAT and VAT were not.
Three patterns could be distinguished based on body compo-
sition changes; muscle stable or gain (n = 36, type 1), muscle
loss and IMAT stable or gain (n = 47, type 2), muscle- and
IMAT loss (n = 34, type 3). Body composition types were
comparable for gender, age,WHO-PS, TNM-status and comor-
bidity index. Type 1 was most predictive for poor OS with a
median OS (95% CI) of 8.9 months (5.4 to 12.3) compared
to 10.7 months (6.5 to 14.9) in type 2 (HR 2.1 95% CI (1.3–
3.4) p = 0.003). There was no signiﬁcant difference in OS be-
tween type 2 and type 3.
Conclusions: In contrast to previous research in non-
pulmonary malignancies, not only decrease of muscle mass
but also IMAT changes are predictive for poor OS in metasta-
tic NSCLC after one cycle of treatment. Early recognition of
body composition changes could be useful for more
personalised supportive intervention during follow-up
treatment.
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Introduction: According to European and American regula-
tory agencies, physical function (e.g. stair climbing test)
would be an approvable (co)primary endpoint of new anti-
cachexia medications; however, it is unknown whether car-
diac function is adequate for physical function tests. We
aimed to explore the cardiac status of a group of patients
conforming to the criteria for inclusion in cachexia clinical tri-
als (i.e., POWER, ROMANA, and MENAC).
Methods: Seventy patients with metastatic non-small cell
lung carcinoma [51.4% male; 96% ECOG 0–1; eligible for
carboplatin-based therapy] were evaluated before start of
1st line chemotherapy. All of the patients were evaluated
by echocardiography, FACIT fatigue and MRC dyspnea scales.
Computed tomography cross-sectional images were utilized
for body composition analysis.
Results: In 9 patients (12.8%), echocardiography revealed
previously undiagnosed, clinically relevant cardiac abnormal-
ities. Seven patients had left ventricular ejection fraction
(LVEF) 32%–47%; 1 patient had severe right ventricular dila-
tion and pulmonary hypertension, and 1 patient with severe
pericardial effusion warranted hospitalization and drainage.
Of these 9 patients, only one patient had a recent history
of heart failure. Ten (14.3%) additional patients had diastolic
dysfunction with preserved LVEF. These cardiac conditions
were associated with worse fatigue (p < 0.05), dyspnea
(p < 0.05) and anemia (p = 0.06). Five out of 7 patients with
LVEF < 50% were sarcopenic.
Conclusions: A detailed evaluation of the cardiac function in
our clinical trial—eligible population reveals a heterogeneous
cardiac proﬁle and symptom burden that may signiﬁcantly
impact on their ability to perform physical activities (such
as stair climbing), which serve as anti-cachexia trial end-
points. Cardiac-related inclusion and exclusion criteria of
aforementioned trials would fail to identify these patients.
Detailed echocardiography might need to be included in the
screening procedure of lung cancer patients for clinical trials
with anti-cachexia therapeutics especially those using physi-
cal activity as primary endpoints.
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Introduction: An international consensus proposed in 2011 a
staging of cancer cachexia (CAX), mainly based on weight loss
(WL), skeletal muscle loss (SML), inﬂammation and anorexia
(Fearon). While CAX deﬁnition relies on well-deﬁned criteria,
those of pre-CAX and refractory CAX remain imprecise. We
initiated this study to reﬁne CAX stages with quantiﬁable
parameters.
Methods: This is a cross-sectional, prospective, multicentric
study conducted in patients with NSCLC. Skeletal muscle
mass (SMM) was assessed by analysing L3 CT-scan images.
Patients completed EORTC QLQ-C30 health-related quality
of life (QoL) questionnaire. For pre-CAX stage deﬁnition we
recorded anorexia based on patient answer to QoL question
on appetite loss. We deﬁned refractory CAX based on ECOG
performance status and WL using the thresholds values asso-
ciated with low survival (<5.4 months) described by Martin.
Endpoints were the frequency and the characteristics of
CAX stages.
Results: 531 patients recruited in 2016 by 56 sites within
3 months were analysed. 312 had SMM assessment. Median
age was 66 years, 79.9% were PS < 2, and the tumor stage
was mainly IIIB-IV (87.3%). 33.8% of patients had pre CAX,
38.7% CAX, and 0.9% refractory CAX. CAX stage progression
was associated with lower functional scale score (except cog-
nitive) of the QoL questionnaire (p < 0.0001). SMM was the
only relevant criteria found in 8.1% of cachectic patients
without WL > 5% and in 43.8% of pre-CAX patients with
WL < 2%. Notably, 48.4% of all the patients and 25.8% of
pre-CAX patients had SML with no anorexia (questioning
SML mechanisms not secondary to decreased intake).
Conclusions: This is the ﬁrst study deﬁning cancer cachectic
stages with quantiﬁable parameters for pre-CAX and refrac-
tory CAX stages. Stage deﬁnitions were supported by associ-
ated functional QoL scores. While measuring SMM is of
poor interest when WL is >5%, it could however be useful
for detecting early nutritional disorders.
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Introduction: Patients with advancing cancer frequently suf-
fer a reduction in daily activities with profound effects on
function and quality of life (Laviano et al. 2005). However,
the rate of decline has not been well described in those with
established cancer cachexia (CACS). The aim of this study was
to assess change in muscle strength and physical function
over 8 weeks in this patient group.
Methods: Patients with lung and gastrointestinal cancer, with
unintentional weight loss of >5% in 6 months or BMI <20
plus 2% weight loss were included. Physical assessments
(baseline, 4 weeks, 8 weeks) included: isometric quadriceps
and hamstring strength, handgrip, standing balance, 10 m
walk time and timed up and go. This was part of a larger
study of activity, motivation and exercise preferences in
established CACS.
Results: Fifty patients (32 male), mean ± SD age 65 ± 10 years
and BMI 24.9 ± 4.3 kg/m2 were recruited. The majority of pa-
tients (n = 43) had a BMI over 20 kg/m2 with 16% of lung pa-
tients and 12% of GI patients being underweight
(BMI < 19.9 Kg/m2). Lung cancer patients had lower muscle
strength and function than those with GI cancer (p < 0.05).
Despite notable attrition, in the 19 (8 lung and 12 GI) patients
who completed all assessments, there was little change in
muscle strength and performance over 8 weeks (p > 0.05).
Baseline variables did not differ signiﬁcantly between com-
pleters and non-completers (p > 0.05).
Conclusions: More than a third of patients with established
cancer cachexia in our study were stable over 8 weeks, sug-
gesting a subgroup that may have potential to beneﬁt from
targeted interventions. Better understanding the physical
performance parameters which characterize and differentiate
these patients has important clinical implications for cancer
multidisciplinary team practice.
Reference:
Laviano, A. et al. 2005. Nat Clin Pract Oncol 2(3), pp. 158–165.
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Joanna Darck Carola Correia Lima1, Fernanda Janku Cabral2, Estefanía
Simões Fernández1, Emídio Marques de Matos-Neto3, Rosangela
Santos-Eichler1, José Otoch Pinhata1, Paulo Sérgio Alcantara
Martins1, Leo Kei Iwai4, Emer Ferro Suavinho1 & Marília Cerqueira
Leite Seelaender1
1University of São Paulo, Brazil, 2University of Campinas, 3University of Piauí,
4Instituto Butantan
Background: Cachexia is a multiorgan syndrome
characterised by progressive and involuntary weight loss
and major effects on skeletal muscle. The pathogenicity and
origin of this syndrome is multifactorial and strongly associ-
ated with systemic inﬂammation due to a complex interac-
tion of reduced food intake and changes imposed on
metabolism by tumour and host factors. To understand the
isolated effects of the tumour microenvironment, the aim
of the present study was to identify changes in the proteome
expression of tumour tissue of cachectic patients and non-
cachectic patients and to investigate possible biological func-
tions related to these proteins.
Methods: Patients with colorectal cancer were recruited after
signature of the informed consent form and tumour biopsies
were collected in surgery. Patients were divided into Weight-
Stable Cancer (WSC n = 2) and Cachectic Cancer (CC n = 2)
groups. Protein was extracted, samples incubated with tryp-
sin and peptides were isotopically marked with light (D0-
TMAB) or heavy (D3-TMAB). Samples were analyzed by mass
spectrometry (LC-MS/MS), and both quantitation (H/L ratios)
and protein/peptide searches in NCBI databank were done
using mascot algorithm. Statistics, proteome validation and
heatmaps for protein expression visualisation were per-
formed with Perseus. Gene Ontology (GO) analysis was car-
ried out with Furinch.
Results/Conclusions: In total, 398 proteins were identiﬁed
and quantitated. From these, 105 proteins were statistically
signiﬁcantly different between the groups (p value and false
Discovery rate (FDR) <0.05). Careful analysis of H/L ratio ex-
pression on heatmap was carried out for selection of the pro-
teins that presented expression proﬁle modulation. 22
proteins were found to be up or down-regulated by cachexia.
GO of these modulated proteins showed that their majority
consisted of proteins related with energetic and protein me-
tabolism, muscle development and contraction, modulation
of immune response and proliferation, growth and cellular
maintenance. In conclusion, tumours if cachectic patients
show a different pattern of protein expression, implying that
one such pattern could be related with the induction of ca-
chexia. Furthermore, the results provide insight on the adop-
tion of tumour sample analysis for precocious diagnosis of
the syndrome.
6-06
Fatty acid proﬁle alterations in plasma and
subcutaneous adipose tissue of cachectic cancer
patients
Katrin Radloff1,3, Daniela Mendes dos Reis Riccardi1, Raquel Galvao
Figuêredo1, Joanna Darck Carola Correia Lima1, Joyce de Cassia Rosa
Jesus-Lima1, Ariene Murari1, José Pinhata Otoch2, Gerhard Paul
Püschel3, Alison Colquhoun1 & Marília Seelaender1
1Institute of Biomedical Science, Cancer Metabolism Research Group, University of
Sao Paulo, Brazil, 2Department of Clinical Surgery, University of Sao Paulo, Brazil,
3Institute of Nutritional Science, Department of Biochemistry of Nutrition,
University of Potsdam, Germany
Background: Systemic inﬂammation and loss of fat mass are
hallmarks of cancer cachexia. Fatty acids (FA) are involved
in inﬂammatory pathways and the adipose tissue as storage
of bulk FA might contribute to promote inﬂammation.
Aim: To assess the FA proﬁle of plasma and adipose tissue
and to measure the gene expression of FA modifying
enzymes in cancer cachexia.
Methods: Volunteers were recruited after signing the
informed consent form at the University Hospital. Patients
subjected to incisional hernia surgery were included in the
control group (Control), while gastrointestinal carcinoma
patients were divided into weight-stable cancer (WSC) group
and cachectic cancer group (CC). Cachexia was diagnosed as
in Fearon et al., 2011. FA were separated and quantiﬁed
using GC/MS. Gene expression of FA modifying enzymes of
subcutaneous adipose tissue (SAT) were measured by real-
time PCR.
Results: In plasma there was a shift from unsaturated to sat-
urated FA. The percentage of palmitic acid was higher in WSC
and CC compared to Control (p = 0.006) and stearic acid con-
tent was higher in CC (p = 0.025). SAT exhibited slide changes
in the bulk fatty acid species. Myristic acid 14:0 was dimin-
ished in plasma (p = 0.019) as well as in SAT (p = 0.06). In
plasma, lower contents of different types of n3 and n6-FA
were measured in both cancer groups compared to controls
or in CC compared to WSC. In SAT only 20:2n6 was signiﬁ-
cantly changed in CC compared to the other groups
(p = 0.04). SAT gene expression of FADS1 and ELOVL5 that
modify long chain FA was not altered while stearoyl-CoA
desaturase expression tended to reduce in cachectic patients
(p = 0.08).
Conclusions: Changes in plasma FA proﬁle were different
from the changes we observed in SAT. The enzyme gene
expression alone cannot explain the FA alterations; hence,
further studies are needed to understand the FA proﬁle in
cancer cachexia.
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A randomized feasibility study evaluating an
exercise intervention for patients with advanced GI
malignancies and cancer cachexia: trial in progress
Richard F. Dunne, Supriya Mohile, Jennifer Peckham, Charles Heckler,
Javier Bautista, Michelle Janelsins, Michelle Porto, Po-Ju Lin, Aram
Hezel & Karen M. Mustian
University of Rochester Medical Center, Rochester 14620, USA
Introduction: Cancer cachexia (CC) is characterized by pro-
gressive loss of weight and lean muscle mass that contributes
to impairments in physical performance and a poorer progno-
sis. Although common in gastrointestinal tract (GI) cancer pa-
tients, there are currently no FDA-approved treatments for
CC. Exercise for Cancer Patients (EXCAP©®) is a home-based,
low-to-moderate intensity exercise intervention consisting of
resistance-band training and a tailored walking prescription.
We are currently conducting a randomized controlled
feasibility trial investigating EXCAP©® to improve physical
performance and function in patients with advanced GI ma-
lignancies and CC.
Methods: Incurable GI cancer patients with >5% weight loss
or >2% weight loss with signs of inﬂammation (glucose intol-
erance, anemia, or hypoalbuminemia) are randomized 1:1 to
usual care with chemotherapy (UC) or a 12-week EXCAP©®
regimen beginning on day 1 of chemotherapy (EXCAP). Sub-
jects undergo physical activity tracking and ﬁtness testing at
baseline, mid-intervention and post-intervention. Cachexia
outcome measures include changes in weight and lean mass
via bioelectrical impedance and computed tomography (CT),
cardiorespiratory and muscle ﬁtness (Short Physical
Performance Battery, VO2 max, hand-grip dynamometry,
and muscle activation by EMG), and inﬂammation and pro-
tein synthesis (C-reactive protein, serum cytokines and
branched-chain amino acids). Since September of 2016, 14
of a planned 40 subjects have enrolled.
Results: In total, 74% (14 of 19) of patients offered the study
consented to participate. The median age of subjects is
67.4 years. The EXCAP group increased their daily steps on av-
erage by 1400 steps, compared to UC whose average activity
declined by 1200 steps. So far, 100% of subjects enjoyed par-
ticipating “very much.” No study-related adverse events have
occurred to date.
Conclusions: Preliminarily, EXCAP©® is feasible, well-liked
and safe in patients with CC. The trial is currently enrolling;
additional subjects are needed to determine whether exer-
cise can impact physical performance and muscle mass in CC.
6-08
Using body composition from expedient image
analysis to predict energy needs in cancer
Sarah A. Purcell1, Vickie E. Baracos2, Jessica R. Lieffers3, Sunita
Ghosh2, Marina Mourtzakis4 & Carla M. Prado1
1Department of Agricultural, Food, and Nutritional Science, Faculty of Agricultural,
Life, and Environmental Sciences, University of Alberta, 2Department of Oncology,
University of Alberta, 3College of Pharmacy and Nutrition, University of
Saskatchewan, 4Department of Kinesiology, Faculty of Applied Health Sciences,
University of Waterloo
Introduction: Resting energy expenditure (REE) is variable in
cancer and inﬂuences energy needs. We assessed the agree-
ment between measured REE (mREE) and predicted REE
(pREE) using anthropometric/demographic variables and
skeletal muscle and total adipose cross-sectional area
(CSA, cm2).
Methods: Patients with advanced colorectal cancer were re-
cruited from the Cross Cancer Institute (Edmonton,
Canada). REE was measured by indirect calorimetry. CSAs
were quantiﬁed via CT images at the 3rd lumbar vertebrae
using Slice-O-Matic, V4.3. Multiple linear regression identiﬁed
the contribution of age, sex, height, weight, skeletal muscle
and total adipose tissue CSAs to REE and generated equations
using signiﬁcant (p < 0.05) variables. Accuracy of new equa-
tions was compared to the Harris–Benedict equation. mREE
was compared to predicted using Lin’s concordance and
Bland–Altman analyses.
Results: 24 patients were included (BMI 26.1 ± 5.3 kg/m2; age
59 ± 13y); mean mREE was 1502 ± 306 kcal/day. Average
pREE from the Harris–Benedict equation was
1542 ± 312 kcal/day; bias = 41 kcal/day; limits of agree-
ment = 212 to 293 kcal/day. Linear regression Model 1 in-
cluded age, sex, height, and body weight; age (p < 0.001),
height (p = 0.001), and weight (p < 0.001) were predictors
of REE (p < 0.001 R2 = 0.870, SEE = 118 kcal/day). Mean pREE
from this model was 1502 ± 285 kcal/day; bias = 0 kcal/day;
limits of agreement = 216 to 216 kcal/day. In Model 2, skele-
tal muscle and total adipose tissue CSA were added. Skeletal
muscle (p = 0.006), age (p < 0.001), weight (p = 0.009), and
height (p = 0.014) were predictors of REE (p < 0.001,
R2 = 0.914, SEE = 99 kcal/day). Mean pREE was
1505 ± 290 kcal/day; bias = 3 kcal/day; limits of agree-
ment = 186 to 173 kcal/day. Lin’s concordance coefﬁcient
was highest for Model 2 equation with a “substantial”
strength of agreement (ρc = 0.958). Model 1 (ρc = 0.9304)
and Harris–Benedict (ρc = 0.905) equations had “moderate”
agreement.
Conclusions: Skeletal muscle is a better predictor of REE on
an individual and group level compared to anthropometric/
demographic data.
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Increased ectopic fat in skeletal muscle and liver is
associated with shorter survival in patients with
colorectal liver metastases
David P.J. van Dijk1,2, Junfang Zhao1,2, Katrin Kemter1,2, Vickie E.
Baracos3, Cornelis H.C. Dejong1,2,4,5, Sander S. Rensen1,2 & Steven W.
M. Olde Damink1,2,4,5
1Department of Surgery, Maastricht University Medical Centre, Maastricht, The
Netherlands, 2NUTRIM School of Nutrition and Translational Research in
Metabolism, Maastricht University, The Netherlands, 3Department of Oncology,
University of Alberta, Edmonton, Canada, 4GROW School for Oncology and
Developmental Biology, Maastricht University, Maastricht, The Netherlands,
5Department of General, Visceral and Transplantation Surgery, RWTH University
Hospital Aachen, Aachen, Germany
Background: Adipose tissue and skeletal muscle mass have
been studied extensively in patients with cancer (cachexia).
While increased adipose tissue is associated with longer sur-
vival, it has been suggested that increased ectopic fat in the
muscle and liver is related to poor survival. Using multiple
computed tomography scans (CT-scans) over time and liver
biopsies, we assessed the relationship between survival and
liver steatosis as well as preoperative changes in muscle fat
content and body composition in patients with colorectal
liver metastases.
Methods: Patients with two available preoperative CT scans
were selected from a cohort of 289 consecutive patients with
colorectal liver metastases undergoing partial hepatectomy.
Scans were analysed using a single CT slice at the L3 level
to assess adipose tissue mass and skeletal muscle mass. Mus-
cle fat content was assessed by calculating the average
Hounsﬁeld units of the muscle tissue at L3 level (radiation at-
tenuation). Liver biopsies were histologically scored for
steatosis using the SAF score.
Results: One hundred and thirty-seven patients had two
available preoperative CT scans with a mean time interval
of 3.2 months. In multivariate cox-regression analysis, reduc-
tion in muscle radiation attenuation, reﬂecting fat accumula-
tion, was associated with shorter disease-free survival (HR
1.98, 95%-CI: 1.20–3.28; p < 0.01) and shorter overall sur-
vival (HR 1.79, 95%-CI: 1.12–2.86; p = 0.01). Liver steatosis
was also associated with shorter overall survival (HR 1.77,
95%-CI: 1.07–2.90, p = 0.03). In contrast, high baseline total
adipose tissue mass was related to increased disease-free
survival (HR 0.60, 95%-CI: 0.45–0.80; p < 0.01) and overall
survival (HR 0.75, 95%-CI: 0.58–0.98, p = 0.03). Changes in
skeletal muscle mass were not signiﬁcantly associated with
survival.
Conclusions: Ectopic fat accumulation in muscle and liver was
associated with shorter disease-free survival and overall sur-
vival, while high total adipose tissue mass seemed to be pro-
tective. This indicates that ectopic fat may be an important
marker of tumour progression.
6-10
Conditioned medium from cachectic pancreatic
tumor organoids inhibits the contractile smooth
muscle cell phenotype
Rianne D.W. Vaes, David P.J. van Dijk, Steven W.M. Olde Damink &
Sander S. Rensen
Department of Surgery and NUTRIM School of Nutrition and Translational Research
in Metabolism, Maastricht University, Maastricht, The Netherlands
Introduction: Pancreatic cancer patients often suffer from
gastrointestinal-related symptoms which may be the conse-
quence of underlying gastrointestinal motility problems (e.g.
gastroparesis). Although muscle loss in cachectic pancreatic
cancer patients is most obvious in skeletal muscle, these clin-
ical symptoms suggest that cachexia manifest itself also in
smooth muscle, a tissue responsible for the contractile func-
tionality of the gastrointestinal tract. We therefore aimed to
investigate whether factors secreted by pancreatic tumor
cells from cachectic or non-cachectic individuals affect the
smooth muscle cell (SMC) contractile phenotype.
Methods: 3D pancreatic tumor organoids were established
from pancreatic tumor tissue, obtained from pancreatic can-
cer patients (n = 3) of whom the degree of cachexia was
thoroughly assessed (weight loss, systemic inﬂammation,
handgrip strength, etc.). Simultaneously, human visceral
SMCs were grown to conﬂuency on basement membrane
matrix coated surfaces and kept for up to 6 days in the pres-
ence of 2% serum allowing SMCs to acquire a contractile phe-
notype. After 6 days, SMCs were exposed to 25% organoid
conditioned medium (CM) for 24 h. mRNA expression of spe-
ciﬁc contractile SMC markers (Acta2, Actg2, Tagln, Smtn) and
extracellular matrix components (Col1a1, Col3a1, Eln) was
analyzed by RT-qPCR.
Results: CM from cachectic pancreatic tumor organoids pro-
voked decreased expression of Acta2 (α-smooth muscle ac-
tin; 1.20-fold) and Actg2 (γ-smooth muscle actin; 1.92-fold),
indicating loss of the mature contractile phenotype. Concur-
rently, we observed increased expression of elastin (Eln;
3.4-fold) supporting a shift from the contractile towards the
so-called synthetic phenotype. Organoids established from
non-cachectic patients (n = 2) did not signiﬁcantly affect ex-
pression of these contractile and synthetic markers. Experi-
ments with organoid CM from 8 additional patients are
ongoing, as are proteomics analyses to identify potential
organoid-secreted factors involved.
Conclusions: These pilot data suggest that pancreatic tumor
cells from cachectic patients secrete factors that diminish
the contractile SMC phenotype, potentially contributing to
gastrointestinal motility problems.
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Role of Electrogastrography (EGG) and effect of
ginger (Zingiber Ofﬁcinale Roscoe) on
gastrointestinal symptoms and inﬂammatory
markers in patients with cancer cachexia
Ravi Bhargava & Martin Chasen
Bruyère Continuing Care - Bruyère Research Institute, Ottawa, Canada
Introduction: Electrogastrography (EGG) is a non-invasive
method for the measurement of gastric myoelectrical activity
(GMA). The aromatic, spasmolytic and carminative properties
of ginger suggest it has direct effects on the GMA. Cancer
cachexia is associated with a variety of gastrointestinal symp-
toms such as nausea and vomiting. There are no data on
pattern of GMA in response to Ginger in patients with cancer
cachexia. Objective of this study is to determine (1) role of
electrogastrography in patients with cancer cachexia, (2)
effect of oral Ginger administration on GMA in patients with
cachexia, and (3) to evaluate GI symptoms using Edmonton
symptom assessment scale (ESAS), patient-generated subjec-
tive global assessment form (PGSGA), dyspepsia symptom
severity index (DSSI) and correlate levels of inﬂammatory
markers and Ghrelin.
Methods: Patients with Cancer cachexia were recruited to
document a baseline and post water load EGG after oral
ingestion of Ginger capsule (1650 mg) once daily, for 14 days.
DSSI, ESAS and PGSGA were completed, and blood test to
measure Ghrelin and inﬂammatory markers was done pre
and post intervention.
Results: Fifteen participants (8M; 7F) with a median age of 58
and varying cancer diagnoses were enrolled. EGG diagnosis
showed that 9 of the 15 patients had a direct improvement
in their GMA. All enrolled subjects showed statistically signif-
icant improvement in nausea, dysmotility-like symptoms and
reﬂux-like symptoms. There was no correlation found for gin-
ger administration and inﬂammatory factors.
Conclusions: Electrogastrography has shown that Gastric
myoelectrical activity may get impaired in patients with
cancer cachexia. By regulating gastric motility, ginger may
improve a range of GI symptoms that can affect oral intake
and quality of life.
6-15
Cachexia in lymphoma patients: preliminary
results of prevalence and risk factors
Joris Mallard1, Cédric Baudinet1,2,3, Manuel Gaviria1, Aline Herbinet1,
Ghislain Quai1, Tarik Kanouni2, Pierre Louis Bernard3 & Guillaume
Cartron2
1V@Si SAS, R&D unit, University of Montpellier, 93 Plan de la Prairie, 34270 Saint-
Mathieu-de-TréviersFrance, vas-i.fr, 2Montpellier University Hospital, Clinical
Hematology clinic, 80 Avenue Augustin Fliche34090, Montpellier, France,
3Euromov, University of Montpellier, 700 Avenue du Pic Saint-Loup 34090,
Montpellier, France
Introduction: Cachexia is a major cancer comorbidity
deﬁned as a multifactorial syndrome characterised by an
ongoing loss of skeletal muscle mass and high mortality.
Inﬂammation with C-Reactive Protein (CRP) level increase
is one of the cachexia mechanisms. Age, gender and Body
Mass Index (BMI) represent risk factors of skeletal muscle
loss. Lymphoma is a hematological cancer and includes
non-Hodgkin and Hodgkin lymphoma. No recent studies
substantiate cachexia prevalence regardless of lymphoma
type or analyze risk factors. This retrospective study aims
to describe cachexia prevalence in non-Hodgkin and
Hodgkin lymphomas and to analyze association of cachexia
with inﬂammation, age, gender and BMI.
Methods: Weight loss was calculated from start of chemo-
therapy (M0) to 6 months later (M6). Cachexia was diagnosed
if weight loss was greater than 5% of total body weight over
past 6 months (Fearon’s deﬁnition, 2011). Correlation be-
tween weight loss and inﬂammation at M6 was investigated
using CRP. Risk factors analyzed were age, gender, and BMI.
Results: 100 patients were included comprising 59 men and
41 women (mean age 62). The cachexia prevalence was
39%, in both men and women. CRP levels were signiﬁcantly
higher in patients with cachexia (p < 0.01). At M6, mean
CRP levels of cachectic patients were signiﬁcantly higher than
the 5 mg/L threshold of inﬂammation in Evan’s deﬁnition
(p < 0.01). There was a weak positive correlation between
weight loss and respectively CRP level at M6 (r2 = 0.42), age
(r2 = 0.12) and BMI (r2 = 0.04).
Conclusions: Cachexia prevalence was 39% in lymphoma pa-
tients. Inﬂammation, age, gender and BMI do not seem to
be relevant risk factors. Since cachexia prevention concerns
all lymphoma patients, exercise could represent one way to
prevent it since diagnosis, by increasing protein synthesis
and muscle hypertrophy. A study assessing effect of exercise
on cachexia prevalence in lymphoma patients will follow
these preliminary results.
6-16
Timed up and go test better explains high-density
muscle mass in gynecological cancer patients
Regielly Candido Silva1, Gabriella Villaça Chaves2, Anke Bergmann1 &
Fernando Tadeu Trevisan Frajacomo1
1Program of Molecular Carcinogenesis, Brazilian National Cancer Institute, Rio de
Janeiro, Brazil, 2Department of Nutrition and Dietetics, Brazilian National Cancer
Institute, Rio de Janeiro, Brazil
Background and aims: Current studies recognize muscle
quality, means high-radiodensity skeletal muscle index
(HRSMI), as a powerful and independent variable to predict
prognosis in cancer survivors. However, it is not clear if
muscle quality attenuation on computed tomography (CT)
imaging may overcome into lower muscle function. This
cross-sectional observational study investigated whether
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HRSMI is associated with muscle function in gynecological
clinical oncology.
Methods: Patients with gynecological cancer prior to treat-
ment were invited to participate. CT images at the third lum-
bar vertebra (L3) were used to assess overall skeletal muscle
index (SMI), calculated in the range 29 to +150 Hounsﬁeld
units (HU). The skeletal muscle attenuation in the range +30
to +150 HU was denominated HRSMI. To assess muscle func-
tion, we included handgrip dynamometer (HGS/kg), arm
curl/30 sec, sit-to-stand/30 sec, sit-and-reach/cm and
Timed-up and go (TUG, sec) test.
Results: Of 73 patients included, mean ages 51.22
(SD ± 14.29), 60.3% had cervical cancer diagnosis. After con-
trolling for BMI, age and cancer stages, we found no evidence
of association between SMI and muscle functional impair-
ment. However, considering HRSMI, it was associated with
higher values of HGS (p = 0.003), arm curl (p = 0.002), sit-
to-stand (p = 0.038), and TUG (p < 0.001). Speciﬁcally,
adjusted linear regression model retained TUG test as the
most sensitive to decode HRSMI in gynecological cancer
(β = 1.45, p = 0.003, R2 = 38%). Further, ROC analysis indi-
cated an optimal cut-point value of 6.48 sec to TUG (77% sen-
sitivity and 75% speciﬁcity) discriminating those individuals in
the 3rd quartile of HRSMI.
Conclusions: Our study reinforced relevance of muscle qual-
ity, rather than muscle quantity, in the oncology setting. In
fact, solely, HRSMI was associated with higher functional
capacity. Further, our ﬁndings suggest TUG test is eligible as
candidate biomarker to elucidate changes in muscle quality
in gynecological cancer patients.
7-01
Disease-related malnutrition factors in patients
with ulcerative colitis
Sergei Ivanov1, Igor Khoroshilov2, Yury Uspenskiy1,3 & Yulia
Fominikh1
1Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian
Federation, 2North-Western State Medical University named after I.I. Mechnikov,
St. Petersburg, Russian Federation, 3Saint-Petersburg State Pediatric Medical
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Background: Underweight is a frequent complication of
ulcerative colitis (UC), but it is not always clear what effect
disease-related malnutrition itself. Our objective is to assess
relationship between the disease-associated factors and the
undernutrition occurrence in UC patients.
Methods: Cross-sectional retrospective analysis included data
of 103 patients with UC. Demographic characteristics (sex
and age), disease behavior (relapse, remission), the extent
of colonic involvement (proctitis/left-sided colitis or
pancolitis), the total number of relapses since the onset of
the disease were analyzed. Underweight was taken into ac-
count when the patient’s body mass index was less than
18.5 kg/m2, according to WHO criteria. A binary logistic
regression was performed to assess the relationship between
disease-related factors and the undernutrition occurrence,
taking into account demographic characteristics. The ad-
justed model included the patient’s age, disease behavior,
the extent of colonic involvement and the total count of
relapses.
Results: The general prevalence of underweight among
patients with UC was 16.5%. Pancolitis and female sex were
associated with a higher incidence of underweight in the
adjusted binary logistic model: OR 7.0 (95% CI: 1.3–38.5)
and 5.7 (95% CI: 1.3–24.9), respectively. However, there was
no reliable relationship between others disease-related fac-
tors and the incidence of undernutrition in patients with UC.
Conclusions: The results of this study may be of great impor-
tance for screening and preventing of the undernutrition in
UC patients with pancolitis.
7-02
High protein, leucine and ﬁsh oil-supplemented
nutrition attenuates right ventricular ﬁbrosis and
skeletal muscle atrophy in mice with cardiac
cachexia
Paulien Vinke1,2, T. Scott Bowen, Renger F. Witkamp2, Volker
Adams1† & Klaske van Norren2†
1Department of Internal Medicine and Cardiology, Leipzig University—Heart Center,
Leipzig, Germany, 2Nutrition and Pharmacology Group, Division of Human Nutrition,
Wageningen University, Wageningen, The Netherlands
†Contributed equally
Introduction: Cardiac cachexia is characterized by ventricular
remodeling that is associated with skeletal muscle wasting.
However, therapeutic strategies that target both cardiac and
skeletal muscle in order to prevent maladaptations remain
sparse. The present study administered a standard chow sup-
plemented with high protein, leucine, ﬁsh oil and oligosac-
charides, to determine whether cardiac and skeletal muscle
remodeling could be attenuated during cardiac cachexia.
Methods: Female mice (C57/BL6) were treated for 8 weeks
with saline (sham; n = 10) or monocrotaline (MCT;
600 mg/kg; n = 10) to induce cardiac cachexia in combination
with a control diet (standard chow AIN-93 M), while a further
MCT-treated group received supplemented nutrition (NS, iso-
caloric) (MCT + NS; n = 10). Subsequent histological analyses
were performed in the right ventricle and tibialis anterior and
microarray analysis was performed for the right ventricle.
Results: Compared to sham mice, relative body weight was
impaired (p < 0.05) in MCT and MCT + NS by 5%. Compared
to shams, MCT mice also showed an increase in heart weight,
right ventricular thickness and ﬁbrosis (all p < 0.05);
however, these alterations were attenuated in MCT + NS
mice. Subsequent Gene Set Enrichment Analysis of the right
ventricle conﬁrmed upregulation in ﬁbrotic pathways in the
MCT—compared to sham-treated mice (P < 0.05), which
were downregulated in the MCT + NS mice. In addition,
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skeletal muscle ﬁber cross-sectional area was reduced
(P < 0.05) by 22% in MCT compared to sham mice, but
preserved in the MCT + NS group (1178 vs 1503 vs
1495 μm2, respectively), with protein expression of the key
E3 ligase MuRF1 also reduced by 30% compared to MCT mice
alone (p < 0.05).
Conclusions: A multi-compound supplemented nutrition sig-
niﬁcantly attenuated both right ventricular and skeletal mus-
cle maladaptations in a mouse model of cardiac cachexia.
These data may provide a novel therapeutic strategy for com-
bating pathophysiological alterations in cardiac cachexia.
7-03
Proﬁle of serum amino acids among community
dwelling older adults from Hong Kong MrOs and
MsOs cohort study: special reference to
sarcopenia
Liu-Ying Zhu1, Ruth Chan1, Jason Leung2, Timothy Kwok1,2 &
Jean Woo1
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
Hong Kong SAR, 2Jockey Club Centre for Osteoporosis Care and Control, The
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Introduction: The availability of blood amino acids, especially
the essential amino acids (EAAs) is the potent stimulus for
muscle protein synthesis. We aimed to compare the proﬁle
of serum amino acids among sarcopenic and non-sarcopenic
community dwelling older adults from Hong Kong MrOs and
MsOs cohort study.
Methods: Baseline data of 2997 Chinese adults aged >65 of
Mr and Ms Os (Hong Kong) Cohort Study were analyzed.
Sarcopenia was deﬁned using the Asian Working Group
Criteria. Serum amino acids levels (EAAs including valine, leu-
cine, isoleucine, methionine, phenylalanine, tryptophan and
non-EAAs including glutamine, arginine, proline, etc.) were
measured. Statistical analyses were performed separately
for male and female.
Results: Mean age of the entire sample was 71.9 years old
and 47.5% was male. There were 156 (5.2%) subjects (male
n = 91, female n = 65) being deﬁned to have sarcopenia. Se-
rum levels of all amino acids of both sarcopenic and non-
sarcopenic groups met the requirement for adults above
18-year-old. When compared to non-sarcopenic men, men
with sarcopenia showed signiﬁcantly lower serum levels of
branched-chain amino acids (leucine, isoleucine and valine
p < 0.0001), methionine (p < 0.01), tryptophan (p < 0.01),
proline (p = 0.039) and tyrosine (p = 0.016). In contrast,
women with sarcopenia only showed lower levels of gluta-
mine, glutamic acid, leucine and valine (p < 0.05) than
women without sarcopenia, whereas no signiﬁcant difference
in other amino acids was observed between the two groups.
After adjusting for age, body mass index, physical activity
scale for the elderly, energy intake and instrumental activities
of daily living impairment, only glutamine (p = 0.045) and
homocysteine (p = 0.031) in male and tyrosine (p = 0.004)
in female showed signiﬁcant difference between sarcopenic
and non-sarcopenic subjects.
Conclusions: The role of amino acid and the effectiveness of
AAs supplements may need further exploration with prospec-
tive randomized controlled trials for sarcopenic elderly.
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Introduction: Chronic low-grade inﬂammation could be one
of the mechanisms underlying the aging process. Interleukin
(IL)-6 and C-reactive protein (CRP), well-recognized markers
of this condition, are positively associated with impaired
physical performance, frailty, sarcopenia and higher mortal-
ity. To date, few interventions have been identiﬁed to reduce
chronic systemic inﬂammation and improve functional per-
formance in seniors. Thus, the purpose of this review was
to examine the state of evidence from relevant randomized
controlled trials on the effects of nutritional and pharmaceu-
tical compounds on established markers of inﬂammation in
middle-aged and older adults.
Methods: A systematic literature search was conducted in
MEDLINE, PubMed and EMBASE databases using combina-
tions of the target compounds which are promising, safe, af-
fordable, acceptable, and practical (omega-3, resveratrol,
vitamin D, probiotics, Angiotensin Receptor Blockers [ARBs],
metformin) with “inﬂammation” OR “c-reactive protein” OR
“interleukin-6.” To be included, studies were limited to ran-
domized controlled trials with placebo or control group re-
ceiving no treatment. Other key inclusion criteria were
participants 45 years and older with chronic low-grade in-
ﬂammation as deﬁned by IL-6 levels between 2.5 and
30 pg/ml and/or CRP levels between 2 and 10 mg/L.
Results: Overall, 49 of 858 studies fulﬁlled the selection
criteria. For IL-6, the following compounds showed a sig-
niﬁcant effect compared to placebo: probiotics
(0.68 pg/ml), ARBs (0.37 pg/ml) and omega-3
(0.19 pg/ml) (Table 1 and Figure 1). For CRP, a
signiﬁcant reduction was observed with probiotics
(0.43 mg/L), ARBs (0.2 mg/L), omega-3 (0.17 mg/L)
and metformin (0.16 mg/L) (Table 1 and Figure 2).
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Conclusions: These results provide support for the potential
of some nutritional and pharmaceutical compounds to signif-
icantly reduce established markers of systemic inﬂammation
in middle-age and older adults. Speciﬁcally, interventions
utilizing probiotics, ARBs and omega-3 produced signiﬁcant
reductions in IL-6 levels, and interventions utilizing
probiotics, ARBs, omega-3 and metformin produced signiﬁ-
cant reductions in CRP.
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Background: Nutritional status may be a modiﬁable factor in
the progression of dementia. Moreover, dementia is an
Table 2
CRP Summary Table
Compound Total studies N(INT) N(PLA) standardized mean differences (INT-PLA) 95% CI P-value
ARBs 6 250 231 0.2 [0.39,0.02] 0.03
Metformin 7 1617 1630 0.16 [0.22,0.09] <0.0001
Omega-3 16 1215 1200 0.17 [0.26,0.09] <0.0001
Probiotic 4 84 86 0.43 [0.75,0.12] 0.0063
Resveratrol 3 74 73 0.27 [0.59,0.06] 0.106
Vitamin D 11 567 568 0.06 [0.18,0.06] 0.317
Table 1
IL-6 Summary Table
Compound Total studies N(INT) N(PLA) standardized mean differences (INT-PLA) 95% CI P-value
ARBs 4 199 181 0.37 [0.59,0.16] 0.0005
Omega-3 9 908 841 0.19 [0.29,0.10] <0.0001
Probiotic 4 89 91 0.68 [1.01,0.35] <0.0001
Resveratrol 3 144 139 0.17 [0.40,0.07] 0.164
Vitamin D 4 276 277 0.09 [0.26,0.07] 0.267
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important cause of mortality, and nutritional status on prog-
nosis and survival will be of interest to health and social care.
A decline of nutritional and functional status is very common
in the end stages of Alzheimer’s Disease (AD). The aim of this
study was to quantify the association between nutritional
and functional status in survival of free-living mild AD
patients`.
Methods: A prospective observational study was conducted
in 79 free-living mild AD patients (32 men; age:
78.2 ± 6.6 years) between 2012 and 2017. Nutrition status
was evaluated with body mass index (BMI) WHO cutoffs,
FFM index ESPEN 2016 cutoffs, MNA full-form score and
bioimpedance analysis. Sarcopenia was deﬁned according to
EWGSOP 2010 criteria. Functional status using gait speed
(GS) and handgrip strength (HGS) was determined. Kaplan–
Meier and adjusted Cox proportional hazard ratio (HR)
methods were applied.
Results: Among the 79 participants, 20 (25.3%) died during
follow-up (mean follow-up period was 70.5 months). Forty-
one participants (51.9%) were underweight, 29.1%
overweight/obesity and the remaining was at normal weight.
Mortality risk was increased in underweight (HR: 3.29; 95%CI:
1.17–9.28; p = 0.024) compared to normal-weight and
overweight-obese participants. HGS tercis (ﬁrst [lowest]: HR:
4.26; 95%CI: 1.18–15.30; p = 0.026), low GS (HR: 2.70;
95%CI: 1.10–6.62; p = 0.029), low phase angle (HR: 2.51;
95%CI: 1.02–6.15; p = 0.044), undernutrition evaluated by
MNA (HR: 4.77; 95%CI: 1.72–13.21; p = 0.003) and weight
loss (HR: 2.92; 95%CI: 1.12–7.60; p = 0.028) increased the
mortality risk. Underweight by BMI and, low muscle function
by GS, were independently associated with higher probability
of non-survival (HRs of 3.65: 95%CI: 1.29–10.35; p = 0.015,
and 2.85: 95%CI: 1.14–7.10; p = 0.024, respectively).
Conclusions: Underweight and low muscle function were as-
sociated with lower probability of survival in free-living AD
patients.
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Introduction: PTEN reduces insulin sensitivity and its expres-
sion increases during sepsis. Considering that critically ill pa-
tients present insulin resistance, we investigated the role of
PTEN expression on glucose control and clinical outcome(s)
in young adult patients hospitalized for trauma in an inten-
sive care unit (ICU) receiving artiﬁcial nutrition.
Methods: This was an observational, single-center study.
Plasma glucose levels and its variability were recorded in
patients. PTEN expression via western blotting analysis was
measured, and the associations between PTEN, plasma
glucose levels and glycemic variability, and calories adminis-
tered were investigated. Parametric and non-parametric tests
were performed, as appropriate, and P < 0.05 was consid-
ered statistically signiﬁcant.
Results: Twenty patients (13 men, mean age of
37.3 ± 12.7 years) were considered. No correlation between
plasma glucose and PTEN was documented (r = 0.15,
P = 0.55), neither between glycemic variability and PTEN ex-
pression (r = 0.00, P = 0.99). However, total kcal/day admin-
istered and PTEN expression signiﬁcantly correlated (r = 0.56,
P = 0.01). Also, patients with PTEN levels below the median
value received less kcal/day than those with PTEN above
the median (P = 0.048). This association was more pro-
nounced when adjusted for body weight (P = 0.03) and for
the average of insulin daily administered (P = 0.02).
Conclusions: PTEN expression might contribute to glucose
homeostasis and disposal in critically ill patients receiving
artiﬁcial nutrition.
References:
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Laviano A, et al. Nat Rev Endocrinol 2010
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Introduction: In the population between 60 and 70 years
prevalence, ratio is from 5 to 13% and in more than 80 year
old people the prevalence is between 11 and 50% 1.
The European Working Group on Sarcopenia in Older
People (EWGSOP) deﬁned a conceptual framework that
shows three level of sarcopenia: pre-sarcopenia, sarcopenia
and high sarcopenia.
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Recent studies indicate that a vitamin D and leucine-
enriched whey protein oral nutritional supplement can im-
prove in muscle mass, and lower-extremity function among
sarcopenic older adults 2.
Aim: To improve the management of sarcopenic patients in
the province of Genoa (IT) and to measure the prevalence
of sarcopenia in elderly institutionalised in Genoa using the
EWGSOP-deﬁned algorithm.
Methods: Transversal, prospective observational study in
nursing homes.
Exclusion criteria: active tumoral disease; severe cognitive
impairment; condition against bioimdenziometric analysis.
Sarcopenia has been evaluated with the deﬁnition and
EWGSOP-deﬁned algorithm physical performance: gait speed
of using the 4-meter walking; hand grip strength test using
Dynax digital dynamometer and evaluation of Skeletal Mus-
cle Index (SMI) using BIA vector analysis.
Results: In this pilot, we test 17 people from 2 different nurs-
ing homes; we found all 17 patient enrolled at high-level
sarcopenia. During observation, the patients were supple-
mented with Leucine and Vitamin D with by the nursing
home physicians. We provide the same test after three
months of therapy, and we found a light modiﬁcation on
EWGSOP indicators as shown in Table 1.
Gait Speed Hand Grip SMI
t0 t3 t0 t3 t0 t3
media 0,6 0,7 10,8 12 7,31 7,83
SD 0,27 0,29 4,65 5,05 1,52 1,46
min 0,36 0,26 3 3,7 4,7 5,7
max 1,5 1,39 18,7 18,3 9,8 10,5
Discussion: The improvement of EWGSOP parameter, even
not signiﬁcant, allow us to be conﬁdent in developing the
next RCT to assess parameters in a larger sample of patients.
References:
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Introduction: Chronic kidney disease (CKD) is highly prevalent
among older adults. Increased risk of cardiovascular disease
is frequent in renal impairment, and metabolic and nutri-
tional derangements are associated with CKD. We compared
the metabolic, nutritional, and cardiovascular impact of re-
duced renal function between patients with and without
known renal disease.
Methods: Consecutive outpatients aged ≥65 years with re-
duced renal function were enrolled and divided into 2
groups: Group A (patients with history of renal disease) and
Group B (patients with unknown renal disease). Nutritional
and metabolic parameters, including involuntary body weight
loss (BWL) in the previous 6 months, mineral metabolism, in-
ﬂammatory indices, and left ventricular mass index (LVMI),
were determined. Parametric and non-parametric tests were
performed as appropriate, and P < 0.05 was considered sta-
tistically signiﬁcant.
Results: Seventy-six patients were enrolled. Group A (n = 39,
M: 24) showed greater BWL with a signiﬁcant reduction of
25-hydroxyvitamin D, transferrin, cholinesterase, albumin,
and greater LVMI with respect to Group B (P < 0.01). In ad-
dition, Group A showed signiﬁcantly increased intact parathy-
roid hormone, total cholesterol, low-density lipoprotein,
triglycerides, and C-reactive protein when compared to
Group B (P < 0.05).
Conclusions: The positive history of renal disease may nega-
tively impact on several nutritional and metabolic parameters
related to increased cardiovascular risk among older adults.
References:
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Introduction: Our previous studies have shown how
Sarcopenia is a prevalent syndrome in CHF patients with a
lower survival and malnutrition risk modiﬁes survival in this
setting too. Sarcopenic Obese account for a signiﬁcant share.
Now we wanted to check if sarcopenic obese modiﬁes sur-
vival and his association with malnutrition risk.
Methods: Prospective cohort study (n = 103) patients with
CHF (NYHA III-IV) were consecutively selected. Nutrition risk
screening (NRS-2002), Mini-Nutritional assesment (MNA)
and Subjective global assessment (VGS) were performed.
Muscle function was measured by hand-grip dynamometry
(kg)- lower limit <20(f); <30(m)-. Appendiceal mass index
and fat mass index were calculated (DUAL Energy-X-
RayAbsorciometry (DXA)) and cut-off values for Sarcopenia
were set according to Rosetta Study. Sarcopenic Obese was
set according Baumgartner study Patients were followed-up
and survival rate (months) registered. Data were stat ana-
lyzed by Kaplan–Meier, Log-Rank Tests and Chi-squared test.
Statistical signiﬁcance was reached at p < 0.05.
Results: One-hundred three patients (50f, 82.5y; 53m, 82.5y)
were selected. Global prevalence of malnutrition was 69.9%
NRS-2002 (67.3% women/71.7% men); 83.3% MNA (83.7%
women/83%men) and 58.8% VGS (59.2% women/ 58.5%
men). Sarcopenic Obese was detected in 17.5% (12.6% of
men; 4.9% of women). Survival rate was not inﬂuenced by
gender (p = 0.56), but was inﬂuenced by risk of malnutrition
(p = 0.017 NRS; p = 0.08 MNA; P = 0.005 VGS) and of
sarcopenic obese (p = 0.032). However, no association was
shown between sarcopenic obese and risk of malnutrition
using the Chi-squared tests (p = 0.095 MNA; p = 0.214 NRS;
p = 0.429 VSG).
Conclusions:
1 The risk of malnutrition is statistically associated with a
lower survival.
2 Sarcopenic obese is statistically associated with a lower
survival
3 No association has been showed between risk malnutri-
tion and sarcopenic obese in our study
4 Further analysis to check if sarcopenic obese modiﬁes risk
malnutrition in this setting.
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Introduction: Several studies have shown that arm circumfer-
ence (AC) and nutritional screening tools have prognostic ca-
pability in patients with cardiovascular disease (CVD).
However, there have been no direct comparisons between
AC and nutritional screening tools. This study was performed
to compare the prognostic predictive capabilities of AC and
nutritional screening tools in older patients with CVD.
Methods: The study population consisted of 1014 admitted pa-
tients aged ≥60 years with CVD. Patients underwent AC mea-
surement and nutritional screening before hospital discharge.
We used the controlling nutritional status index (CONUT score),
the geriatric nutritional risk index (GNRI), and the prognostic
nutritional index (PNI) as nutritional screening tools. The end-
point of the study was all-cause mortality.
Results: The mean age was 73.0 ± 7.0 years, and 68.0% of the
patients were male. A total of 134 deaths occurred over a
median follow-up period of 2.12 years (interquartile range,
2.62 years). After adjusting for preexisting prognostic factors
(including age, gender, body mass index, estimated glomeru-
lar ﬁltration rate, and log B-type natriuretic peptide), AC (haz-
ard ratio [HR]: 0.57; p < 0.001), CONUT score (HR: 1.24;
p = 0.008), GNRI (HR: 0.76; p = 0.031), and PNI (HR: 0.78;
p = 0.006) were signiﬁcant predictors of mortality. However,
adding AC to preexisting prognostic factors (0.733 vs. 0.705,
respectively; p = 0.033), but not CONUT, GNRI, or PNI
(0.717, 0.711, and 0.716 vs. 0.705; p = 0.108, p = 0.280, and
p = 0.139, respectively) signiﬁcantly increased the area under
the curve on receiver operating characteristic analysis.
Conclusions: AC, but not nutritional screening tools, plays a
complementary role to preexisting prognostic factors for
predicting prognosis in older patient with CVD.
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Background and aim: Body composition analysis is manda-
tory in monitoring the effect of dietary therapy. The aim of
this study was to evaluate body composition variable before
and after MNT in obese patients.
Methods: The study involved 714 subjects, 173 men and 541
women, who applied to the Department of Nutrition for MNT
for obesity. The body composition analysis was performed
using Tanita BC 418 MA bioelectric impedance for all pa-
tients. Values of fat mass (FM) and fat free mass (FFM) were
obtained, and then the values of FM-Index (FMI) and FFM-
index (FFMI) were calculated.
Results: Body composition analysis showed that FM and FFM
values are higher in subjects with higher BMI. FMI and FFMI
differed signiﬁcantly among patients within different BMI cat-
egories, as well. These differences are statistically highly sig-
niﬁcant in persons of both sexes (p < 0.001). A statistically
signiﬁcant negative correlation (Pearson correlation 0.222;
p = 0.003) was observed in age-related analysis of FFMI in
male subjects, while in female subjects this relationship was
not statistically signiﬁcant (p = 0.059). After following the
hypocaloric diet, there is a decline in FFMI with increasing
age (Pearson correlation 0.273; p = 0.007). A more detailed
analysis shows that the FFMI value is signiﬁcantly lower in the
group of men older than 55 years (p = 0.005). In the group of
women, this relationship is not observed (p = 0.720). FFMI
decrease is in correlation with MNT duration. People who
have been on regime for more than a month have a lower
FFMI (p = 0.032).
Conclusions: For the purpose of preserving muscle mass, at-
tention should be paid to reduction of FFM in all patients
who are on restrictive regimens for long periods of time. Spe-
cial attention should be given to men older than 55 years in
order to prevent sarcopenia.
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Background/Aims: The Barwon Health Cachexia & Nutrition
Support Service is an outpatient clinic focused on improving
clinical outcomes and quality of life for patients with or at
high risk of cancer cachexia. Patients see an interdisciplinary
team, incorporating a physician, physiotherapist, dietician
and nurse practitioner concurrently. This study aimed to eval-
uate the patient and carer perspective of the service.
Methods: In 2016/17, semi-structured interviews were con-
ducted with 12 patients and 9 carers. Interviews focused on
two broad themes: 1) recounting memories and experience
of the Cachexia & Nutrition Support Clinic and 2) describing
their ideal experience or expectation of a cachexia-speciﬁc
support service. All interviews were recorded and transcribed
verbatim. Thematic analysis was supplemented with data
from reviews of the patient and carer literature.
Results: Analysis generated four superordinate themes that
reﬂected the complex dynamics of the clinic experience.
Themes were improved communication regarding health
literacy/education for patients and carers, empowerment
through person-centred care, evolution of perception of
value, and importance of the interdisciplinary team-based ap-
proach. Generally, patients and carers reported overall posi-
tive experiences with the clinic, particularly with regard to
improved communication and empowerment of the patient.
Conclusions: Findings conﬁrmed that a cachexia-speciﬁc ser-
vice was viewed as having a positive impact on quality of life
and outcomes by patients and carers. A patient-centred and
individualised approach by the interdisciplinary team in par-
ticular were of importance to those interviewed. These in-
sights are a critical step in the development of
recommendations for future clinical management of cancer
cachexia.
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Background: In deﬁning diagnostic criteria for cancer cachexia,
a ﬁrst step was achieved with the classiﬁcation of cancer-
associated weight loss (WL Grades) risk stratiﬁed for mortal-
ity.1,2 Next steps relate to the respective roles of reduced food
intake and altered metabolism in driving WL.3 Here, we tested
the prognostic signiﬁcance of reduced food intake, using a val-
idated clinical tool designed for patient report.4
Methods: Canadian and European patients with cancer
formed an international data set (N = 6301). Included pa-
tients had recorded overall survival (OS), WL Grade (0 to
4),1 and Patient Generated-Subjective Global Assessment
(PGSGA) categories of current food intake.4 Patients relying
exclusively on artiﬁcial nutrition were excluded. Data were
entered into multivariable Cox proportional hazard (out-
come = OS) and multinomial logistic regression (MLR; out-
come = WL Grade) models, adjusted for age, sex, cancer
diagnosis (head and neck, respiratory, colorectal, gastro-
esophageal, others) and stage, performance status, and WL
grade.
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Results: In the adjusted Cox model, PGSGA food intake cate-
gories independently predicted OS (P < 0.001). Compared to
“normal food in normal amount” (N = 2190) categories signi-
fying reduced food intake had worse survival:
“normal food in reduced amount” (N = 2804, HR 1.2; 95%
CI 1.1–1.3, P < 0.001);
“little solid food” (N = 600, HR 1.6; 95% CI 1.4–1.8,
P < 0.001);
“only liquids” (N = 129, HR 1.8; 95% CI 1.5–2, P < 0.001);
“only nutritional supplements (ONS)” (N = 166, HR 1.9; 95%
CI 1.6–2.3, P < 0.001);
“very little of anything” (N = 412, HR 1.8; 95% CI 1.6–2.0,
P < 0.001).
In the adjusted MLR model, patients with reduced food in-
take were more likely to have higher WL grades (Grade 1, 2,
3, or 4 vs. Grade 0, P< 0.001). For example, the probability of
Grade 4 WL for patients with “normal food in normal
amount” = 0.09, “normal food in reduced amount” = 0.25, “lit-
tle solid food” = 0.37, “only ONS” = 0.43, “only liquids” = 0.47,
and “very little anything” = 0.43.
Conclusions: Patient-reported food intake categories provide
a practical clinical assessment prognostic of OS and higher
WL grades.
References:
1. Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the
classiﬁcation of cancer-associated weight loss. J Clin Oncol 2015;
33:90–99.
2. Vagnildhaug OM, Blum D, Wilcock A, et al. The applicability of a
weight loss grading system in cancer cachexia: a longitudinal analysis.
J Cachexia Sarcopenia Muscle 2017.
3. Fearon K, Strasser F, Anker SD, et al. Deﬁnition and classiﬁcation of
cancer cachexia: an international consensus framework. Lancet Oncol
2011; 12:489–495.
4. Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer:
role of the Patient-Generated Subjective Global Assessment. Curr
Opin Clin Nutr Metab Care 2017.
7-18
Current use of parenteral and enteral nutrition in
the oncological setting of a French University
Hospital: adequacy with the recommendations,
efﬁcacy, complications and costs
Lucie Monceau-Baroux1 & Jacques Delarue2
1Brest University Hospital, France, 2Brest University Hospital, France
Introduction: International evidence-based recommenda-
tions regarding the prescription of parenteral (PN) and en-
teral nutrition (EN) in cancer patients are now widely
available (ESPEN, ASPEN). However, data from the literature
shows that real-life practice does not always follow those rec-
ommendations, especially in the palliative situation. Financial
toxicity is a new key parameter in medical oncology because
more expensive antineoplastic drugs become available every
year and the French Social Security might not be able to take
all the costs in charge in the future. Nutritional management
being part of the supportive care provided to cancer patients,
investigating the costs represented by PN and EN is
mandatory.
Methods: The aim of this study was to evaluate if the initial
prescriptions of artiﬁcial nutrition (PN and EN) made to adult
patients with solid tumors in one French University Hospital
during the year 2015 complied with the international recom-
mendations available at that time. Secondary objectives were
to study the evolution of the nutritional status of the patients
under nutritional support, overall survival from the prescrip-
tion time, the rates of septic, metabolic and mechanical com-
plications and the costs.
Results: Between the 01/01/2015 and the 12/31/2015, 111
patients (men: 62%, women 38%) received parenteral nutri-
tion for the ﬁrst time and 137 patients (men: 80%,
women: 20%) received enteral nutrition for the ﬁrst time.
Complete data and analysis will be available in the poster.
Conclusions: The end goal of this study is to have a precise
look at the current practice inside the institution in order to
standardize the prescriptions in the future.
F6-05
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Evaluation of the nutritional status in patients with
incurable cancer
Eliana De Rosa, Lidia Santarpia, Maurizio Marra, Maria Carmen
Pagano, Lucia Alfonsi, Franco Contaldo & Fabrizio Pasanisi
A.O.U. Federico II, Naples, Italy
Introduction: Patients with advanced cancer frequently expe-
rience malnutrition and cachexia which, in turn, may nega-
tively inﬂuence morbidity, mortality and quality of life
(QoL). The aim of this study was to evaluate the nutritional
status of incurable cancer patients and its correlation with
survival and performance status.
Methods: The nutritional status of 30 consecutive incurable
cancer patients (9 men, 21 women, aged 60 ± 9 years), eligi-
ble for home parenteral nutrition, was evaluated. The preva-
lence of cachexia was estimated according to the grading
system developed by Martin et al. in 2015, whilst sarcopenia
was evaluated based on Janssen et al.’s 2004 sex-speciﬁc cut-
points for skeletal muscle (SM) normalized for height.
Results: According to the applied criteria, 100% of patients
were cachectic. The prevalence of moderate and severe
sarcopenia was 44.4% in men and 19% in women, 33.3% in
men and 28.6% in women, respectively. Karnofsky score
was ≤50 in 60% and >50 in 40% of patients. Prealbumin se-
rum levels signiﬁcantly correlated with survival (R2 = 0.430,
p < 0.05). Mean REE (Resting Energy Expenditure)
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normalized for fat-free mass (FFM), (REE/FFM,
30.4 ± 4.5 kcal/kg), was in accordance with age- and sex-
speciﬁc values for healthy subjects reported in the literature.
REE, REE/FFM and phase angle were signiﬁcantly higher in
the subgroup of patients with Karnofsky >50.
Conclusions: Prealbumin dosage and body composition eval-
uation provide useful information on patients’ prognosis and
performance status, in order to identify incurable cancer pa-
tients eligible for nutritional therapy.
7-20
Weight history and nutritional status in advanced
cancer patients
Eliana De Rosa, Lidia Santarpia, Maurizio Marra, Maria Carmen
Pagano, Lucia Alfonsi, Franco Contaldo & Fabrizio Pasanisi
A.O.U. Federico II, Naples, Italy
Introduction: Overweight and obesity are reported in 40–
60% of cancer patients. It’s not clear if obesity provides a sur-
vival advantage in patients with diseases associated with
muscle wasting, certainly it could mask the presence of un-
derlying malnutrition. This study compared the nutritional
status in cancer patients with and without a history of
overweight/obesity.
Methods: We evaluated the nutritional status of 25 consecu-
tive advanced cancer patients (6 men, 19 women, aged
59 ± 8 years) candidate to home parenteral nutrition. Anthro-
pometric measures and weight history were collected. Rest-
ing energy expenditure (REE) was measured by indirect
calorimetry. Body composition and skeletal muscle mass
(SM) were assessed by bioimpedance analysis. Janssen
et al.’s 2004 sex-speciﬁc cut-points for SM normalized for
height (SMI) were used to assess the presence of sarcopenia.
Results: Despite mean body mass index (BMI) was
19.6 ± 3.0 kg/m2, and no patients resulted to be obese at
the visit, mean habitual BMI was 27.4 ± 7.15 kg/m2, in partic-
ular 32% of patients had a history of obesity and 24% of over-
weight. Mean REE and fat-free mass (FFM) were signiﬁcantly
lower (p < 0.05) in patients with habitual BMI <25 kg/m2
(subgroup 1) than in patients with habitual BMI ≥25 kg/m2
(subgroup 2), whilst REE/FFM, SM and SMI showed no signif-
icant differences between the two subgroups. The prevalence
of sarcopenia was 72.7% in subgroup 1 and 37.7% in sub-
group 2. On the other hand, a signiﬁcantly higher
(p = 0.001) weight loss, both absolute and in percentage,
was reported by subgroup 2; similarly, main laboratory
markers of malnutrition (serum albumin, transferrin,
prealbumin, pseudocholinesterase) were signiﬁcantly lower
(p < 0.05) in subgroup 2 than in subgroup 1.
Conclusions: This study highlights the importance of weight
history in the nutritional assessment of cancer patients, since
it allows to identify patients with a higher nutritional risk,
even when body composition seems to be preserved.
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Small-molecule inhibition of MuRF1 attenuates
skeletal muscle atrophy and dysfunction in cardiac
cachexia
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Linke1, Peter Sehr2, Joe Lewis2, Dittmar Labeit3,4, Alexander Gasch3 &
Siegfried Labeit3,4
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Neckargemünd, Germany
Background: MuRF1 is a muscle-speciﬁc ubiquitin E3 ligase
that is activated during clinical conditions associated with
skeletal muscle wasting, like cardiac cachexia, heart failure
or cancer. Yet there remains a paucity of therapeutic inter-
ventions that directly inhibit MuRF1 function, particularly
in vivo. The current study, therefore, developed a novel
compound targeting the central B-box-coiled coil domain
of MuRF1 in order to inhibit muscle wasting in cardiac
cachexia.
Methods: We identiﬁed small molecules that interfere with
the MuRF1-titin interaction from a 130,000 compound
screen based on Alpha technology. A subset of 9 prioritized
compounds were synthesized by Enamine at 10 g scale and
administrated during conditions of muscle wasting, i.e. to
C2C12 muscle cells treated with dexamethasone and to
mice treated with monocrotaline to induce cardiac
cachexia.
Results: The 9 selected compounds inhibited MuRF1-titin
complexation with IC50 values <25 μM; of which 3 were
found to also inhibit MuRF1 E3 ligase activity, with 1 fur-
ther showing low toxicity on cultured myoblasts and
myotubes. This last compound, EMBL chemical core
ID#704946, also prevented atrophy in myotubes induced
by dexamethasone and attenuated ﬁber atrophy and con-
tractile dysfunction in mice during cardiac cachexia. Proteo-
mic and Western blot analyses showed that stress
pathways were attenuated by ID#704946 treatment, includ-
ing downregulation of MuRF1, and normalization of pro-
teins associated with apoptosis (BAX) and protein
synthesis (elF2B-delta). Furthermore, actin ubiquitinylation
and proteasome activity was attenuated.
Conclusions: We identiﬁed a novel compound directed to
MuRF1’s central myoﬁbrillar protein recognition domain.
This compound attenuated in vivo muscle wasting, and con-
tractile dysfunction in cardiac cachexia by protecting de
novo protein synthesis and by downregulating apoptosis
and ubiquitin-proteasome-dependent proteolysis. Further
studies have to show if this newly developed compound
is also suitable to treat atrophy and muscle dysfunction in
other diseases.
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Dantrolene can protect muscle from toxicity
induced by chemotherapy using docetaxel
Baptiste Jude1, Thomas Castel1, Florine Tissier1, Karelle Léon1,
Mickael Droguet1, Marie-Agnès Giroux-Metges1,2 &
Jean-Pierre Pennec1
1EA 4324 ORPHY, IBSAM, UFR Médecine et Sciences de la Santé, Université de
Bretagne Occidentale, Brest, France, 2Explorations Fonctionnelles Respiratoires,
CHRU de Brest, Brest, France
Introduction:Many cancers induce cachexia but chemother-
apy itself can also induce cachexia associated to muscle at-
rophy, inﬂammation and could be a limiting factor of
cancer treatment. The aim of this study was ﬁrstly to inves-
tigate the effects of the docetaxel (Tax), on muscle mass
and inﬂammation. Secondly, an inhibitor of calcium
ryanodine channels, the dantrolene (Dant), was tested in
order to know if it can reduce the muscular toxicity of
docetaxel.
Methods: Three groups were realized: Sham, Tax (docetaxel
at 10 mg/kg), and DanTax (dantrolene at 10 mg/kg 2 h before
and 8 h after docetaxel). In a ﬁrst series, animals were
sacriﬁced 24 h after treatments for determination of plasma
cytokines and for the activated muscle pathways. In a second
series, animals were sacriﬁced 7 days after treatments for
muscle contraction recording and atrophy analyses. All values
are compared to Sham group.
Results: 24 h after treatments, docetaxel-induced muscle at-
rophy up to 12% for soleus, 13% for peroneus and 19% for di-
aphragm whereas in DanTax group it was mitigated with
respectively only 7%, 4.2% and 4.5%. For cytokine proﬁle,
docetaxel led to an increase of INF-γ (+280%), IL-1β
(+780%), IL-6 (+232%) and TNF-α (+400%), but in DanTax
group all concentrations came back to control. 7 days after
treatments, there was no signiﬁcant atrophy in Tax Group
(4.5% for soleus and 17.5% for diaphragm) but in DanTax
group the muscle mass was increased by +9% for soleus and
+7.6% for diaphragm. For peroneus, atrophy was the same in
both groups (4%). Maximal force of peroneus contraction
decreased in Tax group to 179.2 g compared to Sham group
(215.3 g), and in DanTax group the force was restored
(213.8 g).
Conclusions: The results indicated that docetaxel induces
muscle atrophy associated to the release of pro-inﬂammatory
cytokines, and that dantrolene can protect muscle from the
deleterious effects induced by docetaxel.
8-03
ACVR2B/Fc counteracts chemotherapy-induced
loss of muscle and bone mass
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Despite recent progress, chemo- and radiotherapy remain
the primary treatment strategies for cancer, whose develop-
ment is frequently accompanied by the occurrence of ca-
chexia, a debilitating condition mainly characterized by
muscle and fat depletion. We recently showed that chemo-
therapy, among other toxicities, also contributes to the devel-
opment of cachexia by affecting muscle size and strength.
Interestingly, several reports suggest that larger muscle mass
correlates with reduced chemotherapy toxicity and better
outcomes. Along this line, ACVR2B/Fc, an inhibitor of the
Activin Receptor 2B signaling, was shown to preserve muscle
mass and prolong survival in tumor hosts, as well as to in-
crease bone tissue in mouse models of osteogenesis
imperfecta and muscular dystrophy. Hence, we aimed at in-
vestigating the use of ACVR2B/Fc to prevent chemotherapy-
associated toxicities, including muscle and bone depletion.
In order to do so, we compared the effects of ACVR2B/Fc
on body composition, as well as muscle and bone mass in
mice exposed to Folﬁri, a combination of 5-ﬂuorouracil,
leucovorin and irinotecan, for 5 weeks. Here we show that
ACVR2B/Fc signiﬁcantly prevented Folﬁri-induced loss of
muscle mass and muscle strength. Moreover, it completely
counteracted the loss of trabecular bone in both femurs
and vertebrae following Folﬁri administration, as suggested
by the analysis of trabecular bone volume fraction (BV/TV),
thickness (Tb.Th), spacing (Tb.Sp), number (Tb.N) and con-
nectivity density (Conn.Dn). Of interest, Folﬁri or ACVR2B/Fc
did not affect the cortical bone in the mouse femur tissue,
as shown by unchanged cortical bone volume fraction (Ct.
BV/TV), cortical thickness (Ct.Th) and porosity.
Overall, our results suggest that ACVR2B/Fc effectively pre-
vents the loss of muscle and bone mass, as well as muscle
weakness, in animals chronically exposed to chemotherapy.
Future studies will need to validate whether the same protec-
tive effects are observed in combination with different anti-
cancer regimens and/or cancer types.
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A novel Antibody-Oligonucleotide Conjugate (AOC)
platform enables efﬁcient regulation of muscle
targets in mice
Beatrice D. Darimont, Rob Burke, Hanhua Huang,
Venkata Ramana Doppalapudi, Rachel Johns, Palani Balu,
Michael Cochran, Maria Shahmoradgoli, David Chu, Gulin Erdogan,
Y. Chen, H.W. Kwon, Y. Shi, M. Hood, M. Moon, A. Cortes, J.D. Arias,
Anneke K. Raney, Andrew Geall & Arthur A. Levin
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Although muscular dystrophy and other diseases of muscle
are well suited to treatments using antisense oligonucleo-
tides or siRNAs, efﬁcient delivery remains the key challenge
for oligonucleotide-based therapies to fulﬁll their full poten-
tial. Targeting oligonucleotides to an endocytosing liver-
speciﬁc receptor (ASGPR) through conjugation to its ligand
GalNAc enhanced delivery of oligonucleotides into hepato-
cytes and led to various therapies for diseases involving the
liver.
Here we demonstrate that conjugation of oligonucleotide
payloads to antibodies speciﬁc for the transferrin receptor
(TfR1) facilitates efﬁcient delivery of siRNAs and single
stranded morpholino oligonucleotides to muscle and other
organs. A single IV administration of 3 mg/kg of a TfR1
mAb-myostatin siRNA conjugate produced signiﬁcant
(>70%) reductions in levels of myostatin mRNA/protein
in vivo. The knockdown of myostatin lasted for more than
5 weeks and resulted in increasedmuscle size and grip strength
in wild-type mice. An RISC loading assay demonstrated that
these phenotypic effects were mediated through an RNAi
mechanism. A single dose (5 mg/kg) of a TfR1 mAb-morpholino
conjugate enabled exon skipping of exon 23 in dystrophin pre-
mRNA in wild-type mouse skeletal muscle, demonstrating the
ability of antibody oligonucleotide conjugates (AOCs) to sup-
port delivery of diverse oligonucleotide payloads.
The ability to recruit antibodies and other protein-based
scaffolds to deliver oligonucleotides to speciﬁc cell surface re-
ceptors for internalization broadens the number of tissues
and diseases that can be targeted with oligonucleotide ther-
apeutics. The speciﬁcity of these therapies can be enhanced
through careful selection of the targeted receptor and/or the
oligonucleotide payload. In addition, delivery of multiple oligo-
nucleotide payloads and/or the use of therapeutic antibodies
enables potentially greater potency and the regulation of mul-
tiple cellular targets. Studies are ongoing to identify additional
receptors suitable for oligonucleotide delivery and therapeutic
oligonucleotides for the treatment of muscle dystrophies,
sarcopenia, cachexia, and other muscle disorders.
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Mechanisms involved in the cross-talk between
humoral and mechanical cues underlying muscle
wasting in cachexia
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Introduction: Exercise training improves quality of life and sur-
vival of cancer patients. In an animal model of cancer cachexia
we demonstrated that wheel running counteracts cachexia by
releasing the autophagic ﬂux. Exercise pleitropic effects include
the alteration of circulating factors in favour of an anti-
inﬂammatory environment and the activation of
mechanotransduction pathways in muscle cells. Our goal is to
assess whether mechanostransduciton per se is sufﬁcient to
elicit exercise effects in the presence of pro-cachectic factors
of tumor origin. Serum response factor (SRF) is a transcription
factor of pivotal importance for muscle homeostasis, which is
activated with its co-factor MRTF by mechanostranduction in
a way dependent on actin polymerisation.
Methods: We use C26 tumor-bearing mice, in the absence or
presence of wheel running, and mixed cultures of C2C12
myotubes and myoblasts treated with C26 conditioned me-
dium (CM) in the absence or presence of cyclic stretch to
mimic the mechanical stimulation occurring upon exercise.
Results: In vivo both SRF expression and activity are differen-
tially modulated by the C26 tumor, i.e. by humoral factors,
and by exercise. In vitro we showed that CM had a negative
effect on muscle cell cultures, both in terms of myotube atro-
phy and of myoblast recruitment and fusion, and that these
effects were counteracted by cyclic stretch. We showed that
CM repressed SRF-MRTF transcriptional activity, while me-
chanical stretch rescued their transcriptional activity; in addi-
tion, loss of function experiments demonstrated that SRF was
necessary to mediate the beneﬁcial effects of mechanical
stimulation on muscle cells. At least part of the observed ef-
fects were mediated by the balance of pro- and anti-
myogenic factor of the TGFbeta superfamily.
Conclusions: We propose that the positive effects of exercise
on cancer patients and mice may be speciﬁcally due to a me-
chanical response of muscle ﬁbers affecting the secretion of
myokines.
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Efﬁcacy of a novel selective androgen receptor
modulator (TEI-SARM2) with once weekly dosing
in rat unloaded muscle atrophy and Duchenne
muscular dystrophy models
Masanobu Kanou, Kyohei Horie, Katsuyuki Nakamura, Toshie Jimbo,
Hiroyuki Sugiyama & Kei Yamana
Teijin Pharma Ltd, Tokyo, Japan
Introduction: TEI-SARM2, a non-steroidal selective androgen
receptor modulator (SARM), induces strong anabolism in
muscle with minimal effects on reproductive tissues with
once-weekly dosing regimen. In cancer cachexia models,
TEI-SARM2 prevented body weight loss and improved sur-
vival rate. In this study, effects of TEI-SARM2 in animal
models of unloaded muscle atrophy (tail-suspension) and
Duchenne muscular dystrophy (DMD) were examined.
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Methods: Study-1: Female Wistar rats (12-wk-old) were
suspended by the tail to avoid a contact of the hindlimb with
the ground. On day 14, the rats were released from the sus-
pension to recover for further 14 days. Muscle weight was
measured on days 14, 21 and 28. TEI-SARM2 was adminis-
tered orally once weekly at 30 mg/kg for 28 days from the
day of suspension starting. Study-2: DMD rats (dystrophin de-
ﬁcient, 5-wk-old) were administered orally once-weekly at 3–
30 mg/kg. Grip force was measured once a month. After 6-
month treatment, the rats were monitored for hindlimb force
by torque equipment.
Results: Study-1: TEI-SARM2 prevented rapid loss of muscle
weight by tail-suspension and accelerated recovery of gas-
trocnemius muscle weight to the level of intact animals
within 2 weeks after reloading. Study-2: TEI-SARM2 pre-
served grip force during 6 months in DMD rats. After
6 months, preservation of torque force of hindlimb was also
observed. Surprisingly, anabolic effect was not conﬁrmed in
appendicular muscles, suggesting that there is novel mecha-
nism of TEI-SARM2 action to improve muscle function other
than anabolism.
Conclusions: TEI-SARM2 prevents muscle atrophy in atrophic
condition and promotes recovery by once-weekly dosing reg-
imen. In addition, TEI-SARM2 preserves muscle force in DMD
rats apart from muscle hypertrophy. Taken together, TEI-
SARM2 could be a promising drug candidate for various mus-
cle disorders such as disuse muscle atrophy after hip fracture,
DMD and cancer cachexia.
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IL-4 counteracts cancer-induced skeletal muscle
atrophy: the double-edged sword of IL-4
Domiziana Costamagna1,2, Robin Duelen1, Fabio Penna3, Paola
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Background and aims: Terminal cancer patients frequently
present cancer cachexia, a syndrome causing fat and skeletal
muscle weight loss and interfering with antineoplastic thera-
pies. Interestingly, cancer-induced muscle depletion seems
not only due to hyper-activation of the main proteolytic sys-
tems in muscle tissue but also to an impairment of Satellite
Cells (SCs). Indeed, it has already been reported an increase
in the number of activated myogenic precursors in cachectic
muscle, likely unable to complete the regeneration in vivo
(Penna et al., 2010).
Next to SCs, other cell populations are involved in myo-
genic differentiation, such as mesoangioblasts (MABs),
vessel-associated muscle progenitors and Fibro Adipogenic
Progenitors (FAPs). Recently, we demonstrated that BMP-
SMAD-signaling blockade improved MAB myogenic differen-
tiation (Costamagna et al., 2015). Moreover, Fibro Adipogenic
Progenitors (FAPs) have the potential to enhance the differ-
entiation rate of myogenic progenitors after injury and during
disease progression (Joe et al., 2010; Mozzetta et al., 2013).
In this study, we investigated the role of interstitial cells in
colon adenocarcinoma-C26 bearing mice focusing on IL-4
ability to prevent the detrimental adipocyte differentiation
of FAPs in cachectic muscles.
Results: Body weight loss and decreased ﬁber CSA were par-
tially rescued in C26-bearing mice daily treated with IL-4
(C26 + IL-4) with respect to C26 mice. Interestingly, muscle
CSA was increased as well in injured muscles from C26 + IL-
4 mice when compared to injured C26, suggesting a faster re-
generation ability. Moreover, IL-4 was able to induce a de-
crease in FAPs obtained from C26 + IL-4 muscle explants
with respect to C26 ones.
Conclusions: The results demonstrated that IL-4 treatment
can partially rescue muscle atrophy in tumor bearing mice
undergoing cancer cachexia, probably due to anti-
inﬂammatory properties. Further experiments are needed
to analyze which are the pathways activated by IL-4 and
how this could affect different cell types present in the
muscle.
References:
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BIO103 a drug candidate for the treatment of
muscle wasting disorders
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Background: Muscle wasting disorders, including cachexia
and sarcopenia, are multifactorial diseases which contribute
to overall physical frailty. They represent a worldwide health
challenge with limited therapeutic options. The aim of this
study was to characterize a new small molecule, BIO103,
in vitro on myocytes and in vivo on a mouse model designed
to analyse the effects of aging and muscle disuse.
Methods: Mouse C2C12 myoblasts were induced to differen-
tiate, and myotube diameters were measured under ﬂuores-
cent microscopy. Baseline and phosphorylated protein levels
were assessed by Western blot. Relative levels of mRNA ex-
pression were evaluated using qRT-PCR. Oxygen consumption
was recorded using a Seahorse XF Analyzer. For in vivo
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studies, 22-month-old C57BL/6J mice were employed. Whole
animal physical performances, the in situ functionality of
tibialis anterior, and molecular markers of selected muscles
were measured after 4 months of treatment.
Results: Using C2C12 cells, BIO103 increased myotube diam-
eter consistently with a reduction of myostatin and atrogin
gene expression. It led to a rapid activation of AKT/mTOR,
MAPK and AMPK signalling pathways and reduced acetyl-
CoA carboxylase activity, suggesting effects on energy ho-
meostasis and fatty acid synthesis. Moreover, BIO103 was
shown to increase the oxygen consumption rate in muscle
cells. In vivo, BIO103 compensated for the signiﬁcant aging-
related loss of running velocity (p < 0.05). These results were
associated with increased IGF-1 plasma levels (p < 0.05), ele-
vated level of p-AMPKα and p-AMPKβ and lower myostatin
gene expression in the gastrocnemius of BIO103-treated ani-
mals under high-fat diet.
Conclusions: BIO103, a new orally available small molecule,
displays both in vitro and in vivo anabolic properties, acti-
vates AKT/mTOR and AMPK which translates into improved
functional performance, notably in old animals. These inves-
tigations demonstrate the potential of BIO103 in improving
skeletal muscle quality and warrant further studies towards
its development as a drug candidate for the treatment of
muscle wasting disorders.
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Introduction: The mitogen-activated protein kinase family,
especially ERK, is necessary for skeletal muscle mass mainte-
nance. Although rats with diseases such as heart failure and
cancer present muscle atrophy and reduced ERK expression,
the role of ERK in muscle differentiation and phenotype is
poorly understood.
Purpose: To identify phenotypic effects of a decrease in skel-
etal muscle ERK protein, ERK gene was silenced in C2C12
muscle cell culture.
Methods: ERK gene silencing was performed by speciﬁc RNA
interference (siRNA-ERK). Post muscle differentiation phase,
slides were stained with anti-miosin heavy chain antibody
and analyzed by immunoﬂuorescence. Comparison between
groups was performed by Student’s t test.
Results: The number of nuclei in multinucleated cells (≥3 nu-
clei) did not differ between groups (Control 77.7 ± 22.6;
siRNA-ERK 64.7 ± 23.2; p = 0.10). Other data are shown in
the table.
Conclusions: ERK has an essential role in myoblast differenti-
ation into myotube and is important to properly myotube for-
mation and development. These results corroborate the fact
that muscle atrophy is associated with a reduction in ERK
expression.
Control siRNA-ERK
Number of nuclei 116.2 ± 31.7 167.4 ± 79.0*
Number of mononucleated cells 38.6 ± 21.4 102.7 ± 85.1*
Fusion index (%) 67.7 ± 12.9 47.8 ± 23.1*
Myoﬁber area (μm) 9478 ± 7164 6871 ± 4604*
Myoﬁber diameter (μm) 1.04 ± 0.57 0.89 ± 0.46*
Control: normal C2C12 cells, n = 3; siRNA-ERK: ERK gene silencing
C2C12 cells, n = 3; *p < 0.05 vs. Control group.
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Effects of late-life enalapril administration on
cardiac mitochondria of old rats
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S. Carter3, Guglielmina Chimienti2, Angela Maria Serena Lezza2,
Roberto Bernabei1 & Emanuele Marzetti1
1Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of
the Sacred Heart School of Medicine, Teaching Hospital “Agostino Gemelli”,
Rome, Italy, 2Department of Biosciences, Biotechnologies and Biopharmaceutics,
University of Bari, Bari, Italy, 3Department of Aging and Geriatric Research,
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Introduction: Inhibition of the renin-angiotensin system ame-
liorates age-related mitochondrial alterations in several rat
tissues and increases rodent lifespan. Here, we investigated
the effect of late-life enalapril administration on mitochon-
dria biogenesis, mitochondrial dynamics, antioxidant de-
fenses and mitochondrial DNA (mtDNA) content variations
in the heart of old rats.
Methods: Fischer 344 × Brown Norway rats were randomly
assigned to receive enalapril (n = 8), or placebo (n = 8) from
24 to 27 months of age. After sacriﬁce, the heart was col-
lected, and total protein and DNA were puriﬁed.
Results: Enalapril induced a marked increase in mtDNA con-
tent as well as citrate synthase activity, a marker of mitochon-
drial mass. Accordingly, a greater content of mitochondrial
biogenesis proteins [i.e., peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1α), and mitochon-
drial transcription factor A (TFAM)], mitochondrial fusion pro-
tein mitofusin 2 (Mfn2), mitochondrial antioxidant enzymes
superoxide dismutase 2 (SOD2) and peroxiredoxin III (PrxIII)
was found in the same group. Conversely, the expression of
PGC-1β, dynamin-related protein 1 (DRP1) and oxidized PrxIII
(Prx-SO3) were unchanged between groups.
Conclusions: Our data indicate that enalapril enhances mito-
chondrial biogenesis in the heart of aged rats. As both
mtDNA content and mitochondrial biogenesis are crucial for
preserving cellular respiratory capacity, and PGC-1 is
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protective against ROS production and oxidative damage, our
results support the hypothesis that the beneﬁcial effects of
enalapril on the heart is mediated at least partly by mitiga-
tion of oxidative stress. The shift of mitochondrial dynamics
in rats treated with enalapril suggests that enalapril adminis-
tration may promote the dilution of mitochondrial damage
along the network as a further cardioprotective effect.
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Synthetic Ghrelin agonists prevents muscle
atrophy in an in vitro model of muscle wasting in
GHSR-independent manner
Emanuela Agosti2†, Sara Clerici1†, Michele Ferrara1, Elia Angelino1,
Nicoletta Filigheddu2, Claudio Pietra3 & Andrea Graziani1,2
1Dept. of Translational Medicine, University of Piemonte Orientale, Novara, 2Dept.
of Experimental Oncology, University Vita-Salute San Raffaele, Milano, 3Helsinn
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Introduction: Acylated and unacylated ghrelin (AG and UnAG,
respectively) are circulating peptide hormones generated in
the stomach in response to fasting and caloric restriction.
AG, through binding to its acylation-selective receptor,
GHSR1, induces strong GH release, and stimulates food in-
take, adiposity, and positive energy balance. In both patients
and animal models, AG ameliorates cachexia induced by sev-
eral pathological conditions through GHSR-dependent mech-
anisms. However, recent evidence indicates that both AG and
UnAG directly protect skeletal muscle from experimentally in-
duced atrophy, independently of GHSR-1a, thus providing the
evidence for the existence of an alternative anti-atroﬁc
ghrelin receptor expressed in the skeletal muscle (Porporato
et al. J. Clin. Invest. 2013). Anamorelin (ANAM), HM01 are
speciﬁc GHSR1 agonists, with appetite-enhancing and ana-
bolic effects. Different clinical studies have highlighted ANAM
ability to improve the cachectic state in cancer patients by in-
creasing total body mass and food intake, while HM01 was
reported to protect mice in a C26 cancer cachexia model.
Methods and Results: In here, we showed that ANAM and
HM01 activate anti-atrophic and hypertrophic signalling, thus
inducing hypertrophy and protecting cultured myotubes in an
in vitro model of IL6-induced muscle wasting. In addition, the
demonstration that ANAM and HM01 induce hypertrophy in
myotubes from GHSR/ mice provides the genetic evi-
dence that their activity in the skeletal muscle is independent
on GHSR. Finally, HM04, a GHSR antagonist, impairs the
GHSR-independent biological activity of both ANAM and
HM01, as well as that one of AG and UnAG.
Conclusions: Altogether, these observations indicate that i)
synthetic Ghrelin agonists, such as Anamorelin and HM01,
are dual agonists acting both through GHSR, the canonic AG
receptor, and the novel, yet unidentiﬁed AG/UnAG receptor,
ii) the binding pocket of GHSR and the novel AG/UnAG recep-
tor share some structural features, albeit GHSR binding
requires Ghrelin acylation; iii) a direct anti-atrophic activity
in the skeletal muscle may contribute to the biological activ-
ity of synthetic Ghrelin agonists in vivo.
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Sildenaﬁl modulates catabolic pathways and
improves cardiac function in a model of cancer
cachexia-induced cardiomyopathy
Vincenzo Musolino1,2,3, Cristina Carresi1,2,3, Micaela Gliozzi1,2,
Francesca Bosco1,2, Saverio Nucera1,2,3, Miriam Scicchitano1,2,
Delﬁna Tavano1,2, Ernesto Palma1,2, Carolina Muscoli1,2,3 & Vincenzo
Mollace1,2,3
1Institute of Research for Food Safety & Health (IRC-FSH), University of Catanzaro
“Magna Graecia”, Catanzaro, Italy, 2NUTRAMED S.c.a.r.l., Roccelletta di Borgia,
Catanzaro, Italy, 3IRCCS San Raffaele Pisana, Rome, Italy
Introduction: Cachexia is a complex metabolic disorder oc-
curring in late stages of chronic disease including cancer
and characterized by involuntary weight loss caused by an
ongoing wasting of skeletal muscle with or without loss of ad-
ipose tissue. Cachexia also affects the cardiac muscle. Heart
atrophy is caused by the hyperactivation of the main cellular
catabolic pathways, including autophagy and Ubiquitin Pro-
teasome System (UPS). As a consequence of the atrophy of
the heart cardiac function is impaired. Anti-cachectic therapy
in patients with cancer cachexia is so far limited to nutritional
support. Sildenaﬁl, a selective inhibitor of the enzyme
phosphodiesterase-5 (PDE5), has been shown to induce myo-
cardial protective effects, to increase muscle protein synthe-
sis and to reduce muscle fatigue. We hypothesized that
sildenaﬁl ameliorates the wasting process and the heart func-
tion in the Yoshida hepatoma tumor model.
Study design: In this study the effects of sildenaﬁl were
tested in cachectic tumour-bearing rats (Yoshida AH-130).
Rats were treated daily with 30 mg/kg of sildenaﬁl or vehicle
for a period of 16 days. Body weight and composition were
assessed at baseline and at the end of the study. Cardiac
function was analyzed by echocardiography at baseline and
at day 11.
Results: Treatment with 30 mg/kg/d of sildenaﬁl protected
the heart from general atrophy. Tumor-bearing rats displayed
cardiac dysfunction, as indicated by the signiﬁcant impair-
ment of the left ventricular ejection fraction and the left ven-
tricular fractional shortening. In contrast, sildenaﬁl improved
cardiac dysfunction. Western blotting analysis showed an up-
regulation of the autophagy and of the UPS in the hearts of
the vehicle-treated tumour-bearing rats. Treatment with Sil-
denaﬁl, however, was able to modulate the UPS markers
(e.g. TRAF6 and Atrogin-1) in the hearts of tumour-bearing
rats. Moreover, cachexia led to an up-regulation of eNOS
and iNOS in the hearts of tumor-bearing rats. Sildenaﬁl was
able to down-regulate the expression of the enzymes. Al-
though sildenaﬁl did not reduce the loss of lean body mass,
it showed a trend to protect from adipose tissue depletion.
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Conclusions: Sildenaﬁl treatment in the Yoshida hepatoma
model showed an attenuation of fat tissue loss in animals
with progressive weight loss in cancer cachexia. Moreover,
the drug protects the heart from atrophy through a down
regulation of the catabolic markers and presumably through
a modulation of the NOS/NO pathway. This effect led to a sig-
niﬁcant improvement of cardiac function. While mounting ev-
idence supports the implication of the NOS/NO pathway in
muscle wasting, many questions remain unanswered. Larger
studies with longer follow-up and molecular analysis are re-
quired to verify whether sildenaﬁl could ameliorate cardiac
wasting and function by modulating inﬂammation and cata-
bolic pathways.
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Musclin: an exercise-induced myokine useful to
contrast muscle wasting during cancer
Andrea David Re Cecconi, Giulia Benedetta Martinelli, Sara Previdi,
Sergio Marchini, Luca Beltrame & Rosanna Piccirillo
Oncology Department, IRCCS-Mario Negri Research Institute for Pharmacological
Research, Milan, Italy
Introduction: Physical activity extends life span of patients af-
fected by certain types of cancer, also by contrasting the as-
sociated muscle wasting (i.e. cachexia). The most effective
type of physical activity against muscle wasting during cancer
seems to be aerobic exercise. So we asked whether it pro-
motes secretion of proteins by muscles (i.e. myokines) that
may contrast cancer cachexia.
Methods: To mimic aerobic exercise, we infected C2C12
myotubes with PGC1α-expressing adenoviruses, because
PGC1α is the main transcriptional coactivator involved in
muscle adaptation during aerobic exercise.
Results: Our microarray analysis showed musclin as a PGC1α-
induced myokine. We further immunoprecipitated it only
from supernatants of PGC1α expressing myotubes. By Q-
PCR, we found musclin expression unchanged in myotubes
hypertrophying because of activated AKT (to mimic anaerobic
exercise). Among other PGC1α-induced myokines, we found
only musclin strongly downregulated in cachectic muscles
and plasma of C26-bearing mice even at times when their
body weights were not lost yet. Thus, we electroporated
Tibialis Anterior (TA) of C26-bearing mice with musclin-
encoding plasmids and found musclin to preserve ﬁber area.
Dexamethazone-treated myotubes or FoxO3-expressing
myotubes undergo atrophy as measured by increased rates
of proteolysis and MuRF1 induction. Unlike GFP, musclin
was able to contrast the dexamethazone induced-MuRF1 ex-
pression in Luciferase assays. Notably, musclin-containing su-
pernatants of PGC1α expressing myotubes restrained the
FoxO3-induced rates of long-lived protein degradation.
Conclusions: Musclin is a myokine induced speciﬁcally by
PGC1α, typically increased upon aerobic exercise and musclin
overexpression is beneﬁcial against muscle wasting during
C26 growth or in atrophying myotubes. Overall, musclin
would be a good drug option for cancer patients that cannot
exercise and are at risk of developing cachexia.
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Skeletal muscle myotubes show decreased protein
synthesis and viability after treatment with
chemotherapy
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Introduction: Chemotherapy is a very non-speciﬁc treatment
that targets all highly proliferating cells like cancer cells, but
also healthy cells including skeletal muscle cells. Cancer itself
can cause muscle wasting (cachexia); however, limited infor-
mation is available on the direct effect of chemotherapy on
skeletal muscle. A combination of capecitabine (a pro-drug
of 5-ﬂuorouracil) and oxaliplatin is often used as a chemo-
therapy treatment for colorectal cancer patients. This study
aimed at investigating the effects of 5-ﬂuorouracil and
oxaliplatin, either alone or combined, on protein synthesis
(MPS), cell-viability and apoptosis/necrosis in a model for
skeletal muscle (C2C12-myotubes).
Methods: C2C12-myotubes were incubated for 24 h with a
concentration range of oxaliplatin (OX; 2–125 μM, n = 3), 5-
ﬂuorouracil (5FU; 2–250 μM, n = 2), oxaliplatin and 5-
ﬂuorouracil combined 1:1 (OXF; 2–250 μM, n = 3) or left un-
treated (control). Subsequently, after a 4 h serum- and
leucine-free period, MPS was measured by puromycin incor-
poration by the SUnSET method. In parallel, cell viability
was measured by CellTiter-Glo, apoptosis by Caspase-Glo
and necrosis by LDH-release directly after chemotherapy in-
cubation. Statistical analyses by ANOVA with post-hoc LSD
versus control.
Results: MPS was inhibited dose-dependently by both OXF and
OX from 15.6 μM (P < 0.0056). In contrast, 5FU only inhibited
MPS at the highest dose of 250 μM (P < 0.0056). OXF de-
creased cell viability signiﬁcantly from 31.3 μM, whereas OX
decreased cell viability signiﬁcantly from 15.6 μM. Both OX
and OXF increased apoptosis and necrosis from 15.6 μM to
31.3 μM, respectively (P< 0.0056). 5FU decreased cell viability
from 62.5 μM (P < 0.0056) and apoptosis only at 250 μM
(P < 0.0056) while necrosis was unchanged.
Conclusions: Myotubes are compromised by chemotherapy
treatment, with a decrease in protein synthesis and cell via-
bility and increases in apoptosis and necrosis. The impact is
chemotherapy and dose dependent. While the compromised
effect of 5-ﬂuorouracil is evident at levels exceeding pharma-
cological doses, oxaliplatin is more toxic to myotubes than 5-
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ﬂuorouracil, even in low doses and given either alone or
combined.
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Effects of formoterol on atrophy signaling,
autophagy, and muscle phenotype in respiratory
and limb muscles of rats with cancer-induced
cachexia
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Barreiro1 & Francisco J. López-Soriano2,3
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Introduction and purpose: Muscle mass loss and wasting are
characteristic features of patients with chronic conditions in-
cluding cancer. Beta-adrenergic receptor agonists attenuate
muscle wasting. We hypothesize that muscle atrophy signaling
pathways and altered metabolismmay be attenuated in cancer
cachectic animals receiving a treatment with formoterol.
Methods: Rats bearing the Yoshida AH-130 ascites hepatoma
(7 days) were treated daily with formoterol (0.3 mg/kg body
weight, subcutaneously).
Results: In diaphragm and gastrocnemius of cancer cachectic
rats, ﬁber sizes were reduced, levels of structural alterations,
atrophy signaling pathways, proteasome content, protein
ubiquitination, autophagy, and myostatin were increased,
while those of regenerative and metabolic markers (myoD,
mTOR, and PGC-1alpha) were decreased.
Conclusions: Treatment with formoterol attenuates the struc-
tural alterations and atrophy signaling, while improving other
molecular perturbations. These results have relevant therapeu-
tic implications, showing beneﬁcial effects of formoterol in ca-
chectic muscles through several key biological pathways.
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Fenoﬁbrate prevents skeletal muscle loss in lung
cancer-induced cachexia
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Introduction: Cancer cachexia is a systemic metabolic disor-
der with high mortality characterized by catabolism of nutri-
ent rich tissues with no effective treatment. This condition
is particularly prevalent in non-small cell lung cancer (NSCLC),
where loss of skeletal muscle results in functional impairment
and increased mortality. The aim of the current study was to
assess the changes in systemic metabolism in a genetically
engineered mouse model of NSCLC in an attempt to identify
novel therapeutic targets.
Methods: NSCLC was induced in adult KrasG12D/+Lkb1ﬂx/ﬂx (KL)
mice with intranasal adenovirus containing Cre recombinase
and the mice were followed for changes in body weight and
food intake. Cachexia was a priori deﬁned as a 10% loss in body
weight from the peak weight obtained during the study. Serum
and tissue metabolites, hormones, and cytokines involved in
nutrient homeostasis in tumor-bearing mice were measured
and compared to fed and fasted mice using mass spectrometry
and commercially available assays. RNA sequencing of the liver
and skeletal muscle was performed to identify differential var-
iables with adjusted p-values below 0.05 and log-transformed
fold-change greater than 1 between the subgroups of mRNA
expression using DESeq2 (v1.14.1).
Results: Sixty percent of KL mice develop loss of skeletal mus-
cle, loss of adipose tissue, and increased inﬂammatory
markers mirroring the human cachexia syndrome. Using
non-cachexic and fasted animals as controls, we report a
unique cachexia metabolite phenotype that includes the loss
of PPARα-dependent ketone production by the liver. In this
setting, glucocorticoid levels are increased and correlate with
reduced type 2 myoﬁber size and increased markers of he-
patic gluconeogenesis. Restoring ketone production using
the PPARα agonist, fenoﬁbrate, reversed the metabolic
changes in hepatic metabolism and prevented the loss of
body weight and skeletal muscle.
Conclusions: This study characterized a new model of lung
cancer induced cachexia and provides evidence for a novel
therapeutic strategy for cachexia focused on hepatic ketone
production using the well-tolerated, generically available
drug, fenoﬁbrate.
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BGP-15 co-therapy protects against
chemotherapy-induced cachexia
Dean G. Campelj1,2, Cara A. Timpani1,2, James C. Sorensen1,2, Craig A.
Goodman1,2,3, Alan Hayes1,2,3 & Emma Rybalka1,2,3
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Introduction: Chemotherapy-induced muscle wasting and
dysfunction has emerged as a contributing factor to cancer
cachexia1,2 and increases the risk of morbidity and mortality.3
Thus, developing strategies to protect and preserve skeletal
muscle during anti-cancer therapy is paramount. Here, we in-
vestigate the effects of irinotecan (IRI), a topoisomerase-1 in-
hibitor used in the treatment of colorectal cancer, on skeletal
muscle mass and function. Further, we have evaluated the
pharmacological small molecule, BGP-15, a poly-ADP ribose
polymerase-inhibitor, to ameliorate IRI-induced skeletal mus-
cle pathology.
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Methods: 6-week old male Balb/C mice were treated with 6
intraperitoneal injections of either vehicle (0.1% DMSO), IRI
(30 mg/kg) or IRI + BGP-15 adjunct therapy (15 mg/kg) over
two weeks. Through in vivo and ex vivo experiments, body
composition, whole body metabolic and voluntary activity
levels, contractile properties and mitochondrial function
were investigated.
Results: IRI reduced lean mass (p < 0.05) and the absolute
force production of the soleus (SOL; p< 0.0005) and extensor
digitorum longus (EDL; p < 0.05) muscles. Remarkably, BGP-
15 co-therapy was protective, attenuating the IRI-induced
loss of lean mass (p < 0.005) and absolute force production
of both the SOL (p < 0.0005) and EDL (p < 0.05). In ﬂexor
digitorum brevis ﬁbres, IRI (both alone and in combination
with BGP-15) increased the oxidative metabolic potential
(p < 0.05), a marker of mitochondrial functional capacity,
which was achieved by improving coupling efﬁciency
(p < 0.05). BGP-15 co-therapy also improved the glycolytic
metabolic potential (p < 0.05), a marker of anaerobic capac-
ity. These metabolic data are consistent with a reduced whole
body VO2 (ml·min
1·g1) at rest (p < 0.05) in IRI-treated
mice and suggest induction of an “energy conservation” phe-
notype in the skeletal muscle.
Conclusions: Our study is the ﬁrst to show that IRI treatment
induces skeletal muscle dysfunction and wasting, which was
attenuated with BGP-15 co-therapy. These ﬁndings highlight
the potential of BGP-15 to improve patient quality of life dur-
ing and following anti-cancer chemotherapy.
References:
1. Sorensen et al., Cancer Chemo Pharmacol 2016; 78(4):673–83.
2. Gilliam & St. Clair, Antiox Redox Sig 2011; 15(9):2543–63.
3. Kalantar-Zadeh et al., J Cachex, Sarco Mus 2013; 4(2):89–94.
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Creatine supplementation prevents skeletal
muscle atrophy by attenuating systemic
pro-inﬂammatory condition and protein
degradation in tumor-bearing rats
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Aim: To investigate the effects of creatine supplementation
on skeletal muscle protein degradation signaling in Walker-
256 tumor-bearing rats.
Methods: Thirty-two male Wistar rats were assigned to four
(n = 8) groups: control (C), creatine supplemented (Cr),
tumor-bearing (T) and tumor-bearing creatine supplemented
(TCr) rats. Creatine monohydrate was supplied in drinking
water in a total of 21 days (8 g/L). Tumor implantation was
performed on the eleventh day of creatine supplementation;
rats were euthanized ten days after tumor cells inoculation.
Tumor cells inoculation consisted of a suspension of
Walker-256 cells (7.0 × 107cells).
Results: The progressive increase in tumor mass (9% of body
weight at 10th day) coincided with lower (P < 0.05) body
mass (11%) and muscle wasting (31% soleus CSA) in T
compared to C group. In addition, tumor growth promoted
elevated (P < 0.05) systemic leukocytes (1.2-fold, P < 0.05),
increased circulating inﬂammatory interleukins (TNF-α 2.6-
fold and IL-6 4.4-fold increase, P< 0.05) and muscle oxidative
stress demonstrated by increased MDA (54%) and decreased
GSH/GSSG (61%) ratio in T compared to C group. Tumor
growth also promoted increased protein expression of
MuRF1 and Atrogin1. In contrast, creatine supplementation
mitigates body weight loss and muscle wasting (6% and
24% of attenuation in TCr group compared to T, respectively,
P < 0.05). Tumor-induced systemic pro-inﬂammatory condi-
tion, muscle oxidative stress and elevated ubiquitin ligases
were also attenuated by creatine supplementation. There-
fore, decreased expression of MuRF1 and Atrogin1 mediated
by the attenuation of pro-inﬂammatory condition is thought
to be responsible for the preventive effects of creatine sup-
plementation on muscle loss. Mean life span was not differ-
ent between groups (TCr 26.4 ± 2.2 vs T 22.0 ± 2.7, days).
Conclusions: Creatine supplementation prevents cachexia de-
velopment and muscle wasting by attenuating tumor-induced
systemic pro-inﬂammatory condition and muscle oxidative
stress; condition that may down-regulates important regula-
tors of ubiquitin mediated protein degradation Atrogin-1
and MuRF-1 in skeletal muscle.
Supported by Capes-PVE # 88881.068035/2014-01
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Targeting mitochondria with SS-31 in experimental
cancer and chemotherapy-induced cachexia
Riccardo Ballarò1,2, Marc Beltrà1,2, Paola Costelli1,2, Hazel Szeto3 &
Fabio Penna1,2
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Cancer cachexia is a debilitating muscle wasting condition de-
ﬁned also as an energy-wasting syndrome1. Mitochondria
play a central role, being the main energy source. Indeed, mi-
tochondrial alterations and low intracellular ATP have been
found in the skeletal muscle of cachectic animals2.
The present study aimed at evaluating the effects of a
mitochondrial-targeted compound (SS-31) on muscle wasting
in C26-bearing mice either under unrestricted tumor growth
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(C26; 14 days of tumor growth) or treated with chemother-
apy (oxaliplatin + 5-ﬂuorouracil; C26 OXFU; 28 days of tumor
growth).
Animals with unrestricted tumor growth exhibited a reduc-
tion of muscle mass, muscle strength and food intake. OXFU
administration was able to double the lifespan of C26 mice,
although resulted in exacerbated muscle wasting. SS-31 ad-
ministration counteracted body weight and food intake loss
in C26 mice and, while borderline signiﬁcantly protected from
muscle wasting. Regarding mitochondrial markers, both C26
and C26 OXFU animals exhibited a reduction of PGC-1α,
Cytochrome c and SDH protein levels with no effect of
SS-31 administration. In C26 OXFU mice, also the SDH total
activity and ATP content were reduced. In C26 mice SS-31
increased SDH activity and ATP content. Mitochondrial
alterations found in C26 mice also associated with a strong
reduction in protein synthesis that was improved by SS-31
treatment.
In conclusion, targeting mitochondria with SS-31 exerts
some beneﬁcial effects on C26-bearing mice with unre-
stricted tumor growth, partially protecting from body weight
and food intake loss, muscle wasting and counteracting the
impairment of muscle oxidative capacity leading to energy
wasting. Further investigation and treatment optimization is
required in order to demonstrate a potential effectiveness
of SS-31 in the more severe chronic model (C26 OXFU mice).
References:
1. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer ca-
chexia: understanding the molecular basis. Nat Rev Cancer. Nature
Publishing Group;. 2014;14(11):754-762.
2. Pin F, Busquets S, Toledo M, et al. Combination of exercise training
and erythropoietin prevents cancer-induced muscle alterations.
Oncotarget. 2015;6(41):43202-43215.
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Introduction: The andropause is associated with declines in se-
rum testosterone and an associated loss of skeletal muscle
mass and function (i.e. sarcopenia), and insulin resistance.
Two of the major interventions purported to offset sarcopenia
are testosterone (T) therapy and resistance exercise training
(RET); however, the beneﬁts of T coupled to RET are poorly de-
ﬁned—especially on the back drop of ‘anabolic resistance’ of
ageing. The purpose of this study was to determine the effect
of RET plus T (vs. placebo) in relation to body composition,
muscle mass, strength and oral glucose tolerance.
Methods: Sixteen non-hypogonadic healthy older men, 65-
75 y, BMI ≤30 kg·m2 (serum total T > 8.3 nmol·l1) were
randomly assigned in a double-blinded fashion to receive
bi-weekly: either placebo (P, n = 8) or testosterone (T;
Sustanon 250-mg, n = 8) injections over 6-week whole-body
RET. RET consisted of leg extension, leg press, leg curl, lat pull
down, shoulder press and bench press (3 sets, 8–10 reps at
80% 1-RM). Dual energy x-ray absorptiometry (DXA), muscle
ultrasound, isokinetic dynamometry and oral glucose toler-
ance tests (OGTT) were used to quantify body composition,
muscle architecture, maximal voluntary contraction (MVC)
and glycaemic control, respectively.
Results: T adjuvant to RET, augmented total lean mass
(5.29 ± 2.67% vs 1.18 ± 2.84%, P = 0.01, ES = 0.79), appendic-
ular lean mass (24520 ± 2739 g to 26133 ± 3075 g vs.
24978 ± 3813 g to 25166 ± 3438 g, P = 0.023, ES = 0.42), m.
vastus lateralis thickness (VL) (P < 0.0001, ES = 0.38), 1-RM
leg extension (P < 0.0002, ES = 0.61) and leg curl
(P = 0.005, ES = 0.39). However, no group differences
(P > 0.05) were observed in MVC or fascicle
length/pennation angle. Additionally, T decreased body fat
6.40 ± 3.66% (P = 0.017, ES = 0.25) vs. P. There was no signif-
icant impact of T/RET in relation to OGTT (P > 0.05).
Conclusions: T therapy, adjuvant to RET, enhanced muscle
mass (i.e. thus “overcoming” anabolic resistance), whilst simul-
taneously decreasing body fat without impacting glycaemic
control. T therapy coupled to RET is an effective short-term in-
tervention to improve muscle mass/function in older age.
9-02
SARA Clinical program for evaluating safety and
efﬁcacy of Sarconeos in a Phase 2b clinical trial
Waly Dioh1, Carole Margalef1, Philippe Dupont1, Pierre Dilda1, René
Lafont2, Stanislas Veillet1 & Susanna Del Signore1
1Biophytis, UMPC – BC9, 4 place Jussieu75005, Paris, France, 2Sorbonne Universités,
UPMC Univ Paris 06, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005, Paris,
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Introduction: Sarcopenia is a key underlying cause of physical
frailty, a reversible condition in older subjects, which may
lead to mobility disability and dependency. Sarcopenia is
characterized by the loss of muscle mass and function.
Biophytis has developed the drug candidate Sarconeos
(BIO101) acting via Mas, the Angiotensin1–7 receptor for pre-
vention and treatment of Sarcopenia. Mas receptor is one of
the components of the Renin-Angiotensin System.
Methods: Speciﬁcally, the SARA clinical program was devel-
oped with Sarconeos (BIO101) in age-related sarcopenia
and is composed of three main studies:
• The completed SARA-PK Phase 1 study that evaluated
Sarconeos safety proﬁle in young and elderly volunteers
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up to 1400 mg/day in single administration and up to
900 mg/day after 14-day multiple oral administration.
• The ongoing SARA-OBS observational study that aims to
validate applicability of inclusion criteria based on
sarcopenia deﬁnition according to the Foundation of NIH
(Studenski et al., 2014) and a very low Short Physical Per-
formance Battery (SPPB; Guralnik J et al., 1994). This study
will also evaluate functional (6 minutes walking distance:
6MWD and 400 meters test) and three Patient Reported
Outcomes (SF-36; SarQoL, TSD-OC) parameters.
• The SARA-INT interventional phase 2 study that will evalu-
ate safety and efﬁcacy of two oral doses of Sarconeos ver-
sus placebo in older sarcopenic patients (scheduled for
second semester 2017).
All data are hosted within the SARA dedicated platform,
allowing real-time monitoring.
Results: Our presentation will focus on 1) Sarconeos effects
on a battery of pharmacodynamic plasma biomarkers (Myo-
globin, PIIINP etc.) as observed in SARA-PK. 2) Preliminary
baseline data of SARA-OBS on target population and primary
(6 MWD/400 meters and Patient Reported Outcomes) and
secondary endpoints. And, 3) SARA-INT methodology for in-
vestigating Sarconeos safety and efﬁcacy in sarcopenic older
patients.
Conclusions: The SARA clinical program will allow to outline
the effects of Sarconeos on age-related sarcopenia.
9-03
Neuromuscular electrical stimulation (NMES)
during hemodialysis improves muscle mass and
function in chronic renal disease patients
Ana C. Marini1, Reika D. Motobu1, Bruna M. Giglio1, Renata C.
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2Immunometabolism Research Group, Department of Physical Education, São
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Background and aims: Renal failure patients undergoing he-
modialysis experience signiﬁcant loss of muscle mass and
function, which in turn contributes to poor clinical outcome.
Physical inactivity contributes to loss of muscle mass and
function. NMES elicits muscle contraction and has been
shown to attenuate muscle atrophy when physical activity is
not feasible or tolerated. Therefore, we hypothesized that
regular NMES during dialysis sessions may improve muscle
mass and function.
Methods: Adult renal failure patients, receiving hemodialysis
3 times/week, were considered for the study. Patients were
randomly assigned to usual care (control group) or to NMES.
NMES was applied bilaterally to both thighs and calves, at the
origin and insertion points of muscle for 40 min during each
hemodialysis session for 1 month. Skeletal muscle mass index
(SMI; g/m2), muscle function and performance were assessed
at the beginning and at the end of the study period by an-
thropometry, BIA, handgrip strength (Kg) and gait speed (m/
sec). Results were statistically analyzed by Student’s t-test,
and data are reported as M ± SD.
Results: Twenty-one patients were studied (x = 8 women,
x = 13 male; 45.8 ± 10.6 yr). In NMES-treated patients
(n = 10; 6 M/4F), SMI increased signiﬁcantly at the end of
the study when compared to control group (+0.35 kg/m2 vs.
0.41 kg/m2, respectively; p = 0.007). Gait speed improved
in NMES-treated patients at the end of the study (+0.07 m/
s; p = 0.04), whereas it remained unaltered in the control
group (0.02 m/s; p = 0.70). At the end of the study period,
no signiﬁcant change in handgrip strength was observed in
NMES and control groups (p = 0.28 and p = 0.08, respectively).
Conclusions: Thirty days of NMES targeting muscles of the
legs may improve muscle mass and function in patients with
chronic renal failure and undergoing hemodialysis.
10-01
Changes in muscle quality following 12 weeks of
power training in mobility-limited older adults: a
randomized controlled trial
Jonathan Vaarst1, Mikkel Kolind1, Lars N. Hvid2, Marianne Andersen3
& Paolo Caserotti1
1Department of Sports Science and Clinical Biomechanics, SDU Muscle Research
Cluster (SMRC), University of Southern Denmark, Odense, Denmark, 2Section for
Sport Science, Department of Public Health, Aarhus University, Aarhus C, Denmark,
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Introduction: Aging is associated with a loss of muscle
strength that exceeds the loss of muscle mass, which ulti-
mately translates into reduced muscle quality (MQ: strength
per unit of muscle mass). The decline in muscle strength is
greater in mobility-limited older adults compared to well-
functioning older adults, and MQ may be even poorer in this
group. There is evidence that power training counteracts the
loss of function, although it is unclear to which extent this ex-
ercise regime affects muscle mass, strength and quality, espe-
cially in mobility-limited older adults. This study investigated
the effect of 12 weeks of progressive high-intensity (70–
80% of 1 RM) power training on muscle quality in mobility-
limited participants aged 75+.
Methods: Sixty-ﬁve older adults with usual gait speed
<0.9 m/s (age: 82.4 ± 4.8(mean ± SD), 66.2% female) were
randomized to a control group (CG) or training group (TG).
Fifty-one participants had complete cases (CG: n = 27, age
82.8 ± 5.2, 77.8% women); (TG: n = 24, age 82.6 ± 4.5, 50%
women). Muscle strength was assessed as an isometric
single-leg maximum voluntary contraction (MVC) normalized
to body weight (N/kg). Leg muscle mass (LMM) of the
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dominant leg was determined using dual-energy X-ray ab-
sorption (DXA – Hologic Inc, Bedford, MA). MQ was calcu-
lated as MVC divided by LMM.
Results: Muscle strength increased by 2.6 ± 2.9 N/kg (27.2%)
in the TG with no changes in the CG (TG vs CG; p < 0.01).
LMM did not change in either group. MQ increased by
28.6 ± 32.0 N/kgLMM (27.9%) in the TG with no changes in
the CG (TG vs. CG; p < 0.01).
Conclusions: The results indicate that progressive power
training is effective in improving MQ in mobility-limited older
adults and that these changes primarily are mediated by in-
creases in muscle strength with no changes in muscle mass.
10-02
Physical mobility and survival in older Chileans
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Saguez1, Florencia Danioni3, Patricia Arroyo2 & Felipe Salech2
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Background: Physical Mobility is a key issue for maintaining
independence in older people.
Objective: To study the association of self-reported physical
mobility, deﬁned as ability to walk eight blocks and leisure
time physical activity (LTPA) practice, with survival in older
Chileans.
Methods: Follow up of the Alexandros cohorts designed to
study disability associated with obesity in community-
dwelling people 60 y and older living in Santiago/Chile. At
baseline 2395 participants, mean age 69.6 ± 7.1 y (min 60;
max 100), 67.1% women, underwent home interviews includ-
ing history of chronic diseases, self-reported
disability/functional limitations, ability to walk 8 blocks and
LTPA were performed. Anthropometry, dynamometry and
physical performance were measured. Information about
deaths was available for the whole sample. Cox proportional
hazard models and Survival probabilities according ability to
walk eight blocks and LTPA at baseline were built.
Results: At baseline 62% of the participants reported no lim-
itations in walking eight blocks, 30.3% some limitations and
7.7% inability. Only 10.8% reported LTPA at least 3 times
per week with 74.2% of the sample never practicing. After
10–14 years of follow up and 24459 person/years at risk
469 people were died. After adjusting by age, sex, BMI,
smoking and education, the hazard ratios for death associ-
ated with limitation for walking 8 blocks was HR = 1.84
(95%CI:1.49–2.28) and the protective effect of practicing
physical activity ≥3 times/week was HR = 0.04
(95%CI:0.006–0.305).
The probability of survival at 12–14 y according ability to
walk eight blocks was 0.84 (95%CI 0.82–0.86) for people with
no limitations and 0.62(95%CI 0.58–0.66) for people with
limitations/inability.
For people practicing LTPA ≥3 times/week the probability
of survival at 12–14 y was 0.988 (0.9633–0.9961) vs. 0.748
(0.6987–0.7907) for people practicing LTPA 1–2 times/week
or never.
Conclusions: Ability to walk 8 blocks and physical activity ≥3
times per week are independently associated with higher sur-
vival in older Chileans.
Funding: Fondecyt Grants 1080589 & 1130947
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Concurrent training does not impair myonuclei
addition in elderly
Miguel Conceição1,3, Claudia Cavaglieri1, Cleiton Libardi2, Felipe
Vechin3, Mara Patricia Chacon-Mikahil1, Aline Bacurau3, Patricia
Chakur Brum3 & Carlos Ugrinowitsch3
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Introduction: It is well known that aging is associated with
sarcopenia and cardiovascular problems. To reduce the burden,
elderly should perform both resistance training (RT) and endur-
ance training (ET), called concurrent training (CT). However, CT
can hamper muscle strength and hypertrophy gains compared
to RT alone, phenomenon known as interference effect. Inter-
estingly, the physiological mechanisms behind interference ef-
fect are uncertain. Recently, it was showed the importance of
satellite cells (SC) to muscle hypertrophy. After activation, SC
enter the cell cycle, proliferate and may fuse and donate their
nuclei to existing muscle ﬁbres. The donation of myonuclei is
nedeed when increased transcription capacity is required, such
as to promote protein accretion. Nevertheless, no study has in-
vestigated changes in myonuclei number after CT, in elderly.
Objective: To compare myonuclei number after 12 weeks of
CT and RT in elderly.
Methods: 24 healthy subjects (64 ± 4 years, 64 ± 4 kg,
1.64 ± 0.11 m) were randomly allocated in one of the follow-
ing groups: concurrent training (CT, n = 8), resistance training
(RT, n = 9) or control group (GC, n = 7). A muscle biopsy was
undertaken before and 48 after the last training session. Max-
imum strength test (1-RM), maximal oxygen uptake
(VO2max) test and magnetic resonance imaging (MRI) were
also assessed pre- and post-training. RT was performed twice
a week in the leg press 45° (4 × 10 at 70–80% of 1-RM). CT
performed the same RT protocol followed by
walking/running at 60–85% of VO2max during 40–50 min.
Results: CT and RT signiﬁcantly increased muscle strength
and hypertrophy after intervention with no difference be-
tween them. There were no changes in myonuclei number
in all groups.
Conclusions: 12 weeks of CT increase muscle strength and hy-
pertrophy similarly to RT. Also, neither CT nor RT showed
myonuclei addition suggesting that pre-existing myonuclei in-
duced muscle growth.
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Introduction: Aging-related changes in body composition and
muscle strength, together with sarcopenia prevalence, are
greatly inﬂuenced by physical activity (PA) and sedentary be-
haviors (SB). However, these associations have been barely
explored in elder adults at high cardiovascular risk. We exam-
ined the associations of leisure-time PA and SB with
sarcopenia prevalence, body composition and muscle
strength in elder adults with overweight/obesity and meta-
bolic syndrome from the PREDIMED-PLUS trial.
Methods: Cross-sectional baseline analysis including 1,539
men and women (65 ± 5y). Sarcopenia was deﬁned as low
muscle mass (lowest sex-speciﬁc tertile for skeletal muscle
mass index) plus low muscle strength (lowest sex-speciﬁc
tertile for 30-second chair-stand test). We applied
multivariable-logistic regression for the associations of self-
reported leisure-time PA and SB with sarcopenia; and
multivariable-linear regression for the associations with
DXA-derived bone mass, fat mass, lean mass and lower-limb
muscle strength.
Results: Inverse associations were observed between
sarcopenia and each hourly increment in total [odds ratio
0.76 (95% conﬁdence interval, 0.63, 0.94)], moderate [0.74
(0.57, 0.97)], vigorous [0.44 (0.23, 0.85)], and moderate-
vigorous PA (MVPA) [0.68 (0.53, 0.87)]. Incrementing
1 h/day total-PA and MVPA was inversely associated with
BMI, waist circumference (WC), fat mass, and positively asso-
ciated with bone mass and lower-limb muscle strength (all
P < .05). One h/day increase in total SB, screen-based SB
and TV-viewing was positively associated with BMI, WC and
fat mass. Light-PA was not signiﬁcantly associated with any
outcome.
Conclusions: Total-PA and PA at moderate and high intensi-
ties may protect against the prevalence of sarcopenia, have
a beneﬁcial role on body composition and prevent loss of
muscle strength. SB, particularly TV-viewing, may have detri-
mental effects on body composition in elderly adults at high
cardiovascular risk.
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Lean mass is better predictor of bone mineral
density than physical ﬁtness in elderly people
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Introduction: Within the older population, osteoporosis is a
critical age-related disorder because of the bone loss that oc-
curs during the ageing process (1). A better understanding of
the factors underlying increased bone fragility in elderly will
lead to the deﬁnition of appropriate screening and diagnostic
strategies.
Purpose: The aims of this study were to examine the associ-
ation of bone mineral density (BMD) with some of the most
widely used physical ﬁtness tests and lean mass and to deter-
mine the differences in bone mass by ﬁtness status in elderly.
Methods: Lean mass and BMD (subtotal body, lumbar spine
and femoral neck) were measured with dual energy x-ray ab-
sorptiometry in 204 elderly (144 women) aged 73.4 ± 5.6 years
from Zaragoza (Spain). Physical ﬁtness was evaluated with
the Senior Fitness Test battery and 2 additional tests (static
balance and 30-meter walking speed). The association be-
tween physical ﬁtness-related variables and lean mass with
BMD variables was tested by linear regression adjusting by
age and sex. Finally, physical ﬁtness of osteoporotic partici-
pants was compared to that of non-osteoporotic with age
and sex adjusted ANCOVAs.
Results: Physical ﬁtness-related variables did not signiﬁcantly
predict BMD, while lean mass signiﬁcantly predicted BMD in
all measured sites (4% for the femoral neck, 9% for the lum-
bar spine and 6% for the subtotal body; all p < 0.05). More-
over, no differences were found for physical ﬁtness variables
between osteoporotic and non-osteoporotic participants.
Nevertheless, non-osteoporotic participants presented higher
subtotal lean (39.30 ± 4.33 vs. 36.73 ± 4.27 kg), arms lean
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(3.91 ± 0.57 vs. 3.82 ± 0.56 kg) and legs lean (12.91 ± 1.59 vs.
12.05 ± 1.56 kg) masses than osteoporotic participants (all
p < 0.05).
Conclusions: BMD is associated to lean mass and not physical
ﬁtness in elderly people. Therefore, BMD may be more suscep-
tible to changes in leanmass than to changes in physical ﬁtness.
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Background: Patients with advanced cancer frequently suffer
a decline in activities associated with involuntary loss of
weight and muscle mass (cachexia). This has profound effects
on function and quality of life. Although exercise participa-
tion can maintain physical and psychological function in pa-
tients with cancer, uptake is low in cachectic patients who
are underrepresented in exercise studies. To understand
how such patients’ experiences inﬂuence exercise participa-
tion, we investigated exercise history, self-conﬁdence, and ex-
ercise motivations in patients with established cancer
cachexia, and relationships between relevant variables.
Methods: Lung and gastrointestinal cancer outpatients with
established cancer cachexia (n = 196) completed a question-
naire set exploring exercise history and key constructs of
the Theory of Planned Behaviour relating to perceived con-
trol, psychological adjustment and motivational attitudes.
Results: Patients reported low physical activity levels and few
undertook regular structured exercise. Exercise self-efﬁcacy
was very low with concerns it could worsen symptoms and
do harm. Patients showed poor perceived control and a
strong need for approval but received little advice from
healthcare professionals. Preferences were for low intensity
activities, on their own, in the home setting. Logistical regres-
sion analysis revealed no signiﬁcant factors related to the in-
dependent variables.
Conclusions: Frequently employed higher intensity, group ex-
ercise models do not address the motivational and behav-
ioural concerns of cachectic cancer patients in this study.
Developing exercise interventions which match perceived
abilities and skills are required to address challenges of self-
efﬁcacy and perceived control identiﬁed here. Greater en-
gagement of health professionals with this group in exploring
potential beneﬁts of exercise is required.
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functioning during acute hospitalization and
predict functional recovery following discharge in
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Introduction: Poor sleep quality, frequent in older adults, is
associated with reduced physical function and well-being.
However, little is known about the relationship between
sleep quality and the recovery of physical function after hos-
pitalization. Thus, we conducted this study to examine the as-
sociation between sleep quality and functional recovery after
an acute hospitalization in community dwelling older adults.
Methods:Older adult patients (N = 27,mean age = 74 ± 8 years)
were recruited during hospitalization (average length of stay
3.9 days) with Cardiovascular (56%), Pulmonary (22%), or
Metabolic (13%) admission diagnosis. Testing was performed
prior to discharge (baseline) and 1-month post-discharge.
Functional performance was measured using the Short Phys-
ical Performance Battery (SPPB) consisting of three parts:
gait, balance and chair rise. Sleep quality was measured using
Pittsburgh Sleep Quality Index (PSQI) global score. Sleep efﬁ-
ciency and minutes awake after sleep onset was assessed
using actigraphy (Actiwatch 2).
Results: Pearson correlations revealed signiﬁcant associa-
tions between PSQI and baseline SPPB total or baseline gait
scores. Separate regression models revealed baseline PSQI
score predicted change scores from baseline to 1-month
post-discharge for balance or gait; with a trend for SPPB total
scores. Pearson correlations revealed signiﬁcant associations
between sleep efﬁciency and baseline balance, baseline SPPB
total, SPPB total change, SPPB total percent change, balance
change, balance percent change, or gait percent change.
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Minutes awake after sleep onset was negatively associated
with SPPB percent change score or gait percent change. Re-
gression found that higher sleep efﬁciency predicted
greater percent change in SPPB score and higher minutes
awake after sleep onset predicts lower SPPB percent
change score.
Conclusions: For older adults, actigraphy-assessed sleep efﬁ-
ciency and subjectively measured poorer sleep quality is as-
sociated with worse physical functioning during acute
hospitalization. Sleep efﬁciency, minutes awake after sleep
onset and baseline sleep quality also predicted recovery of
physical functioning following hospitalization. These results
suggest that interventions to improve sleep might help en-
hance functional recovery from hospitalization and increase
physical function levels.
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Introduction: Chronic kidney disease (CKD) patients on he-
modialysis present a reduction in muscle mass and functional
capacity. These reductions are associated with greater mor-
tality risk and impairments in quality of life (QoL). Resistance
training (RT) is a viable strategy to attenuate muscle wasting
and loss of strength. The aim of this study was to investigate
the effect of two distinct intradialytic RT protocols on body
composition, sarcopenia prevalence, functional capacity and
QoL in CKD patients.
Methods: The study consisted of a 12-week randomized clin-
ical trial that enrolled 50 participants (age 54.6 ± 11.6) di-
vided into three groups: high-intensity intradialytic RT (HIG,
n = 14); moderate-intensity intradialytic RT (MIG, n = 16)
and control (CG, n = 20). Body composition was assessed by
dual-energy X-ray absorptiometry, functional capacity by the
Short Physical Performance Battery score, and QoL by Kidney
Disease Quality of Life Instrument.
Results: After the training period leg lean mass was
higher in HIG compared with CG [P = 0.040; large effect
size (ES) = 0.92]. HIG also displayed improvements in QoL
in pain and physical function domains (P = 0.04 for
both). Skeletal muscle index was increased in both RT
protocols (P = 0.007; ES = 1.16 and 0.81 for HIG and
MIG, respectively), and functional capacity (P = 0.002;
ES = 0.33 and 0.52 for HIG and MIG, respectively) when
compared to CG.
Conclusions: High-intensity intradialytic RT was associated
with gains in lean mass and QoL compared with lower-
intensity while functional capacity and appendicular muscle
mass were improved, regardless of RT intensity.
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Introduction: Intramyocellular (IMCL) and extramyocellular
lipid (EMCL) is associated with muscle metabolic dysfunction.
The combined effect of vitamin D and exercise on muscle
lipid has not been investigated. We compared the magnitude
of changes in myocellular lipid stores and local muscle oxygen
consumption following combined treatment of vitamin D and
aerobic training (DAT) compared with vitamin D alone (D),
aerobic training alone (AT), and control (Ctl).
Methods: Subjects (>60 YO) with vitamin D insufﬁciency
(25(OH)D < 32 ng/mL) were randomized to a double
blinded design. Vitamin D3 (10,000 IU × 5 days/week) or
placebo was provided for 12 weeks with 1 additional week
(7 consecutive days) of aerobic training or no training.
Gastrocnemius IMCL and EMCL were measured with mag-
netic resonance spectroscopy and fat segmentation. Hybrid
near-infrared and diffuse correlative spectroscopy measured
local tissue blood ﬂow, oxygen saturation, and VO2 during
and following (recovery) a gastrocnemius fatiguing protocol.
All measurements were completed at week 0 and at
end-study.
Results: Fifteen men and 16 women completed all measures.
Mean age and BMI were 68 ± 6 YO and 25.5 ± 3 kg/m2, re-
spectively. Mean 25(OH)D increased signiﬁcantly in subjects
receiving vitamin D (41 ± 4 ng/mL) vs. placebo (7 ± 6 ng/
mL) (p < 0.05). No group or group by time differences were
observed with EMCL (p > 0.05). DAT trended (p = 0.103) to-
ward the greatest change in IMCL and corresponded to a 18%
increase in rVO2 during full exercise recovery in DAT com-
pared to a 2%, 11%, and 18% reduction in AT, D, and Ctl,
respectively.
Conclusions: Vitamin D, when combined with AT, may poten-
tiate the metabolic beneﬁts of exercise by reducing IMCL and
altering tissue-level VO2. Future work will test the hypothesis
that vitamin D promotes muscle lipid availability for β-
oxidation in response to exercise, thereby preventing
lipotoxicity, and improving muscle anabolic sensitivity in pop-
ulations at risk for sarcopenia and cachexia.
Supported by NIH grants R21AG046762, UL1TR000117,
and T32DK007778-16
1078
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 999–1080
DOI: 10.1002/jcsm.12255
10-10
Inﬂuence of serum testosterone, insulin-like
growth factor 1 (IGF-1), insulin-like growth
factor-binding protein-1 (IGFBP-1) and 3 (IGFBP3)
on muscle strength gain after 6 months of
progressive resistance training in older subjects
Antonio Paoli1, Tatiana Moro1,2,3, Antonino Bianco4, Mario Plebani5
& Giuseppe Marcolin1
1Department of Biomedical Sciences, University of Padova, Padova, Italy,
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Introduction: Loss of strength is an important contributor to
disability and poor quality of life in the elderly. Resistance
training (RT) is one of the main treatments suggested to re-
duce strength and muscle loss during aging process. Even
though basal hormonal levels could play a pivotal role in de-
termining elderly’s muscle mass (Stilling et al., 2017) there is
no agreement about the real role of basal hormonal levels on
RT exercise’s response.
Methods: We sough to investigate if basal hormonal levels
inﬂuence strength improvement after 6 months of progres-
sive RT in a group of elderly subjects. We analysed 23 sub-
jects (14 men M and 9 women F), 62.4 ± 3.1 years. We
tested lower limb strength on leg extension before after
6 months of training. We analysed free fat mass, total testos-
terone (tT), free testosterone (fT), IGF-1, IGFBP-1, and IGFBP3
before and after the training period.
Results: No correlation was found between tT, fT, IGF-1,
IGFBP-1 and IGFB3 and free fat mass considering M and F
or merged. Moreover, no correlation was found between fT,
tT and strength increase considering men and women. No
correlation was found between IGF-1 and strength. We found
a positive, signiﬁcant correlation between strength improve-
ment (p < 0.05, r = 0.435) and basal IGFBP1 concentration
considering men and women merged and a signiﬁcant nega-
tive correlation between IGFBP3 and strength gains in female
(P = 0.006; r = 0.791).
Conclusions: Our results are suggestive of a more complex re-
lationship between androgens, IGF1, IGFBPs and the re-
sponse to 6 months of RT. Whilst a negative correlation
between IGFBP1 and muscle mass was found in older woman
(Stilling et al., 2017) our results suggest instead that higher
serum IGFBP1 is related to a better RT response in the elderly
(irrespective to gender) whilst higher IGFBP3 is a predictive
factor for a poor strength increase in older women.
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Low-intensity blood ﬂow restriction training in
combination with protein supplementation: a new
approach for the prevention and treatment of
sarcopenia
Christoph Centner1, Denise Zdzieblik1, Steffen Oesser2,
Albert Gollhofer1 & Daniel Koenig1
1Department of Sport Science, University of Freiburg, Germany, 2CRI, Collagen
Research Institute GmbH, Kiel, Germany
Preservation of skeletal muscle mass and strength is of vital
importance in older age for maintaining musculoskeletal
and functional capacity and thus independence. Recent re-
search has indicated that high-intensity resistance training
(RT) is an effective strategy to counteract the age-related de-
cline of muscle mass and function. According to the American
College of Sports Medicine training loads of 70–85% of each
individual’s one repetition maximum (1RM) are necessary
to produce substantial muscle growth. However, mainly due
to comorbidities such as coronary heart diseases, diabetes
and joint or muscle impairments, many elderlies are not ca-
pable of lifting heavy loads. Hence, there is an increasing
need of identifying more suitable training modalities that
combat sarcopenia and other causes of muscular atrophy,
particularly in aged people with serious concomitant dis-
eases. Recently, several studies have demonstrated that
low-intensity exercise (20–40% 1RM) combined with partial
vascular occlusion elicits muscular hypertrophy to a similar
extent to what is typically seen after high-intensity resistance
training. Although the effectiveness blood ﬂow restriction
(BFR) training has been well investigated, no study to date
has combined this training method with an additional nutri-
tional intervention. Besides an optimal training stimulus, an
adequate protein intake has been shown to stimulate protein
synthesis and thus increasing muscle mass and strength. Pre-
vious studies from our research group have demonstrated
that collagen peptides enhance the effects of a 12-week RT
regarding its inﬂuence on muscle mass and fat reduction.
Therefore, we hypothesize that BFR training in combination
with a protein supplementation is a promising alternative in
order to prevent and treat sarcopenia, especially in popula-
tions for whom high-intensity exercise programs are contra-
indicated. We will present the method of BFR training and
additionally discuss possible explanations for improved mus-
cle mass and function by this concept.
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Circulatory levels of oxidative stress markers and
BMD in postmenopausal women
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Objective: Osteoporosis is a signiﬁcant health issue which is set
to rise alarmingly worldwide. In addition to some well-
characterized factors, oxidative stress is also suggested to con-
tribute to bone loss in osteoporosis seen in menopause. Oxida-
tive stress is the result of an imbalance between the production
of reactive oxygen species (ROS) and the removal of their reac-
tive intermediates. There is much controversy regarding the
possible pathological role of oxidative stress on bone mineral
density (BMD). This study was aimed at measuring serum oxi-
dative stress parameters i.e., Catalase, Peroxiredoxin 2
(PRX2), Superoxide dismutase 1 (SOD1), Superoxide dismutase
2 (SOD2) and Thioredoxin (TRx1) in postmenopausal women
with normal, osteopenic and osteoporotic bone density.
Methods: The study population included 64 post-menopausal
women of whom 23 had normal BMD, 38 had osteopenia and
13 had osteoporosis. Serum oxidative stress parameters were
measured using the Multiplex system (Millipore) and read on
the Magpex ELISA platform.
Results: Serum levels of Catalase, SOD2 and PRX2 were found
signiﬁcantly lower in postmenopausal women with low BMD
group as compared to women with normal BMD (p = 0.031,
0.044 and 0.041 respectively). These ﬁndings support that ox-
idative stress plays an important role in pathogenesis of post-
menopausal osteoporosis. However, levels were not
signiﬁcantly different in women with osteopenia as compared
to those with osteoporosis. Furthermore, levels did not corre-
late signiﬁcantly with BMD of the hip or spine.
Conclusions: These data provide insights into the possible role
of oxidative stress on the pathogenesis of postmenopausal os-
teoporosis. However, the lack of association between studied
oxidative stress markers and BMD may indicate that osteopo-
rosis may be rather multivariate and complex.
Acknowledgment: This study is supported by Kuwait Founda-
tion of Advancement of Science (KFAS) projects no. 2013–
1302-02 and PR17-18SL-01.
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Anthropometric and physical changes in normal
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old adults during a 12 week resistance exercise
program
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Introduction: Resistance exercise is important for the preven-
tion of sarcopenia and physical dependence of old adults.
However, little is known whether overweight/obesity affect
the outcomes of a resistance exercise program.
Methods: Community dwelling Icelandic old adults (N = 236,
73.7 ± 5.7 years) participated in a 12-week resistance exercise
program. Anthropometrics, muscular strength and physical
function were measured at baseline and endpoint. Partici-
pants were grouped retrospectively into normal-, overweight
and obese according to international BMI cut off values. Sta-
tistical analyses were corrected for age and gender.
Results: Of the participants, 22.0% were normal, 41.4% were
overweight and 36.6% were obese. BMI categories were nei-
ther related to drop-out (11.9%) nor to attendance (88.4%).
All groups experienced improvements in outcome measure-
ments, but improvements in obese individuals were less pro-
nounced compared to normal weight individuals. There was
similar weight gain in the groups (+0.48 kg, P < 0.001), how-
ever, normal weight individuals gained more lean mass
(+0.70 kg, P = 0.015), appendicular muscle mass (+0.42 kg,
P = 0.007) but tended to loose more fat mass (0.75 kg,
P = 0.081) as compared to obese. This resulted in a greater
change in body fat percent in normal weight subjects as com-
pared to obese (1.5%, P = 0.014).
Absolute gains in quadriceps strength were similar be-
tween groups, but relative to body weight, normal weight
subject gained more than obese subjects (+0.31 N/kg,
P = 0.017). This translated into a greater improvement in 6-
minute walk-for-distance (+24. m, P < 0.001) compared to
obese subjects. Interestingly, grip strength increased more
in obese subjects (2.4 lb, P = 0.020). Timed-up-and-go im-
proved similarly in all groups (0.64 sec, P < 0.001).
Discussion: Independently from their body weight status, old
adults beneﬁted from a resistance exercise program in terms
of body composition and physical function. However, obese
individuals improved signiﬁcantly less than normal weight
participants although there was similar attendance to the ex-
ercise classes. Great care has to be taken of obese elderly in
order to maintain their physical independence as long as
possible.
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